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1  Summary 
Tumour necrosis factor (TNF) plays a critical role in inflammatory processes and is 
involved in the regulation of immune responses. Depending on the cellular context, TNF 
initiates a complex cascade of signalling events that can lead to induction of 
proinflammatory cytokines, cell proliferation, differentiation or cell death. Most of the 
pleiotropic effects of TNF are mediated by the death-domain (DD) containing TNF-R1. 
Ligand-induced trimerisation of TNF-R1 leads to the formation of an intracellular multi-
protein complex, the TNF-R1 signalling complex (TNF-RSC). To be able to comprehend 
the complex network of signalling pathways emanating from TNF-R1, the TNF-RSC and its 
composition need to be understood at the molecular level. 
Using a modified tandem affinity purification approach, HOIL-1 and HOIP were 
identified as two novel, functional components of the native TNF-RSC. Together they were 
shown to form a linear ubiquitin chain assembly complex (LUBAC), catalysing the 
formation of linear head-to-tail ubiquitin chains. LUBAC mediates ubiquitination of NEMO 
with linear ubiquitin chains, required for efficient NF-κB activation following TNF 
stimulation. In this thesis, it could be demonstrated that the stimulation-dependent 
recruitment of LUBAC to the TNF-RSC is impaired in cIAP1/2-deficient mouse embryonic 
fibroblast (MEF) cell lines. Furthermore, it was shown that the E3 ligase activity of cIAPs, 
but not of TRAF2, is required for HOIL-1 recruitment to the TNF-RSC. This result, together 
with the ability of HOIL-1 and HOIP to bind polyubiquitin chains of various linkage types, 
suggests that LUBAC is recruited to the TNF-RSC via cIAP-generated ubiquitin chains. It 
was also found that LUBAC enhances NEMO interaction with the TNF-RSC, that it 
stabilises this protein complex and that LUBAC is required for efficient TNF-induced 
activation of NF-κB and JNK, resulting in apoptosis inhibition. Finally, it is shown in this 
thesis that the catalytic activity of LUBAC is required for stabilisation of the TNF-RSC, 
thereby adding a novel form of ubiquitin linkage to TNF signalling.  
The identification of HOIL-1 and HOIP as functional constituents of the TNF-RSC 
provides evidence that LUBAC is an important regulator at the apex of TNF-induced 
signalling cascades and increases the combinatorial complexity of ubiquitin modifications 
within this receptor complex. 
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2  Introduction 
2.1  Ubiquitin and tumour necrosis factor (TNF) signalling: a historical overview 
TNF is a pleiotropic cytokine with both proinflammatory and immunoregulatory functions. 
Its diverse activities are mediated via two cell membrane receptors, TNF-Receptor 1 
(TNF-R1) and TNF-R2, which activate separate signal transduction pathways and evoke 
distinct biological effects. Over the past 4 decades, it became evident that the ubiquitin 
system has a key function within these TNF-induced signal cascades and that TNF 
signalling and the ubiquitin network are inseparably connected (Figure 2.1). 
In 1974, a 76 residue polypeptide was isolated from bovine thymus during the 
isolation of thymopoietin and termed ubiquitin (Goldstein, 1974; Schlesinger et al., 1975). 
This small protein was later to become an important player not only for cellular protein 
degradation processes but also in signal transduction induced by TNF as well as many other 
ligand-receptor systems. At the time of its isolation these roles could not have been 
anticipated as neither the function of ubiquitin nor TNF itself were known. TNF was 
identified in 1975 as an endotoxin-induced serum factor that causes necrosis of tumours 
(Carswell et al., 1975), and both the human and the murine protein were cloned about 
10 years later (Marmenout et al., 1985; Pennica et al., 1984). By that time great advances 
had been made in characterising ubiquitin: In 1978, Ciechanover et al. described a heat 
stable component of an ATP-dependent proteolytic system from reticulocytes (Ciechanover 
et al., 1978). This elegant study demonstrated that degradation of proteins is not carried out 
by a single protease but requires an additional small and heat-stable protein, which at that 
time was called ATP-dependent proteolysis factor 1 (APF-1). Two years later, it was shown 
that covalent attachment of APF-1 to proteins is a prerequisite for proteolytic degradation 
(Ciechanover et al., 1980; Hershko et al., 1980). In the same year, APF-1 was found to be 
identical to ubiquitin (Wilkinson et al., 1980) and only shortly afterwards the system of 
ubiquitin-mediated protein degradation that had been reported in vitro could be verified in a 
cellular context (Ciechanover et al., 1984; Finley et al., 1984).  
In parallel to that and in the following years some insight into TNF-mediated 
processes and cellular responses was obtained: TNF was shown to induce not only necrosis 
in several tumour models (Balkwill et al., 1986; Brouckaert et al., 1986; Pennica et al., 
1984; Talmadge et al., 1988) but also apoptosis (Laster et al., 1988) as well as the activation 
of pro-survival signalling pathways such as the nuclear factor κB (NF-κB) pathway (Duh et 
Introduction  3  
al., 1989; Israel et al., 1989; Lowenthal et al., 1989; Osborn et al., 1989). In addition it could 
be demonstrated that stimulation of cells with TNF initiates several signalling pathways, 
including the activation of p38 (Raingeaud et al., 1995), c-Jun N-terminal kinase (JNK) 
(Kallunki et al., 1994; Minden et al., 1994b; Sluss et al., 1994) and the transcription factor 
activator protein 1 (AP-1) (Brenner et al., 1989). These signalling pathways are initiated by 
binding of TNF to TNF-R1 and TNF-R2, which were both cloned in 1990 (Gray et al., 
1990; Heller et al., 1990; Loetscher et al., 1990; Schall et al., 1990). 
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Figure 2.1: Timeline of important discoveries in the ubiquitination and TNF signalling field. The orange 
line indicates a strong connection between ubiquitination and TNF signalling, beginning at the time when both 
systems were reported to play an important role in the activation of NF-κB. 
 
 
The discovery that ubiquitin was not only involved in unspecific degradation of old or 
misfolded proteins, but also had a role in targeted and even partial protein degradation, as in 
the case of the processing of the NF-κB precursor p105 to p50 (Fan and Maniatis, 1991; 
Palombella et al., 1994) provided an important role for ubiquitin in the activation of this 
transcription factor. Via their respective roles in NF-κB activation, TNF and ubiquitin 
became linked for the first time.  
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The role for ubiquitin in this process was strengthened by the finding that degradation of the 
Inhibitor of κB (IκBα), which allows the release of preformed NF-κB dimers and their 
translocation to the nucleus, required not only phosphorylation but also ubiquitination of 
IκΒα (Alkalay et al., 1995; Chen et al., 1995; DiDonato et al., 1996; Palombella et al., 
1994). The addition of polyubiquitin chains to internal lysine residues of a protein or to its 
N-terminus was shown to depend on sequential action of three enzymes, the ubiquitin 
activating enzyme (E1), the ubiquitin carrier protein (E2) and a ubiquitin ligase (E3) 
(Ciechanover et al., 1982; Hershko, 1983; Hershko et al., 1983). In case of protein 
degradation the C-terminus of ubiquitin is attached to lysine 48 (K 48) of the preceding 
ubiquitin molecule (Chau et al., 1989). Although the K48-linked ubiquitin chains were the 
first to be associated with TNF signalling, these chains were not to remain the only type of 
ubiquitin linkage in TNF-induced signal transduction.  
As molecular mechanisms of TNF-mediated signalling came into focus, the 
composition of the receptor-proximal multi-protein complex was an important aspect of this 
investigation. Intensive studies over several years led to the identification of the adaptor 
protein TNF-R1-associated death domain (TRADD) (Hsu et al., 1995), the receptor 
interacting protein 1 (RIP1) (Hsu et al., 1996a; Ting et al., 1996), the TNF-receptor 
associated factor 2 (TRAF2) (Shu et al., 1996) and the cellular inhibitor of apoptosis 
proteins 1 and 2 (cIAP1 and cIAP2) (Rothe et al., 1995; Shu et al., 1996; Vince et al., 2009) 
as the main signalling proteins, which are recruited to the TNF-R1 signalling complex 
(TNF-RSC) upon TNF stimulation.  
Both, TRAF2 and cIAP1/2 have been reported to be the E3 ligase in the ubiquitination 
process of RIP1 (Deng et al., 2000; Ea et al., 2006; Wertz et al., 2004), which modifies 
RIP1 with K63-linked ubiquitin polymers. This type of ubiquitin chain does not act as a 
degradation signal but rather functions in non-proteolytic signalling pathways (Arnason and 
Ellison, 1994; Spence et al., 1995), and in case of RIP1 has been implicated in the 
recruitment of the TAB-TAK as well as the IKK complex (Ishitani et al., 2003; Kanayama 
et al., 2004; Sato et al., 2005; Wang et al., 2001; Zhang et al., 2000). The attachment of 
K63-linked ubiquitin chains to RIP1 as well as other components of the TNF-RSC (Shi and 
Kehrl, 2003) provides another connection between TNF and ubiquitin and introduces a 
second ubiquitin-linkage type to TNF signalling. 
The importance of K63-linked ubiquitin chains in TNF signal transduction is 
underlined by the finding that deubiquitinases (DUBs) such as A20 and the tumour 
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suppressor Familial Cylindromatosis Protein (CYLD), which cleave K63-linked 
polyubiquitin, were shown to inhibit or terminate TNF-mediated signalling (Brummelkamp 
et al., 2003; Trompouki et al., 2003; Wertz et al., 2004). Accordingly, to be able to 
comprehend the complex network of signalling pathways emanating from the TNF-RSC, 
the multifaceted regulatory functions of the ubiquitin network need to be understood. 
 
 
2.2  TNF signalling 
2.2.1  TNF and the tumour necrosis factor superfamily (TNF-SF) 
TNF is the founding member of a cytokine family with about twenty proteins, which all 
display structural similarities (Aggarwal, 2003; Locksley et al., 2001). These cytokines play 
a central role in the regulation of the immune system, the modulation of cell proliferation 
and in the protective function of pathogen sensitive cells (Locksley et al., 2001).  
A characteristic feature of TNF-SF proteins (Table 1) is their extracellular domain, 
which displays more than 20 % sequence homology amongst all family members. This 
conserved, highly hydrophobic domain is responsible and essential for the trimerisation of 
the ligands in solution (Locksley et al., 2001). Accordingly, TNF is only bioactive as a self-
assembled and stable, but non-covalently linked trimer (Fesik, 2000). 
Apart from LTα and TWEAK, which are directly secreted, all cytokines of the 
TNF-SF are expressed on the cell surface as type-II-transmembrane proteins. Some of these 
ligands can be cleaved by metalloproteases and released into the extracellular milieu (Idriss 
and Naismith, 2000). For instance, TNF is initially expressed as a 26 kDa precursor on the 
cell membrane and is released as a 17 kDa soluble form via proteolytic cleavage by the 
TNF-α converting enzyme (TACE) (Black et al., 1997). 
As trimerisation of TNF already takes place in the cytosol (Tang et al., 1996), TACE 
treatment leads to the release of soluble and fully active TNF-trimers (Black et al., 1997; 
Moss et al., 1997). Notably, differences in bioactivity between the membrane-bound and the 
soluble ligand forms have been shown for TNF (Grell et al., 1995; Grell et al., 1998), 
TRAIL (Muhlenbeck et al., 2000; Wajant et al., 2001), and CD95L (O'Reilly et al., 2009; 
Schneider et al., 1998). The soluble, mature form of TNF is able to bind to both TNF-R1 
and TNF-R2, but only TNF-R1 is fully activated. In contrast, membrane bound TNF has 
been demonstrated to activate TNF-R1 as well as TNF-R2 effectively (Grell et al., 1995; 
Grell et al., 1998; Krippner-Heidenreich et al., 2002). 
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2.2.2  The TNF-Receptor superfamily 
The members of the TNF-SF exert their biological functions via interaction with their 
cognate membrane receptors, comprising the TNF-R SF. In contrast to the ligands, receptors 
of the TNF-R SF are type I transmembrane proteins. They are characterised by one to six 
cysteine rich domains (CRDs) within their extracellular portions, which mediate binding of 
the respective ligand (Hymowitz et al., 1999; Kim et al., 2003; Mongkolsapaya et al., 1999). 
These CRDs are defined by intrachain disulphide bonds generated by highly conserved 
cysteine residues within the receptor chain (Hehlgans and Pfeffer, 2005). Variation in the 
number of CRDs exist among the receptor family members, from B-cell activating factor 
receptor (BAFF-R) with only a partial CRD, to TNF-R1 and TNF-R2 bearing four CRDs 
and up to six CRDs found in CD30. Another conserved domain, responsible for the ligand-
independent, homophilic receptor interaction, was identified in the extracellular part of 
TNF-R1, TNF-R2, CD95, TRAIL-R1 and CD40 by sequence analysis (Aderem and 
Ulevitch, 2000). This pre-ligand-binding assembly domain (PLAD) is located within the 
first CRD and mediates the formation of di- or trimeric receptor complexes in the absence of 
the ligand. The PLAD differs from the domains responsible for ligand binding (CRD2 and 
CRD3), but is also essential for TNF binding as has been shown in PLAD deletion mutants 
of TNF-R1 and TNF-R2 (Chan et al., 2000; Deng et al., 2005). The preformed oligo-
merisation of PLAD-expressing receptor molecules appears to be a common feature for the 
members of the TNF-R SF and may allow the formation of higher-order receptor complexes 
upon ligand binding, resulting in more efficient signal transduction (Chan et al., 2000).  
 
Table 2.1: Cytokines of the TNF-superfamily and their receptors 
Receptor Intracellular 
signalling motif Cytokine 
TNF-R1 DD TNF, LTα 
TNF-R2 TIM TNF, LTα 
CD95 (APO-1/Fas) DD CD95L 
DCR3 soluble VEGI, CD95L 
DR3 DD VEGI, LIGHT 
TRAIL-R1 (DR4) DD TRAIL 
TRAIL-R2 (DR5) DD TRAIL 
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TRAIL-R3 (DCR1) - TRAIL 
TRAIL-R4 (DCR2) - TRAIL 
DR6 DD, TIM unknown 
EDAR DD, TIM  EDA-A1 
NGFR DD, TIM NGF 
OPG soluble RANKL, TRAIL 
RANK TIM RANKL 
LTβR TIM LTα, LTβ, LIGHT 
FN14 TIM TWEAK 
HVEM TIM LIGHT, LTα 
CD27 TIM CD27L 
CD30 TIM CD30L 
CD40 TIM CD40L 
4-1BB TIM 4-1BBL 
OX40 TIM OX40L 
GITR TIM GITRL 
BCMA TIM BAFF, APRIL 
TACI TIM BAFF, APRIL 
BAFF-R TIM BAFF 
XEDAR TIM EDA-A2 
TROY TIM unknown 
RELT TIM unknown 
 
Legend: BAFF: B-cell-activating factor, BCMA: B-cell maturation antigen, RANK: receptor activator of 
NF-κB, DD: death domain, EDA: ectodermal dysplasin, EDAR: ectodysplasin-A-receptor, FN14: fibroblast 
growth factor-inducible 14, GITR: Glucocorticoid-induced TNF-R family receptor, HVEM: herpes virus entry 
mediator, LT: lymphotoxin, NGF: nerve growth factor, OPG: osteoprotegerin, RANKL: receptor activator of 
nuclear factor κB ligand, RELT: Receptor expressed in lymphoid tissues, TACI: transmembrane activator and 
calcium-signal modulating cyclophilin ligand (CAML) interactor, TIM: TRAF-interacting motif, TNF: 
Tumour necrosis factor, TRAIL: TNF-related apoptosis-inducing ligand, TWEAK: TNF-like weak inducer of 
apoptosis, VEGI: vascular endothelial cell-growth inhibitor, XEDAR: X-linked EDA-A2 receptor. 
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Regarding the intracellular domains, different subclasses of receptors can be defined. 
Firstly, members of the death receptor subgroup, including CD95, TNF-R1, TRAIL-R1/2, 
EDAR and DR3, contain a DD in their intracellular part. DDs are homologous sequences of 
about 80 amino acids which form six anti-parallel α-helices with a highly conserved 
topology (Aravind et al., 1999; Lahm et al., 2003). These domains are essential for the 
apoptosis-inducing functions of all death receptors (Itoh and Nagata, 1993; Tartaglia et al., 
1993). The second group of receptors includes the TNF-R family members TNF-R2, CD27, 
CD30, CD40, LTβR, OX40, 4-1BB, BAFF-R, B-cell maturation antigen (BCMA), receptor 
activator of NF-κB (RANK), transmembrane activator and calcium-signal modulating 
cyclophilin ligand (CAML) interactor (TACI), fibroblast growth factor-inducible 14 (Fn14), 
herpes virus entry mediator (HVEM), Glucocorticoid-induced TNF-R family receptor 
(GITR), X-linked EDA-A2 receptor (XEDAR) and TROY. These receptors do not possess a 
DD-domain, but in most cases contain TRAF-interacting motifs (TIMs) in their cytoplasmic 
domain instead (Aggarwal, 2003; Hehlgans and Pfeffer, 2005). Activation of TIM-
containing TNF-R SF members leads to the recruitment of TRAF proteins to the respective 
receptor. Until today, seven mammalian TRAFs (TRAF1 to TRAF7) have been identified 
(Xu et al., 2004) with homologues found in Drosophila melanogaster and Caenorhabditis 
elegans. Upon recruitment, TRAF proteins interact with a number of additional signalling 
molecules, leading to the induction of different signal transduction pathways like JNK, p38, 
Phosphoinositide 3-kinases (PI3Ks) and ERK1/2 (Dempsey et al., 2003). Another group of 
receptors, including TRAIL-R3, TRAIL-R4 and osteoprotegerin (OPG), do not contain any 
known signalling motifs or lack an intracellular domain completely. The exact biological 
function of these receptors remains to be resolved. 
Over the past years it has become apparent that several members of the TNF SF 
interact with more than one receptor of the TNF-R SF (Table 1). This cross-utilisation of 
ligands and receptors suggests redundancy in the biological functions. However, by using 
genetic approaches, it was possible to define the physiological function linked to specific 
ligand/receptor systems in detail and it became clear that almost every receptor-ligand 
interaction within the TNF/TNF-R SF appears to have unique and nonredundant functions. 
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2.2.3  Biology of the TNF/TNF-R system 
TNF is currently known to perform multiple physiological functions, mostly related to 
immune responses and inflammation. Stimulation of cells with TNF initiates a complex 
cascade of signalling events leading to induction of proinflammatory cytokines, cell 
proliferation, differentiation and, depending on the cellular context, also to cell death (Chen 
and Goeddel, 2002; Wajant et al., 2003).  
The pleiotropic biological effects of TNF are mediated by TNF-R1 and TNF-R2. The 
ability of TNF to exert such diverse functions stems from the broad expression of TNF-
Receptors and the multitude of intracellular responses they are able to initiate. TNF-R1 is 
expressed in most tissues, excluding erythrocytes, whereas TNF-R2 could mainly be 
detected on cells of lymphoid origin (Wajant et al., 2003). In contrast to TNF-R1, which is 
constitutively expressed in many cell types, TNF-R2-expression is highly regulated by 
several factors (Wajant et al., 2003). TNF binding induces receptor aggregation, resulting in 
the recruitment of a number of cytoplasmic signalling proteins to the distinct TNF-RSCs 
(Section 2.2.4.1). Due to the wide expression pattern of TNF-Receptors, most cells show at 
least some TNF responsiveness. 
All cytokines of the TNF SF are mainly expressed and secreted by cells of the 
immune system. TNF itself is predominantly produced by macrophages and dendritic cells, 
but also by monocytes, lymphocytes, keratinocytes as well as a broad variety of other 
tissues in response to proinflammatory stimuli. It possesses characteristics that allow the 
modulation of the immune response as well as proinflammatory and pathophysiological 
activities. Although TNF has systemic endotoxic activity leading to fever, hypotension and 
shock (Malik and Balkwill, 1992), it is also one of the most prominent inflammatory 
mediators and central in initiating inflammatory responses of the innate immune system. 
In response to the presence of Lipopolysaccharide (LPS) and other bacterial products 
large amounts of TNF are released. Neutralisation of TNF, using antibodies (Infliximab) or 
soluble TNF-Receptor molecules (Enbrel), demonstrated that the host defence against 
pathogens is severely impaired in the absence of TNF (Aggarwal, 2003). During infection, 
TNF enhances the production of proinflammatory cytokines by surrounding cells and 
increases the phagocytic ability of macrophages (Bekker et al., 2001). At the same time 
TNF plays a critical role in the control of endothelial cell function and regulates trafficking 
of circulating leukocytes into tissues and to the site of infection by stimulating inflammatory 
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local vascular endothelial cells to express chemokines and cell adhesion molecules (Roach 
et al., 2002). Consistently, it has been shown that TNF and TNF-R1 are essential for the 
survival of infections with a variety of bacterial pathogens such as Listeria monocytogenes, 
Mycobacterium tuberculosis, M. avium and Salmonella typhimurium (Ehlers et al., 2003; 
Pfeffer et al., 1993). Studies in mouse infection models revealed that TNF and TNF-R1 are 
necessary for the development of functional granulomas upon infection with 
M. tuberculosis. TNF-R1-deficient animals do initially form granulomas but fail to maintain 
their functionality (Bean et al., 1999; Ehlers et al., 2000).  
However, in other infection models, TNF knockout mice showed delayed pathological 
reactions when challenged with pathogens (Goncalves et al., 2001; Zganiacz et al., 2004). 
Furthermore, macrophages and dendritic cells pre-treated with TNF produced smaller 
amounts of the proinflammatory cytokines Interleukin 12 (IL-12) and IL-23 after 
stimulation with Interferon γ (IFN-γ) and LPS as compared to cells that had not been treated 
with TNF (Zakharova and Ziegler, 2005). Independent of its role in host defence, TNF 
might therefore also play a role in downregulating the immune system after a successful 
response. Thereby, at later stages of infection, TNF may be involved in controlling the 
strength, the duration and the resolution of an immune response and it is likely that the 
specific role of TNF in infection is highly dependent on the type of the pathogen, the 
general context and the stage of infection. 
Gene knockout studies in mice provided essential information about the distinct 
physiological functions of TNF and the two TNF-Receptors concerning organogenesis and 
the maintenance of lymphoid microarchitecture. TNF-, TNF-R1- and TNF-R2-deficient 
mice were viable, fertile and showed no apparent phenotypic abnormalities. These mice did 
not exhibit significant developmental defects in most tissues with the exception of 
secondary lymphoid organs. TNF and TNF-R1 knockout mice completely lack primary 
B cell follicles and cannot form organised follicular dendritic cell (DC) networks and 
germinal centres in spleen, lymph nodes and Peyer’s patches (Pasparakis et al., 1996; 
Pasparakis et al., 1997). Furthermore, TNF signalling is also critically required for the 
physiological maturation of the humoral immune response (Pasparakis et al., 1996; 
Pasparakis et al., 1997). Due to a normal content and localisation of DCs in both lymph 
nodes and Peyer’s patches and a normal segregation of lymphocytes into T and B cell areas, 
these studies suggest that the structural lymphoid abnormalities observed in TNF and 
TNF-R1 knockout mice are not associated with defects in lymphoid organogenesis, but that 
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the TNF/TNF-R system is rather required for the establishment of the correct architecture of 
secondary lymphoid organs and for the structural organisation of B cell follicles in 
secondary lymphoid tissues.  
Due to the pleiotropic nature of TNF-induced signalling events, dysregulation of TNF 
expression can cause or enhance many acute diseases as well as autoimmune diseases, e.g. 
cerebral malaria, rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease) and 
asthma (Beutler and Cerami, 1989; Kwiatkowski, 1992; McInnes and Liew, 2005; O'Shea et 
al., 2002; van der Poll and Lowry, 1995). Significant clinical improvements were achieved 
when patients of both rheumatoid arthritis and Crohn’s disease were treated with TNF 
neutralising agents and the successful usage of anti-TNF drugs indicated its importance for 
the pathogenesis of these disorders (Feldmann and Maini, 2001; Taylor and Feldmann, 
2009; Van Deventer, 1997). On the other hand, there is also evidence derived from recent 
animal studies and corresponding clinical trials that neutralisation of TNF not always 
improved autoimmune disease severity. Systemic blockade of TNF in multiple sclerosis 
patients led to immune activation and increased central nervous system (CNS) lesions and 
disease activity (Kassiotis and Kollias, 2001). Furthermore, in the absence of TNF, myelin-
specific T cell reactivity fails to regress and expansion of activated T cells is abnormally 
prolonged, leading to exacerbated myelin oligodendrocyte glycoprotein (MOG)-induced 
experimental autoimmune encephalitis (EAE), a mouse model for multiple sclerosis 
(Kassiotis and Kollias, 2001). This is in contrast to the proinflammatory action of TNF at 
early stages of EAE (Eugster et al., 1999; Kassiotis et al., 1999), indicating that precise 
control of TNF levels or function are required to minimise the risk of autoimmune disease 
development. 
Thus, these independent studies suggest a rather differential role of TNF concerning 
its proinflammatory and immunosuppressive functions in acute or chronic diseases and 
indicate that the overall TNF signalling outcome is determined by important parameters like 
tissue type, precise cellular context as well as timing and duration of TNF action. 
Using an animal model, in which a septic abdominal infection is caused by cecal 
ligation and puncture (CLP) and which leads to immunoparalysis characterised by a reduced 
capacity to produce TNF, Echtenacher et al. showed that injection of recombinant human 
TNF during the phase of immunoparalysis can be beneficial or deleterious, depending on 
the location of TNF activity, timing of TNF administration or the type of superinfection that 
increased lethality in this model (Echtenacher et al., 2003). The diametrical effects of TNF 
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administration observed here are also reflected in further, recent studies: on the one hand, 
TNF, in concert with other cytokines, is considered a key component in the pathogenesis of 
the septic shock syndrome (Mannel and Echtenacher, 2000). On the other hand, however, 
chronic and prolonged exposure to low concentrations of TNF can result in a wasting 
syndrome, cachexia (Beutler et al., 1985) and suppresses effector functions of immune cells 
including T-cells and Natural Killer (NK) cells (Gordon and Wofsy, 1990; Wu et al., 2002). 
The lack of such suppression may also contribute to the development of autoimmune 
diseases like systemic lupus erythematosus (Gordon et al., 1989; Jacob and McDevitt, 
1988).  
Due to the potent (patho-) physiological effects, the cellular expression and 
upregulation of TNF is tightly controlled at multiple levels by complex regulatory 
mechanisms, including Tnf gene transcription, Tnf mRNA stability, and Tnf mRNA 
translation (Han et al., 1990; Tsai et al., 2000). The p38 MAPK (Mitogen-activated protein 
kinase) pathways is implicated in the regulation of Tnf mRNA stability (Dumitru et al., 
2000; Hitti et al., 2006) and in addition to NF-κB, JNK also plays an important role in Tnf 
gene transcription as shown in JNK1/2-deficient mouse embryonic fibroblasts (MEFs), 
macrophages and T cells (Das et al., 2009; Ventura et al., 2003). The Tnf gene contains at 
least four known NF-κB binding motifs and JNK responsive promoter elements that are 
required for full Tnf gene expression, including a divergent AP-1 site that selectively binds 
heterodimeric complexes of ATF2 and cJun (Tsai et al., 2000). 
An additional step of Tnf gene expression control is based on the AU-rich element 
(ARE) within the 3' untranslated region (UTR) of the Tnf mRNA. The TNF ARE has a 
destabilising effect on the Tnf mRNA in unstimulated conditions and after cell stimulation, 
it serves as a binding site for different proteins, which regulate mRNA stability and 
translation (Carballo et al., 1998; Kontoyiannis et al., 1999). 
In summary, the TNF/TNF-Receptor system has been demonstrated to be essential in 
host defence mechanisms and the control of inflammatory processes. However, 
dysregulation of TNF can result in pathophysiological conditions leading to chronic 
inflammation and septic shock syndromes. The different biological functions and roles of 
TNF are reflected by a complex network of intracellular signalling pathways, which are 
induced upon TNF stimulation and required for specific TNF-R1/2 signal transduction. 
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2.2.4  TNF-R1 signal transduction 
2.2.4.1  The TNF-Receptor signalling complex 
TNF-R signalling depends on the ligand-induced formation of an intracellular multiprotein 
complex, the TNF-RSC, which is essential for the initiation of different signalling cascades, 
like the NF-κB and MAPK pathways (Figure 2.2). 
 
TNF
TNF-RSC
Complex IIMAPKactivation
TNF-R1
AP-1, ATF
activation
Caspase
activation
NF-κB
activation
Cell deathGene regulation
 
 
Figure 2.2: Overview of TNF-induced signalling pathways. The membrane proximal TNF-RSC and the 
cytosolic Complex II are shown in grey boxes (→: activation; ↔: interaction). 
 
To understand how the initiating molecular events after TNF-Receptor crosslinking are 
regulated, the composition of the TNF-RSC has been extensively studied for more than a 
decade. The characterisation of the TNF-R associated complexes started in the mid 1990s as 
M. Rothe and D. V. Goeddel found TRAF1 and TRAF2 as well as cIAP1 and cIAP2 to be 
associated with the intracellular domain of TNF-R2 (Rothe et al., 1995; Rothe et al., 1994).  
As the members of the TNF-R SF lack enzymatic activity, signal transduction is 
mediated by cytosolic adaptor proteins which are recruited to the intracellular domains of 
the receptors. This leads to the formation of stimulation-dependent multiprotein complexes 
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in which signalling molecules are activated, initiating an intracellular signal transduction 
cascade (Aggarwal, 2000). 
Upon binding of TNF to TNF-R1, the adaptor protein TRADD is recruited via its DD 
to the RSC (Hsu et al., 1995). TRADD then serves as an assembly platform for binding of 
TRAF2 and RIP1 (Hsu et al., 1996a; Hsu et al., 1996b; Shu et al., 1996; Tsao et al., 2000). 
In cells lacking TRADD, RIP1 is still recruited to the TNF-RSC, most likely due to a direct 
DD-DD interaction with TNF-R1 (Ermolaeva et al., 2008; Haas et al., 2009; Pobezinskaya 
et al., 2008). However, this is not sufficient for formation of a fully functional RSC as 
evident by the lack of RIP1 ubiquitination in TRADD-deficient MEFs (Ermolaeva et al., 
2008; Haas et al., 2009; Pobezinskaya et al., 2008). TRAF2 binds directly to cIAP1 and 
cIAP2 via a cIAP1/2 interacting motif (CIM) and is essential for the recruitment of cIAP1 
and cIAP2 to the TNF-RSC (Vince et al., 2009). Complementary, the baculoviral IAP repeat 
(BIR) 1 domain of cIAP1/2 and several key residues within this region were shown to 
mediate cIAP1/2 binding to TRAF2 (Samuel et al., 2006; Varfolomeev et al., 2006). 
Recently, the crystal structure of the TRAF2-cIAP2 complex was resolved, showing that a 
TRAF2 trimer interacts with one cIAP2 molecule in an asymmetric manner (Zheng et al., 
2010).  
TRADD, RIP1, TRAF2 and cIAP1/2 form the core of the TNF-RSC and genetic 
knockout studies during the last few years provided new evidence for the specific function 
and importance of these cytosolic signalling proteins in TNF signalling. Recruitment of 
these main TNF-RSC components is followed by a series of ubiquitination events 
(Section 2.3), that are critically involved in recruiting further signalling proteins and in 
initiating TNF-mediated activation of NF-κB or MAPK pathways and the induction of 
apoptosis upon TNF stimulation (Sections 2.2.4.2-2.2.4.5). 
 
2.2.4.2  TNF-induced NF-κB activation 
In mammalian cells, the NF-κB family of transcription factors consists of five members 
(p65 (RelA), c-Rel, RelB, p50 and p52), which can form homo- or heterodimers (Rothwarf 
and Karin, 1999). In recent years, it became evident that these NF-κB dimers are crucially 
involved in the transcriptional activation of a variety of anti-apoptotic and inflammation-
related proteins, which are important mediators of TNF-/TNF-R1-induced signalling events. 
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Figure 2.3: Scheme of TNF-induced NF-κB activation. Upon binding of TNF, TRADD and also RIP1 are 
recruited to TNF-R1 via homophilic interaction of their death domains. TRADD then serves as a recruitment 
platform for TRAF2 and additional RIP1 proteins. TRAF2 in turn recruits cIAP1 and cIAP2, which are 
responsible for the generation of ubiquitin chains on several components of the complex such as NEMO (Tang 
et al., 2003b), cIAP1/2 itself and especially RIP1. These polyubiquitin chains are required for the recruitment 
of the TAB/TAK complex. The IKK complex is recruited to ubiquitin as well which brings it into close 
proximity to TAK1. TAK1 can phosphorylate and thereby activate IKKβ. In addition, via binding to RIP1, 
MEKK3 can also participate in the IKKβ activation process. Once the IKK complex is active, it leads to the 
phosphorylation of IκBα, a prerequisite for its K48-linked ubiquitination and degradation. Subsequently, 
NF-κB translocates to the nucleus and induces transcription of target genes. (Components of the core 
TNF-RSC are shown in grey boxes; ubiquitination and phosphorylation processes are indicated by blue or red 
arrows, respectively; ↔: interaction). 
 
 
The current model of TNF-mediated NF-κB activation is based on the recruitment of the 
IKK complex, consisting of the two catalytic subunits, IKKα and IKKβ, and the regulatory 
subunit NEMO (NF-κB essential modulator, IKKγ), to the TNF-R1 complex via RIP1 
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(Figure 2.3). TRAF2 and cIAP1/2 are believed to attach K63-linked ubiquitin chains to 
RIP1, which then serves as a recruitment platform for the ubiquitin-binding IKK signalling 
complex (Bertrand et al., 2008; Ea et al., 2006; Hoeller et al., 2006; Varfolomeev et al., 
2008; Wertz et al., 2004). In contrast to TRAF2, the E3 activities of cIAP1/2 are essential 
for TNF-mediated ubiquitination of RIP1 and NF-κB activation (Bertrand et al., 2008; Haas 
et al., 2009; Mahoney et al., 2008; Varfolomeev et al., 2008), and it could be shown that 
cIAP1/2 can directly ubiquitinate RIP1 in vitro, which has not been demonstrated for 
TRAF2 (Bertrand et al., 2008; Park et al., 2004). Therefore, it is most likely that TRAF2 
plays a structural role, recruiting cIAPs to the vicinity of RIP1 (Vince et al., 2009). Once the 
IKK complex has been recruited, phosphorylation of IKKβ is the next essential step in 
NF-κB activation, but the biochemical mechanism leading to the activation of the IKK 
complex is still not completely understood.  
RIP1 belongs to a family of kinases and besides its DD it also possesses a kinase 
domain at the N-terminus. Yet, reconstitution of RIP1-deficient cells with a kinase-dead 
RIP1 protein restores NF-κB signalling, indicating that the kinase activity of RIP1 is not 
required for IKK phosphorylation (Lee et al., 2004; Ting et al., 1996). Therefore, RIP1 is 
commonly thought to act as an adaptor protein, required for initiation of the canonical, anti-
apoptotic NF-κB pathway. Consistently, RIP1-deficient MEFs are highly sensitive to TNF-
induced cell death (Kelliher et al., 1998; Pimentel-Muinos and Seed, 1999). Apart from its 
role in recruiting the IKK complex, RIP1 may also be indirectly involved in the activation 
of this kinase complex. Receptor recruitment can lead to IKKβ oligomerisation, resulting in 
the trans-auto-phosphorylation of the IKK complex (Tang et al., 2003a). Another possibility 
is that RIP1 acts as an adaptor not for recruitment of the IKK complex itself but also for 
upstream kinases involved in IKKβ phosphorylation. Indeed two kinases were reported to 
be recruited in a RIP1-dependent manner: the MAPK/ERK kinase kinase 3 (MEKK3) can 
bind to RIP1 and is able to activate the IKK complex by phosphorylation of IKKβ (Yang et 
al., 2001). Studies of MEKK3-deficient MEFs further underline an important role of this 
mitogen-activated protein kinase for TNF-mediated NF-κB activation. In these cells, TNF-
mediated NF-κB activation is severely impaired, accompanied by a significantly increased 
sensitivity to TNF-induced apoptosis (Yang et al., 2001). In addition, several studies 
demonstrated a critical role for the TGF-β-activated kinase 1 (TAK1) regarding activation 
of the IKK complex. TAK1 is recruited together with TAK1 binding protein 2 or 3 (TAB2 
or TAB3) and TAB1 to the TNF-R1 complex in a RIP1-dependent manner (Cheung et al., 
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2004; Kanayama et al., 2004; Lee et al., 2003). By analysing crystal structures of the TAB2 
Npl4-type zinc finger (NZF) domain bound to K63-linked ubiquitin chains, Kulathu and 
colleagues showed that TAB2 binds adjacent ubiquitin moieties via two distinct binding 
sites. The conformational constraints on a K63 ubiquitin chain caused by the two-sided 
binding mode of TAB2 cannot be adopted by other ubiquitin chains, explaining the high 
affinity of TAB2 for K63-linked chains (Kulathu et al., 2009). The recruited TAB proteins 
facilitate the dimerisation or oligomerisation of TAK1, thereby promoting the trans-
autophosphorylation and activation of TAK1 (Kanayama et al., 2004). Shim et al. showed 
that TNF-mediated IKKβ as well as NF-κB activation were dramatically impaired in TAK1-
deficient embryonic fibroblasts (Shim et al., 2005). 
Once activated, IKKβ phosphorylates IκBα at residues serine 32 and serine 36 
(DiDonato et al., 1996). In unstimulated cells, IκBα retains NF-κB dimers in an inactive 
state in the cytosol by masking their nuclear localisation sequence. Phosphorylation of IκBα 
leads to its polyubiquitination and proteasomal degradation, resulting in translocation of 
NF-κB dimers into the nucleus and specific transcription of NF-κB target genes (Ghosh and 
Karin, 2002). Recognition of phosphorylated IκBα is mediated by the F-box/WD protein 
β-TrCP (β-transducin repeat-containing protein), which targets the Skp1/Cul1/Roc1/F-box 
E3 complex to modified IκBα, thereby inducing its K48-linked polyubiquitination at 
residues K21 and K22 (Ben-Neriah, 2002). Whereas NEMO and IKKβ are shown to be 
essential for the TNF-mediated NF-κB signalling, it could be demonstrated that IKKα is 
dispensable for this process in most cell types (Chu et al., 1999; Hacker and Karin, 2006; 
Hu et al., 1999; Li et al., 1999). 
In a normal physiological context, activation of NF-κB by TNF is a transient process 
and failure to downregulate NF-κB transcriptional activity can result in chronic 
inflammation and tumour formation (Karin and Greten, 2005; Pikarsky et al., 2004). In a 
negative feedback loop, TNF stimulation leads to the induction of at least two NF-κB target 
genes, A20 (Krikos et al., 1992) and CYLD (Jono et al., 2004), which encode for K63 
deubiquitinases. Both DUBs remove K63-linked polyubiquitin chains from molecules like 
RIP1, TRAF2 and NEMO (Heyninck and Beyaert, 2005; Kovalenko et al., 2003), resulting 
in loss of interaction with downstream mediators or inhibition of enzymatic activity and 
thus, downregulation of activated TNF signalling pathways. Moreover, A20 was shown to 
posses a K48 ubiquitin ligase activity in addition to the K63 DUB function. Upon removal 
of K63-linked polyubiquitin chains from RIP1, A20 can subsequently ubiquitinate the same 
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substrate with K48-linked chains by its C-terminal zinc-finger domain. Hence, A20 is 
thought to mediate the replacement of K63-linked polyubiquitination by K48-linked 
polyubiquitination of RIP1, resulting in its rapid proteasomal degradation and, 
consequently, termination of NF-κB activation (Wertz et al., 2004). Gene knockout studies 
in mice confirmed the essential role of A20 in the control of inflammatory responses. 
A20-deficient animals were hypersensitive to TNF and died prematurely due to severe 
multiple organ inflammation and cachexia (Lee et al., 2000). Unlike A20, the precise 
physiological function of CYLD is yet to be determined. 
However, the role of K63-polyubiquitinated RIP1 in TNF signalling has been 
challenged in several recent studies. As shown by Wong et al., RIP1 is not essential for 
NF-κB activation after TNF stimulation in MEFs (Wong et al., 2010). It could also be 
demonstrated, that the IKK complex can still be recruited to the TNF-RSC in RIP1-deficient 
fibroblasts, suggesting that RIP1 is not the only protein, which is ubiquitinated upon TNF 
stimulation. Indeed, Devin and colleagues showed that TRAF2 can functionally substitute 
for RIP1 by binding and recruiting the IKK complex in RIP1-deficient MEFs (Devin et al., 
2000). Besides RIP1, TRADD (Micheau and Tschopp, 2003), TRAF2 (Brown et al., 2002; 
Habelhah et al., 2004; Li et al., 2002) and cIAP1/2 (own observation) were also modified by 
polyubiquitin chains in the TNF-RSC. In line with that, using a ubiquitin-replacement 
strategy, Xu et al. found that, in contrast to IL-1β signalling, K63-linked ubiquitin chains 
were not required for IKK activation upon TNF stimulation (Xu et al., 2009a). Future 
studies are required to show whether other signalling proteins which are also potentially 
modified by ubiquitin chains upon TNF stimulation like TRADD, TRAF2, cIAP1/2, can 
substitute RIP1 in RIP1-deficient cells and which ubiquitin chain linkage types are actually 
present in the TNF-RSC and functionally important for TNF signalling. 
 
2.2.4.3  TNF-induced MAP kinase activation 
The pleiotropic biological effects of TNF stimulation result form its ability to initiate 
different intracellular signalling pathways. In addition to NF-κB activation, TNF-induced 
signalling leads to the activation of different MAPK cascades (Figure 2.4). These kinases 
are also activated by different kinds of cellular stress (UV, heat-shock, high osmolarity) as 
well as by cytokines like IL-1β or other members of the TNF-SF (Ip and Davis, 1998). With 
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regard to TNF-R1 signalling events, JNK and p38 MAPK are the most potently activated 
MAP kinases (Karin and Gallagher, 2009).  
The JNK kinase family, also known as stress-activated protein kinases (SAPK), 
consists of three members, JNK1, JNK2 and JNK3, which all belong to the MAPK 
superfamily. The JNK isoforms and the p38 MAPK are downstream components in specific 
MAPK cascades, in which signal transduction is mediated through phosphorylation and 
activation of single kinases in a hierarchically structured order (Davis, 2000; Platanias, 
2003). This evolutionarily highly conserved system consists of MAP kinases (MAPKs), 
which are activated by upstream MAPK kinases (MAP2Ks), which in turn can be activated 
by MAP2K kinases (MAP3Ks). Further downstream, the phosphorylated MAPKs are able 
to regulate transcription factors and other signalling proteins and can therefore influence 
various cellular functions in response to external stimuli (Schaeffer and Weber, 1999). In 
this regard, the JNK and p38 cascades mostly mediate activation of members of the 
transcription factor AP-1, a heterodimeric complex composed of proteins of the Jun (cJun, 
JunB and JunD), Fos (cFos, FosB, Fra-1 and Fra-2), JDP (JDP1 and JDP2) and ATF 
subgroups (CREB, ATF2, ATF3 and B-ATF) (Shaulian and Karin, 2002).  
However, the precise molecular mechanisms leading to the activation of JNK and p38 
MAPKs upon TNF stimulation and the interplay between the NF-κB and MAPK pathways 
are still poorly understood. Several studies suggest that crosstalk between the different TNF-
induced signalling pathways are important for determining the biological outcome of TNF 
stimulation (De Smaele et al., 2001; Papa et al., 2004b; Schwabe and Brenner, 2006; Tang 
et al., 2001). 
Following binding of TNF to TNF-R1, JNK isoforms are rapidly but transiently 
activated by dual phosphorylation on tyrosine and threonine residues. As shown in 
overexpression studies, JNK can be activated by two MAP2Ks, MKK4 and MKK7 
(Derijard et al., 1995; Tournier et al., 1997). Detailed analyses using MKK4- and MKK7-
deficient MEFs revealed an essential role for MKK7 in TNF-induced JNK activation, 
whereas MKK4 is necessary for maximal JNK activation, though unable to evoke this 
activation on its own (Tournier et al., 2001). Concerning the p38 MAPK pathway, MKK3 
and MKK6 can function as MAP2Ks, resulting in p38 phosphorylation (Davis, 2000; 
Johnson and Lapadat, 2002). Interestingly, MKK4 might also phosphorylate p38, pointing 
to a possible link between different MAPK pathways in the same tissue and cell type 
(Davis, 2000; Johnson and Lapadat, 2002). 
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Regulation of the MAP3K protein family, which are involved in MAP2K 
phosphorylation and activation, is more complex. Ninomiya-Tsuji et al. showed that TAK1-
deficient MEFs were unable to induce TNF-dependent JNK activation, suggesting an 
important role for TAK1 in TNF-mediated activation of this pathway (Ninomiya-Tsuji et 
al., 1999). In line with this is the finding that MEFs prepared from TAK1flox/flox mice, in 
which TAK1 has been ablated ex vivo, failed to activate NF-κB, JNK and p38 MAPKs in 
response to stimulation with either TNF or IL-1β (Ninomiya-Tsuji et al., 1999). 
Interestingly, analysis of TAB1-/- and TAB2-/- MEFs revealed that neither factor is required 
for activation of JNK or NF-κB following TNF or IL-1β stimulation (Shim et al., 2005). 
Future genetic studies will have to show whether there is functional redundancy amongst the 
TAB proteins or whether the TAB complex is not involved in TNF-induced TAK1 
activation. 
MEKK1 and MEKK3 are found to be potent JNK and p38 MAPK activators in 
overexpression experiments (Blank et al., 1996; Minden et al., 1994a). However, deletion of 
the MEKK3 gene in embryonic stem cells shows that the overall contribution of MEKK3 to 
MAPK activation by TNF is modest, although it may have a more important role in 
activation of the IKK complex (Lee et al., 2003; Yang et al., 2001). MEKK1 can directly 
phosphorylate MKK3, 4, 6 and 7. In line with the observation that TNF-induced JNK 
activation is strictly TRAF2-dependent (Reinhard et al., 1997; Yeh et al., 1997), MEKK1 
was also shown to bind to oligomerised TRAF2 (Baud and Karin, 2001; Baud et al., 1999), 
establishing a link between TNF-induced TNF-RSC formation and MAPK cascade 
activation. Furthermore, MEKK1 gene deletion in embryonic stem cells and MEFs 
confirmed the role of MEKK1 for JNK and p38 activation upon TNF stimulation (Xia et al., 
2000). Consistent with a specific role of MEKK1 for MAPK activation, the absence of 
MEKK1 had no effect on NF-κB and IKK activation in these cell lines (Xia et al., 2000; 
Yujiri et al., 2000). 
Besides MEKK1, it could be shown that another group of kinases, the germinal centre 
kinases (GCKs), was able to bind to TRAF2 directly, leading to the activation of TNF-
induced MAPK pathways (Shi et al., 1999). This kinase family of serine-threonine kinases 
can be subdivided into two groups due to differences within their respective regulatory 
domain (Kyriakis and Avruch, 2001). Whereas GCKs of group II do not stimulate any of the 
currently known MAPK pathway, overexpression of group I GCKs led to phosphorylation 
of MAP3Ks, underlining their possible role as apical MAP4Ks in TNF-induced signalling 
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pathways (Kyriakis, 1999). Furthermore, several group I kinases like GCK, GCK-related 
(GCKR) and HPK1/GCK-related kinase (HGK) become activated upon TNF stimulation 
and are subsequently able to activate MEKK1 in a phosphorylation-dependent manner (Shi 
and Kehrl, 1997; Yao et al., 1999; Yuasa et al., 1998). Thus, group I GCKs seem to 
influence JNK activity upon TNF stimulation by concomitant interaction with TRAF2 and 
subsequent phosphorylation of MAP3Ks like MEKK1. However, further genetic knockout 
studies are necessary to define the specific importance of the various GCKs for TNF-
induced JNK activation. 
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Figure 2.4: Scheme of TNF-R1-mediated MAPK activation. In addition to NF-κB activation, TNF-induced 
signalling from the TNF-RSC leads to the activation of different MAPK cascades, which ultimately result in 
the activation of p38 and JNK MAPK (See text for further details). Components of the core TNF-RSC are 
shown in grey boxes; ubiquitination and phosphorylation processes are represented by blue or red arrows, 
respectively. The poorly defined connection between MKK4 and p38 activation is indicated by a dotted line 
(→: activation; ↔: interaction). 
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Besides the acute JNK activation, which is induced by signalling proteins like TAK1 and 
MEKK1 at the level of the TNF-RSC, a second sustained and prolonged phase of JNK 
activation was also described (Tobiume et al., 2001). This activation phase is thought to be 
mediated by another member of the MAP3K family, apoptosis signal-regulating kinase 1 
(ASK1). Matsuzawa et al. showed that ASK1-deficient MEFs exhibit a defect in the 
induction of extended JNK signalling and cell death following TNF stimulation (Matsuzawa 
and Ichijo, 2008). One possible mechanism for the induction of the late JNK activity stage is 
based on the generation of reactive oxygen species (ROS) upon TNF stimulation in a 
TRAF2-dependent manner (Chandel et al., 2001). ASK1 is normally kept inactive by 
thioredoxin (Trx), a redox regulatory protein that is inactivated by ROS, resulting in the 
subsequent activation of ASK1. In addition, recent studies by the group of M. Karin 
revealed that ROS oxidised and inactivated MAPK phosphatases (MKPs), which are 
essential for the dephosphorylation of activated JNK. TNF-induced ROS were shown to 
oxidise critical cysteine residues in the catalytic site of various MKPs, including MPK1, 
MPK3, MPK5 and MPK7, leading to their inactivation (Kamata et al., 2005). In vivo, the 
involvement of ROS-mediated JNK activation is supported by the observation that treatment 
of mice with an antioxidant prevents JNK phosphatase oxidation, sustained JNK activity 
and TNF-mediated fulminant liver failure in a concanavalin A (ConA) hepatitis animal 
model (Kamata et al., 2005). 
Collectively, TNF induces specific signalling pathways that lead to activation of either 
pro-survival mediators or effectors of cell death. Two phases of TNF-stimulated JNK 
activation appear to mediate different cellular responses (Ventura et al., 2006): Whereas the 
initial transient phase of TRAF-mediated JNK activation may signal cell survival (Lamb et 
al., 2003), the later sustained phase of JNK activation is thought to execute a pro-apoptotic 
function and contribute to ROS-induced cell death (Ventura et al., 2004).  
 
2.2.4.4  JNK-mediated regulation of apoptosis 
Like other death receptor ligands, TNF is able to induce apoptosis in a variety of cell lines. 
However, compared to CD95 or TRAIL-R1/2 signalling, TNF-induced apoptosis seems to 
have only a minor role amongst the collectivity of TNF-mediated processes in vivo. 
Remarkably, mice deficient in p65 or other components involved in NF-κB activation, like 
IKKβ and NEMO, are embryonally lethal or die early after birth due to massive TNF-
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dependent liver failure (Beg et al., 1995). Further studies have shown that NF-κB activation 
is also crucial for protecting hepatocytes against TNF-induced hepatotoxicity in adult mice. 
For instance, mice with a hepatocyte-specific deletion of either IKKβ or NEMO are more 
sensitive than wild-type mice to the hepatotoxic effects of ConA or TNF (Luedde et al., 
2005; Maeda et al., 2003). Consequently, the death-inducing capability of TNF is 
predominantly masked in vivo by concomitant activation of NF-κB. TNF-mediated NF-κB 
activation results in the expression of critical genes encoding anti-apoptotic proteins, such as 
the caspase-8 inhibitor cellular FLICE-inhibitory protein (cFLIP), the Bcl-2 family members 
Bcl-XL and A1/Bfl-1, X-linked inhibitor of apoptosis (XIAP) and cIAP1/2. However, many 
of these anti-apoptotic proteins can only partially protect from death induced by TNF, 
indicating the existence of other NF-κB-dependent protective mechanisms (Dutta et al., 
2006). At least some of the cytoprotective effects of NF-κB in TNF-induced hepatotoxicity 
are mediated by suppression of JNK activity following TNF challenge (Papa et al., 2006; 
Schwabe and Brenner, 2006). Independent studies by M. Karin and G. Franzoso 
demonstrated that the sustained phase of JNK activity rather than the initial and transient 
phase is responsible for the pro-apoptotic function of JNK in the particular cellular context 
(Chang et al., 2006; De Smaele et al., 2001; Papa et al., 2004b; Tang et al., 2001). Thus, 
NF-κB-mediated suppression of this prolonged activation seems to be crucial for inhibition 
of TNF-induced apoptosis. 
Evidence for this crosstalk between NF-κB and MAPK pathways in vivo is based on 
analysis of hepatocytes with defects in NF-κB activation. The proapoptotic effects of ConA-
induced hepatitis are increased in IKKβ-deficient hepatocytes and are correlated with 
persistent activation of JNK (Maeda et al., 2003). Liver cell death in this model is TNF-
dependent because ConA causes significantly reduced hepatitis in both TNF-R1 and 
TNF-R2-deficient mice (Kusters et al., 1997; Maeda et al., 2003). Therefore, the interplay 
between these different pathways seems to have an important role for the cellular fate and 
the induction of apoptosis upon TNF stimulation. 
An explanation for the pro-apoptotic function of JNK on the molecular level could be 
the finding by Chang et al. that TNF induces proteasomal degradation of the anti-apoptotic 
protein cFLIP in wild-type but not in JNK1-deficient cells (Chang et al., 2006). Prolonged 
activation of JNK1 leads to phosphorylation and activation of the ubiquitin ligase Itch. Once 
activated, Itch promotes ubiquitination and subsequent degradation of cFLIP. Thus, Itch 
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mutant mice, which do not display cFLIP degradation during liver injury, are protected 
against hepatotoxicity induced by ConA, LPS/D-galactosamine (GalN) as well as 
TNF/GalN. In addition, Itch-deficient MEFs showed persistent activation of the 
IKK complex after stimulation with TNF or IL-1β (Chang et al., 2006). This could be due to 
the fact that Itch is also involved in the recruitment of A20 to RIP1 in a TNF-dependent way 
and that Itch is an essential subunit of the A20 ubiquitin-editing complex as removal of Itch 
impaired targeting and inactivation of RIP1 (Shembade et al., 2008). 
Three NF-κB target genes, XIAP, Gadd45β (growth arrest DNA damage-inducible 
gene 45β) and A20, have been described as potential candidates for NF-κB-mediated 
control of TNF-induced JNK activation. The JNK inhibitory effect of Gadd45β results from 
blocking the catalytic activity of the MAP2K MKK7 (Papa et al., 2004a). Besides Gadd45β, 
overexpression of XIAP diminishes JNK activation by TNF in p65-deficient cells (Tang et 
al., 2001). However, a non-redundant JNK-inhibitory role for these proteins remains to be 
proven in genetic knockout models. In addition to its function as a negative regulator for 
NF-κB signalling, A20 overexpression was shown to block TNF-induced JNK activation 
(Lademann et al., 2001).  
Another mechanism important for the pro-apoptotic role of JNK was recently 
discovered through the analysis of mice deficient for the pro-apoptotic BH3-only family 
members Bid and Bim (Kaufmann et al., 2009). Here, JNK contributed to TNF-induced cell 
death in hepatocytes by activating Bim and the combined loss of Bid and Bim protected 
mice from LPS/GalN-induced hepatitis (Kaufmann et al., 2009). 
Despite considerable progress in determining the functional outcome of JNK 
activation in vitro using tumour cell lines (Deng et al., 2003; Verheij et al., 1996), 
fibroblasts (Dietrich et al., 2004; Liu et al., 2004) and cultured hepatocytes (Chang et al., 
2006; Kamata et al., 2005; Maeda et al., 2003; Wang et al., 2006), the exact role of TNF-
stimulated JNK in the regulation of cell survival and/or death in vivo remains controversial 
(Varfolomeev and Ashkenazi, 2004). A recent study by Das et al. analysing JNK1/2-
deficient mice demonstrates that JNK indeed plays a critical role in mouse models of TNF-
dependent hepatitis (Das et al., 2009), which is consistent with other findings (Chang et al., 
2006; Kodama et al., 2009; Maeda et al., 2003; Wang et al., 2006). However, this analysis 
also showed that JNK is not directly required for TNF-mediated hepatocyte apoptosis, but 
instead essential for the expression of TNF by hematopoietic cells, like bone marrow-
Introduction  25  
derived macrophages, Kupffer cells and T cells, causative for the observed development of 
hepatitis in JNK1/2-deficient mice (Das et al., 2009).  
In addition, it is not clear yet, whether the two major, ubiquitously expressed JNK 
isoforms, JNK1 and JNK2, have specialised functions in cell survival, growth and the 
induction of cell death. As partial JNK-deficiency results in adaptation and a gain-of-
function phenotype caused by the remaining JNK isoforms (Jaeschke et al., 2006), further 
studies are required to clarify the specific role of JNK1 and JNK2 in this regard.  
 
2.2.4.5  TNF-mediated formation of death inducing signalling complexes 
Studies from knock-out and mutant mice demonstrate that all death receptors investigated so 
far critically depend on the death domain-containing adaptor protein FADD and caspase-8 
to induce cell death (Varfolomeev et al., 1998; Yeh et al., 1998). It was thought that the 
TRADD-RIP1-TRAF2 complex was required for activation of NF-κB signalling pathways 
upon TNF-R1 stimulation (Baud and Karin, 2001), whereas the interaction between 
TRADD and FADD allows the recruitment and activation of caspase-8 (Hsu et al., 1996b). 
However, this model has been challenged by the discovery that neither FADD nor caspase-8 
could be found in the native TNF-R1 signalling complex (Complex I) formed at the cell 
membrane (Harper et al., 2003; Micheau and Tschopp, 2003). 
In 2003, Micheau and Tschopp provided important insights into the basis for this 
dichotomy of TNF signalling. In addition to the membrane-bound RSC, a second, 
cytoplasmic complex (Complex II) is formed when the intracellular proteins disassemble 
from TNF-R1. The binding of TRADD to TNF-R1 can be substituted by a binding to 
FADD, resulting in the dissociation of Complex I from the cell membrane (Micheau and 
Tschopp, 2003).  
Following the formation of a cytosolic, FADD-containing Complex II, pro-caspase-8 
is recruited and activated by further auto-catalytic processing. Caspase-8 is a member of a 
family of cysteine-dependent, aspartate-specific proteases (caspases). Caspases are 
synthesised as inactive pro-caspases consisting of a pro-domain, a small and a large subunit. 
Upon death receptor engagement, the pro-forms of the initiator caspases 8 and 10 are auto-
catalytically activated, initiating the activation of a caspase cascade. In addition, a second 
pathway is initiated by active caspases 8 and 10 that involves cleavage of Bid into tBid, 
which then translocates to the mitochondria and activates the pro-apoptotic Bcl-2 family 
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members, Bcl2-associated X protein (Bax) and Bcl2 antagonist/killer (Bak). This leads to 
the release of cytochrome c and other pro-apoptotic factors from mitochondria. Once 
cytochrome c is released it binds to Apoptotic protease activating factor 1 (Apaf1), resulting 
in the formation of an intrinsic protein complex, the apoptosome. Caspase-9 is then 
recruited and activated at this protein complex. The amplification of pro-apoptotic 
signalling through mitochondria is essential for the induction of death in certain cell types 
(Falschlehner et al., 2007).  
Subsequently, the activation of initiator caspases results in the cleavage of 
downstream effector caspases, i.e. caspases 3, 6 and 7 (Shi, 2002). Effector caspases then 
process a variety of defined substrates like poly(ADP)-Ribose-Polymerase (PARP), ICAD 
(inhibitor of caspase-activated DNase), gelsolin and lamin (Fischer et al., 2003). The 
proteolysis of effector caspase substrates is responsible for the characteristic morphological 
changes observed in apoptotic cells undergoing programmed cell death. 
The role of RIP1 in the formation of Complex II and the question, whether RIP1 is 
pro-apoptotic or anti-apoptotic has been controversial ever since RIP1 was identified 
(Stanger et al., 1995). Addressing this topic, Wang et al. showed that TNF was able to 
induce apoptosis through two distinct caspase-8 activation pathways that can be 
characterised by their differential dependences on RIP1 (Wang et al., 2008b). Inhibition of 
protein synthesis or knockdown of cFLIP sensitised cells to TNF-induced cell death, a 
process independent of RIP1. Since cFLIP is a prominent NF-κB target gene, this pathway 
is under control of the pro-survival TNF-induced NF-κB activation. In contrast, caspase-8 
activation triggered by Smac mimetic (SM) treatment following TNF stimulation requires 
RIP1 and downregulation of RIP1 by siRNA blocks this form of apoptosis (Wang et al., 
2008b). Due to Smac mimetic-induced cIAP1/2 degradation, RIP1, although recruited to the 
TNF-RSC, is not modified by ubiquitin chains (Haas et al., 2009). Notably, the 
deubiquitinase CYLD was also shown to be required for activation of the RIP1-dependent 
death inducing signalling complex (DISC) (Wang et al., 2008b). Thus, deubiquitination of 
RIP1 seems to be important for the release from the membrane-bound, pro-survival 
Complex I and formation of the cell death-inducing Complex II, capable of recruiting 
FADD and caspase-8. Whether RIP1 deubiquitination occurs before or after its dissociation 
from the receptor, and the exact biochemical mechanism of this dissociation, however, 
remain to be resolved. 
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Several cell lines that cannot initiate or propagate the apoptotic signalling cascade 
upon TNF stimulation die by necrosis, a type of cell death that is typically not associated 
with activation of caspases. It is characterised by cytoplasmic swelling, irreversible plasma 
membrane damage and organelle breakdown and distinguishes itself from apoptosis by its 
proinflammatory effects (Festjens et al., 2006; Fiers et al., 1999). It was recently 
demonstrated that the kinase RIP3, another member of the RIP family, is indispensable for 
TNF-induced necrotic cell death and that RIP1 propagates necrotic signalling through 
association with RIP3 (Cho et al., 2009; He et al., 2009; Zhang et al., 2009). In contrast to 
its adaptor function in TNF-mediated NF-κB activation, an essential role for RIP1 kinase 
activity could be demonstrated for death receptor-induced necrotic signalling (Degterev et 
al., 2005; Holler et al., 2000). In line with this, both RIP1 and RIP3 must be catalytically 
active and interaction via the RIP homotypic interaction motif (RHIM) was shown to be 
essential for the initiation of programmed necrosis in vitro and in vivo (Cho et al., 2009). 
Upon induction of necrosis, RIP3 is recruited to RIP1 to form a necrosis-inducing complex, 
consisting of RIP1 and RIP3, FADD and caspase-8, suggesting a role for RIP3 as a 
molecular switch between apoptosis and necrosis following TNF stimulation. The analysis 
of RIP3-deficient mice, which are protected against acute pancreatitis and exhibited 
severely impaired virus-induced tissue necrosis, inflammation, and control of viral 
replication, indicate relevance for the TNF-induced necrotic pathway in vivo (Cho et al., 
2009; He et al., 2009; Zhang et al., 2009). However, further investigation is required to 
elucidate the mechanistic details underlying the regulation between induction of apoptosis 
or necrosis and to identify further mediators as well as necrosis-associated substrates of 
RIP1 and RIP3 that contribute to the necrotic signalling pathway. 
 
2.3  The ubiquitin system 
Protein phosphorylation and ubiquitination are the two most important forms of post-
translational modification for the initiation and maintenance of TNF-R1 signal transduction 
and during the last decades, many parallels between phosphorylation and ubiquitination 
were revealed. The modification by phosphate groups was first discovered in 1954 when 
G. Burnett and E.P. Kennedy described a liver enzyme that catalysed the phosphorylation of 
casein (Burnett and Kennedy, 1954) and in 1992 the Nobel Prize was awarded to Edmond 
Fischer and Edwin Krebs for their discoveries concerning reversible protein 
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phosphorylation as a biological regulatory mechanism (Cohen, 2002). Phosphorylation can 
regulate protein functions by inducing allosteric conformational transitions, based on the 
changed electrostatic characteristics of the modified protein. In addition, phosphorylated 
serine, tyrosine or threonine residues are recognised by specialised phosphate-binding 
domains (PBDs), enbling specific protein-protein interactions (Pawson and Scott, 2005). In 
mammals, protein phosphorylation is controlled by 518 protein kinases detected so far 
(Manning et al., 2002). As the reversibility of stimulation-induced protein modification is 
essentially required for temporary and transient signal events, the human genome also 
encodes approximately 120 protein phosphatases (Manning et al., 2002). 
By comparison, ubiquitination is performed by two E1 enzymes, 37 E2 enzymes and 
more than 600 E3 ligases in human cells (Deshaies and Joazeiro, 2009; Markson et al., 
2009; Michelle et al., 2009). The E2s often lack substrate specificity and are therefore 
dependent on a very large number of E3s that can bind both the E2 and the substrate protein. 
Similar to phosphorylation, protein ubiquitination is reversible, and approximately 
85 deubiquitinases are encoded in the human genome (Komander et al., 2009a; Reyes-Turcu 
et al., 2009). One of their functions is to create free mono-ubiquitin as ubiquitin itself is not 
expressed as a single molecule but rather as linear ubiquitin polymers encoded by four 
different ubiquitin genes (Komander et al., 2009a). 
Using the pool of free ubiquitin monomers as a substrate, ubiquitination is achieved in 
an ordered multi-step enzymatic process that results in the formation of an isopeptide bond 
between the carboxyl group of the C-terminal glycine of ubiquitin and usually the ε-amino 
group of a target lysine residue. The enzymatic cascade involved in ubiquitination requires 
the concerted action of the E1, E2 and E3 proteins (Ciechanover, 1994; Dikic et al., 2009; 
Hershko and Ciechanover, 1998; Ikeda and Dikic, 2008). In the first step of ubiquitination, 
ubiquitin is activated in an ATP-dependent manner by the formation of a thioester bond 
between the C-terminal carboxyl group of ubiquitin and the catalytically active cysteine 
residue of an E1 enzyme. Subsequently, the ubiquitin moiety is transferred to a catalytically 
active cysteine residue of an E2 enzyme, again via thioester bond formation. The last step of 
protein ubiquitination involves the third class of proteins, the E3 ligases, which facilitate 
formation of an isopeptide bond between the carboxyl-terminal glycine of ubiquitin and 
either the N-terminal amino group or the ε-amino group of a lysine residue of a target 
substrate (Figure 2.5). 
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Figure 2.5: Reaction mechanism for the catalysis of isopeptide bond formation in ubiquitin chain 
synthesis. (A) Ubiquitin (Ub) is first activated by a ubiquitin-activating protein (E1), which couples ATP 
hydrolysis to the formation of a high energy thioester bond between the active-site cysteine of the E1 and the 
carboxyl terminus of ubiquitin. The E1 then transfers the activated ubiquitin to the active-site cysteine of a 
ubiquitin-conjugating enzyme (E2). (B) RING-domain family of E3s facilitate the final step in ubiquitination 
by positioning the E2-ubiquitin conjugate next to the substrate, allowing the ε-amino group of a lysine on the 
substrate to nucleophilically attack the E2-ubiquitin thioester bond, resulting in the formation of an oxyanion 
intermediate (Passmore and Barford, 2004; Pickart and Eddins, 2004; Wu et al., 2003). This reaction depends 
on the deprotonation of the attacking amide group, as well as stabilisation of the negatively charged oxyanion 
by polar and hydrophilic amino acid residue within the E2 and E3 protein. Completion of the reaction results 
in an isopeptide bond between the ubiquitin carboxyl terminus and the substrate lysine (|B denotes a general 
base). 
 
 
Ubiquitin E3 ligases can be classified into three different types, RING (Really 
Interesting New Gene), U-box and HECT (homologous with E6-associated protein C-
terminus), which function as scaffolds to position the substrate protein in close proximity to 
an E2-ubiquitin complex. A catalytic cysteine residue present in the HECT domain usually 
accepts ubiquitin molecules from a cognate E2 enzyme before transferring them to 
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substrates (Scheffner et al., 1993). In contrast, the RING and U-box E3s do not form 
covalent intermediates with ubiquitin. Instead, they mainly function as scaffolds to position 
substrates in close proximity to an E2-ubiquitin covalent complex, which facilitates the 
direct transfer of ubiquitin from E2 enzymes to substrates (Fang and Weissman, 2004; 
Hatakeyama et al., 2001). Under certain circumstances, additional factors such as E4 
ubiquitin elongating factors may be required to further lengthen a ubiquitin oligomer to its 
full length (Hoppe, 2005). 
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Figure 2.6: Different forms of ubiquitination. In principle, ubiquitin modifications can occur in three 
general forms: monoubiquitination, multiple-monoubiquitination and polyubiquitination, all resulting in 
specific fates. Polyubiquitination can be further subdivided into homotypic chains (each ubiquitin chain 
contains only one linkage type) or heterotypic ubiquitin chains (containing either alternating or branched 
linkages types). 
 
Ubiquitination and phosphorylation are employed in a wide range of cellular processes and 
many similarities between phosphorylation and ubiquitination are apparent, e.g. the quantity 
Introduction  31  
of transferases (ligases/kinases) as well as hydrolases (DUBs/phosphatases) and the 
evolutionarily development of specific phosphate- and ubiquitin-binding domains. 
However, due to the ability of ubiquitin to form polymers, ubiquitination has an additional 
layer of complexity (Figure 2.6): target-proteins can be modified by either a single ubiquitin 
(mono-ubiquitination), several single ubiquitin molecules (multiple-mono-ubiquitination) or 
polyubiquitin chains (polyubiquitination) (Fang and Weissman, 2004; Pickart and Eddins, 
2004; Weissman, 2001). 
Besides its role in DNA-damage response (Alpi et al., 2008; Sigismund et al., 2004), it 
could be shown by the group of I. Dikic, that multiple-monoubiquitination of receptor 
tyrosine kinases (RTKs) is an important signal for their endocytosis and lysosomal 
degradation and that monoubiquitination is the principal signal responsible for the 
movement of RTKs from the plasma membrane to the lysosome (Haglund et al., 2003a; 
Haglund et al., 2003b). 
Ubiquitin has seven internal lysine residues (K6, K11, K27, K29, K33, K48 and K63) 
and all seven residues can participate in ubiquitin-ubiquitin bonds, giving potential for 
enormous complexity (Peng et al., 2003). In addition, the α-amino group at the N-terminus 
of ubiquitin proteins can also be used for coupling, resulting in head-to-tail or linearly 
linked ubiquitin chains (Kirisako et al., 2006). During the ubiquitination process, linkage 
specificity is predominantly determined by the E2s (Jin et al., 2008; Kim et al., 2007; 
Kirkpatrick et al., 2006). Finally, recent studies also demonstrate the existence of mixed 
ubiquitin chains that contain more than one type of ubiquitin linkage, caused by alternating 
linkages in a single ubiquitin chain or by branched chains (Figure 2.6), where different 
lysine residues of one ubiquitin unit are extended (Ben-Saadon et al., 2006; Kim et al., 
2007). 
 
2.3.1  Ubiquitin chain structure and ubiquitin receptors 
Depending on the lysine-residue, which serves as acceptor for attachment of further 
ubiquitin molecules, differently linked polyubiquitin chains adopt distinct structures 
resulting in heterogenous recognition patterns. The different polyubiqitin chains can be 
specifically bound by a variety of ubiquitin-binding domains (UBDs) present in receptor 
proteins and thereby enable linkage-specific interactions between ubiquitin chain and 
ubiquitin receptor (Pickart and Fushman, 2004).  
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The eukaryotic genomes encode a large number of proteins bearing UBDs of various 
kinds (Hicke et al., 2005). These include ubiquitin-associated (UBA) domains, ubiquitin-
interacting motifs (UIMs), Gga and Tom1 (GAT) domains, NZFs, coupling of ubiquitin 
conjugation to endoplasmic reticulum (ER) degradation (CUE) domains, ubiquitin-
conjugating enzyme variant (UEV) domains, GRAM-like ubiquitin-binding in Eap45 
(GLUE) domains, VHS (Vps27, HRS, STAM) domains and polyubiquitin-associated zinc 
finger (PAZ) domains (Hicke et al., 2005). UBDs are generally small (20-150 amino acids) 
and most UBDs bind monoubiquitin with weak affinity (KD ~ 10-500 µM), but they usually 
exhibit a much higher affinity towards polyubiquitin chains of a certain linkage type (Hicke 
et al., 2005). One reason for the low-affinity UBD-monoubiquitin interactions might be the 
relatively high concentration of free ubiquitin in cells. Thus, an exposed UBD with high 
affinity would be constitutively occupied with free ubiquitin and unavailable for binding to 
a ubiquitinated partner. In vitro experiments showed that most UBDs in isolation display no 
selectivity for ubiquitin chain linkages (Raasi et al., 2005). However, in cells, non-covalent 
ubiquitin chain binding by UBDs is often influenced by additional domains present in the 
protein or by other subunits within a protein complex that comprises the ubiquitin receptor. 
These additional factors may turn an otherwise promiscuous UBD into a linkage-specific, 
chain-binding domain. All UBDs that have been characterised so far contact a conserved 
hydrophobic interface on ubiquitin that includes Isoleucine 44 (I44) and in some cases 
Leucine 8 (L8) and Glycine 47 (G47) (Hicke et al., 2005). In addition, all of the described 
interactions between ubiquitin and the cellular E1, E2 and E3 conjugation system as well as 
ubiquitin-interactions with different DUB enzymes also use the I44 surface of ubiquitin 
(Hamilton et al., 2001; Hu et al., 2002; Johnston et al., 1999; Walden et al., 2003). The 
relative position of the I44 surfaces of adjacent ubiquitins within a chain is therefore 
decisive for its specific recognition by ubiquitin receptors. 
Structurally, K63-linked ubiquitin chains are much more elongated than K48 ubiquitin 
chains leading to distinguishable intersubunit interfaces of K63-linked polyubiquitin chains 
compared to K48-linked chains (Tenno et al., 2004; Varadan et al., 2004). Regarding K48-
linked ubiquitin chains, the I44 patches of two ubiquitin units interact due to their 
hydrophobic nature, and the linking residues are closely packed against the ubiquitin 
moieties. This creates unique modules composed of aligned ubiquitin moieties which form a 
pseudo-tetragonal structure, resulting in a more rigid conformation. In contrast, K63-linked 
chains are extended and adopt an open configuration, with no direct contact surfaces 
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between the neighboring ubiquitin subunits and therefore freely accessible I44 patches 
(Cook et al., 1994; Eddins et al., 2007; Phillips et al., 2001). 
The molecular mechanism for the distinguishable overall structure of the different 
ubiquitin chains is based on the geometrical arrangement of the seven lysine residues. All 
these lysines are positioned at different surfaces of the ubiquitin molecule, pointing in 
different directions (Figure 2.7). An important exception is the N-terminal amino group of 
methionine 1 (M1), which is located close to K63. Thus, linear chains display an equivalent 
conformation to K63-linked ubiquitin chains. However, the chemical environment of the 
isopeptide linkage in K63-linked ubiquitin chains differs significantly from the peptide bond 
between G76 and M1 in linear chain. Due to the connecting peptide bond, linear chains are 
conformationally restrained compared to more flexible isopeptide linkage of lysine-linked 
chains (Komander et al., 2009b). 
Comparison of the crystal structures of K63-linked or linear diubiquitin in complex 
with their UBDs provided interesting new insights regarding binding specificity. Human 
Rap80 contains tandem UIM motifs, which are separated by a linker of conserved length, so 
that simultaneous, high-affinity interactions are ideal with K63-linked ubiquitin chains, but 
unfavourable or impossible with other polyubiquitin topologies or mono-ubiquitin (Sato et 
al., 2009; Sims and Cohen, 2009). Different linker length may therefore control selectivity 
for other ubiquitin chain types, suggesting a general principal for polyubiquitin linkage 
selectivity and affinity. On the other hand, UBAN (ubiquitin-binding domains found in 
ABINs and NEMO) domains display a greater affinity to linear chains than to K63-linked 
chains (Komander et al., 2009b; Lo et al., 2009; Rahighi et al., 2009). Crystal structures 
revealed that the UBAN motif forms a parallel coiled-coil dimer which assembles a 
heterotetrameric complex with two linear diubiquitin molecules. Importantly, the 
methionine-glycine linkage site of the linear ubiquitin chain interacts directly with the large 
surface on the UBAN domains in the NEMO dimer, resulting in high specificity for linear 
chains (Rahighi et al., 2009). 
Consistently, sterical differences in the ubiquitin chain structure translate into distinct 
functions as ubiquitinated proteins are linked to different cellular signalling processes via 
their respective ubiquitin receptors. 
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2.3.2  Physiological roles for protein ubiquitination 
Ubiquitinated substrates may be sorted into different pathways based on the distinguishable 
polyubiquitin structures (Pickart and Fushman, 2004). Historically, the best studied 
ubiquitin chain types are K48- and K63-linked chains. Whereas K48-linked polyubiquitin 
chains serve as a signal for proteasomal degradation (Finley, 2009; Thrower et al., 2000), 
K63-linked polyubiquitin chains rather seem to function as scaffolds for the recruitment of 
other signalling proteins upon cytokine stimulation in the context of signal-transduction and 
are involved in a range of other non-degradative processes, including protein trafficking and 
DNA repair (Figure 2.7 and (Chen and Sun, 2009; Hoeller et al., 2006)).  
 
 
 
Figure 2.7: The linkage type of a polyubiquitin chains is crucial for its specific function. The three-
dimensional layout of ubiquitin demonstrates that all seven lysine residues are located on different surfaces of 
the molecule. By elongating a ubiquitin chain using either one of the different lysine residues or the 
N-terminus of the substrate ubiquitin, distinct target fates can be achieved (as indicated). Notably, M1, which 
is essential for generating linear chains, is spatially close to K63. Red numbers in parentheses refer to the 
relative abundance of the particular linkage in S. cerevisiae (Xu et al., 2009b) and all lysine residues are 
labelled (modified from (Komander, 2009)). 
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Recently, the level of polyubiquitin linkages was analysed by mass spectrometry in yeast 
cell lysates. Strikingly, polyubiquitin chains, other than K48- and K63-linked polymers, 
account for more than 50 % of the conjugated ubiquitin pool (Xu et al., 2009b). Based on 
the absolute quantification of all seven linkages, the percent abundance of individual 
linkages is: K6 (11 %), K11 (28 %), K27 (9 %) K29 (3 %), K33 (3 %) K48 (29 %) and K63 
(17 %). The same study also indicated that protein modification by the unconventional K6-, 
K11-, K27-, K29-, K33-linked ubiquitin chains are mainly involved in promoting target 
protein degradation through recognition by the 26S proteasome, and thus, all chain types, 
except for K63-linked polymers, accumulated in yeast cells when the proteasome was 
inhibited (Xu et al., 2009b). However, the roles of these atypical types of ubiquitin chains in 
biological processes are not well understood, in spite of a few intriguing observations:  
K6 linkages, which are catalysed by the heterodimeric RING E3 ligase complex 
BRCA1/BARD1 might regulate DNA repair (Nishikawa et al., 2004).  
K11 linkages were suggested to act as efficient proteasomal targeting signals in vitro 
and in vivo for certain protein targets (Baboshina and Haas, 1996; Jin et al., 2008; Kim et 
al., 2007; Kirkpatrick et al., 2006). For instance, K11-linked chains have been implicated in 
the degradation of misfolded ER proteins (ER-associated degradation or ERAD) (Xu et al., 
2009b). In addition, recent studies by Jin et al. and Matsumoto et al. showed that the human 
Anaphase-Promoting Complex (APC/C) together with the E2 UbcH10 preferentially 
function by assembling K11-linked chains. As APC/C orchestrates progression through 
mitosis by decorating cell cycle regulators with ubiquitin chains, this finding suggests a role 
for K11-linked ubiquitin chains in cell cycle regulation (Jin et al., 2008; Matsumoto et al., 
2010). 
Both K27 and K33 linkages may be assembled by U-box-type E3 ligases during stress 
responses (Hatakeyama et al., 2001). Interestingly, two AMPK (AMP-activated protein 
kinase)-related kinases may be modified with K29- and/or K33-linked polyubiquitin chains 
in cells. Such modification was shown to inhibit the enzymatic activity of these kinases, 
revealing a regulatory role of ubiquitin modification for AMPK family kinases activation 
(Al-Hakim et al., 2008). Furthermore, a recent report suggested that the two E3 ligases Cbl-
b and Itch cooperate to induce K33-linked ubiquitination of the T cell receptor-ζ (TCR-ζ) 
chain, which affects its phosphorylation status and association with the zeta-chain 
associated protein of 70 kDa (Zap-70) in a proteolysis-independent manner (Huang et al., 
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2010). This indicates a role for K33 polyubiquitination of cell surface receptors in 
regulating T cell activation (Huang et al., 2010). Finally, K29-linked chains may participate 
in lysosomal rather than proteasomal degradation pathways (Johnson et al., 1995). 
As both phosphorylation and ubiquitination are involved in regulation of the same 
signalling pathways, crosstalk between these reversible posttranslational modifications 
occurs at several levels. Phosphorylation can promote or inhibit ubiquitination, which in 
turn can lead to proteasomal degradation (e.g. IκBα), protein processing (e.g. 
NF-κB2/p100) or regulate intracellular trafficking of membrane proteins (e.g. EGF-R). In 
many cases, previous phosphorylation of certain target proteins is required for the 
subsequent proteasomal degradation mediated by K48-linked ubiquitin chains. Several 
serine/threonine phosphorylated proteins are for example recognised by members of the 
Skp1/cullin/F-box (SCF) family of E3 ligases, which contain phosphopeptide-binding 
domain proteins as substrate binding adaptors (Cardozo and Pagano, 2004). 
Phosphorylation can also positively or negatively regulate the activity of E3 ligases 
responsible for ubiquitin transfer. IL-1R-associated kinase 1 and 4 (IRAK1 and IRAK4) are 
shown to phosphorylate several Pellino isoforms upon cytokine stimulation, resulting in 
enhanced E3 ubiquitin ligase activity of Pellino. In turn, Pellino can ubiquitinate IRAK 
kinases with K63-linked ubiquitin chains, an important initial event in Toll-like receptor 
(TLR) and IL-1 signalling (Ordureau et al., 2008). In addition, protein kinases are subject to 
ubiquitin-dependent degradation or activation. For instance, stress-induced activation of the 
ERK1/2 MAP kinases can be downregulated by ubiquitin-mediated degradation of ERK1/2. 
This process is mediated by MEKK1, which exhibited E3 ubiquitin ligase activity toward 
ERK1/2 in addition to its kinase function (Lu et al., 2002). Furthermore, the kinase activity 
of TAK1 was also shown to be regulated in a ubiquitin-dependent manner (Chen et al., 
2006; Wang et al., 2001). 
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3  Aims and Objectives 
TNF-induced trimerisation of TNF-R1 on target cells leads to the recruitment of different 
cytosolic proteins, resulting in the formation of a multi-protein complex, the TNF-RSC. 
Consequently, a complex network of downstream signalling pathways, emanating from the 
TNF-RSC, is activated. Therefore, the elucidation of the biochemical composition of the 
TNF-RSC as well as the functional interplay between the TNF-RSC constituents is crucial 
for the understanding of TNF-induced signalling events and their diverse biological 
outcomes. 
Purification of the TNF-RSC by a modified tandem affinity purification technique and 
subsequent mass spectrometric analysis led to the previous identification of the RING 
domain-containing proteins HOIL-1 and HOIP as two novel components of this complex.  
 
Based on this finding, the aims of this thesis are: 
 
1. Defining the mechanism of how the two novel components are recruited to the TNF-RSC 
by using different MEF cell lines, which are deficient for one of the main components of the 
TNF-RSC.  
 
2. Functional characterisation of HOIL-1 and HOIP as E3 ubiquitin ligases in the context of 
ubiquitin chain linkage type and substrate protein specificity. 
 
3. Investigating the role of HOIL-1 and HOIP within TNF-mediated signal transduction 
pathways by analysing NF-κB and JNK activation upon TNF stimulation as well as TNF-
induced gene and cell death induction in the presence or absence of HOIL-1/HOIP. 
 
4. Investigating whether absence of HOIL-1/HOIP affects the composition and functionality 
of the TNF-RSC. 
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4  Materials and Methods 
4.1  Materials 
4.1.1  Chemicals and reagents 
All chemicals and biologically reactive reagents were purchased from Roth, Sigma/Aldrich 
(Fluka), Merck (Calbiochem), Invitrogen (Gibco; Molecular Probes), AppliChem, Pierce, 
Honeywell (Riedel-de Häen) or Amersham Biosciences. All chemicals were purchased in 
pA quality unless indicated otherwise. 
 
4.1.2  Specific inhibitors 
Tabelle 4.1: Specific inhibitors 
Inhibitor Source 
AEBSF Sigma 
Aprotinin Sigma 
Complete Protease Inhibitor 
Cocktail Roche 
E-64 Sigma 
Gö6983 Merck (Calbiochem) 
Leupeptin Sigma 
Pepstatin Sigma 
zVAD-fmk Axxora 
 
4.1.3  Buffers and solutions 
Bacteria lysis buffer                   1 x PBS 
                                70 µM AEBSF 
                                5 µM E-64 
                                1.2 µg/mL Aprotinin 
                                1 µM Pepstatin 
                                1 mM DTT 
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Blocking buffer  (western blotting)         1 x PBS 
5 % milk powder (w/v) 
                                0.05 % Tween-20 (v/v) 
 
Citrate buffer                       0.025 M citric acid (pH = 4.5) 
 
Crystal violet solution                 1 % Crystal violet (w/v) 
                                50 % Ethanol (v/v) 
 
ELISA assay buffer                   1 x PBS 
0.5 % BSA (w/v) 
                                0.05 % Tween-20 (v/v)  
 
FACS buffer                        1 x PBS 
5 % FCS (v/v) 
                                0.05 % NaN3 (w/v) 
 
Freezing medium                    90 % FCS (v/v) 
10 % DMSO (v/v) 
 
GST-elution buffer                   1 x PBS 
                                50 mM reduced glutathione 
 
2 x HBS (pH = 7.0)                   50 mM HEPES 
                                280 mM NaCl 
                                1.5 mM Na2HPO4 x 2 H2O 
 
IP-lysis buffer                       30 mM Trizma Base (pH 7.4) 
(+ Complete Protease Inhibitor cocktail)     120 mM NaCl 
                                2 mM EDTA 
                                2 mM KCl 
                                10 % Glycerol (v/v) 
                                1 % Triton X-100 (v/v) 
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Luciferase assay buffer A (pH = 7.8)       20 mM HEPES 
                                33.3 mM DTT 
                                8.0 mM MgCl2 
                                130 µM EDTA 
                                530 µM ATP 
                                470 µM Luciferin 
                                270 µM Coenzyme A 
 
Luciferase assay buffer B (pH = 5.0)        15 mM Na4P2O7 
                                7.5 mM NaOAc 
                                400 mM NaSO4 
                               10 mM CDTA 
                                25 µM APMBT 
                                1 % Methanol (v/v) 
                                2 µM Benzyl-Coelenterazin 
 
Maintenance buffer                   50 mM Trizma Base 
                                100 mM NaCl 
                                0.02 % Tween 20 (v/v) 
                                2 mM DTT 
                                0.5 M L-Arginine 
 
MES running buffer (pH = 7.7)           50 mM MES 
                                50 mM Trizma Base 
                                3.5 mM SDS 
                                1 mM EDTA 
 
MOPS running buffer (pH = 7.7)          50 mM MOPS 
                                50 mM Trizma Base                
                                3.5 mM SDS 
                                1 mM EDTA 
 
MTT solution                       2.5 mg/mL in PBS 
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Nicoletti buffer                      0.1 % Sodiumcitrate (w/v) 
                                0.1 % Triton X-100 (v/v) 
                                50 µg/mL Propidiumiodid 
 
PBS (pH = 7.4)                      137 mM NaCl 
                                8.1 mM Na2HPO4 
                                2.7 mM KCl 
                                1.5 mM KH2PO4 
 
Pull-down buffer                     150 mM NaCl 
50 mM Trizma Base (pH 7.5) 
5 mM DTT 
0.1 % NP-40 (v/v) 
 
Stripping buffer (pH = 2.3)              50 mM Glycine 
 
TAE buffer (10x)                    400 mM Tris/HCl 
                                200 mM Acetic Acid 
                                10 mM EDTA 
 
TB buffer                          10 mM Pipes 
                                55 mM MnCl2 
                                15 mM CaCl2 
                                250 mM KCl 
 
Transfer buffer                      192 mM Glycine 
                                25 mM Trizma Base 
                                0.01 % EDTA (w/v) 
                                20 % Methanol (v/v) 
 
Ubiquitination buffer                  20 mM Trizma Base (pH = 7.5) 
                                5 mM MgCl2 
                                2 mM Dithiothreitol (DTT) 
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Wash buffer (western blotting)           1 x PBS 
0.05 % Tween-20 (v/v) 
 
4.1.4  Antibodies 
Table 4.2: Primary antibodies (WB: western blotting; IP: immunoprecipitation; FACS: fluorescence activated 
cell sorting) 
Antibody Isotype Source Application 
anti-Actin (A5441) mIgG1 Sigma WB 
anti-Bid (#2002) rabbit Cell Signaling WB 
anti-Caspase 7 (#551237) mIgG1 BD Biosciences WB 
anti-Caspase 8 (ALX-804-429) mIgG2b Axxora life sciences WB 
anti-cIAP1 rat John Silke WB 
anti-cIAP Pan (MAB3400) mIgG2a R&D Systems WB 
anti-FLAG (M2) mIgG1 Sigma WB, IP 
anti-HA (3F10) mIgG1 Roche Applied Science WB, IP 
anti-His (BMG-His-1) mIgG1 Roche Applied Science WB, IP 
anti-IκBα (C-15) mIgG1 Santa Cruz WB 
anti-IKKα (B8) mIgG2b Santa Cruz WB 
anti-NEMO (FL419) rabbit Santa Cruz IP 
anti-NEMO (B3) mIgG1 Santa Cruz WB 
anti-PARP (C-2-10) mIgG1 Biomol WB 
anti-p-IkBα (5A5) mIgG1 Cell Signaling WB 
anti-RIP1 (#610459) mIgG2a BD Biosciences WB 
anti-TAK1 (#4505) rabbit Cell Signaling WB 
anti-TNF-R1 (H-5) mIgG2b Santa Cruz WB 
anti-TNF-R1 (ab19139) rabbit abcam WB 
anti-TNF-R1 (MABTNFR1-B1) mIgG2a Pharmingen FACS 
anti-TNF-R2 (hTNFR-M1) rIgG2a Pharmingen FACS 
anti-TRADD (clone 37) mIgG1 BD Biosciences WB 
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anti-TRADD (H-278) rabbit Santa Cruz WB 
anti-TRAF2 (C-20) rabbit Santa Cruz WB 
anti-TRAF2 (AP1040) rabbit Calbiochem WB 
anti-Ubiquitin (FK1) mIgM Biomol WB 
anti-Ubiquitin (FK2) mIgG1 Biomol WB 
anti-Ubiquitin (#07-375) rabbit Millipore WB 
anti-Ubiquitin (HWA4C4) 
(K63-linkage-specific) mIgG2a Biomol WB 
anti-V5 (V5-10) mIgG1 Sigma WB, IP 
 
Table 4.3: Secondary antibodies 
Antibody Source 
Goat-anti-mIgG1-HRP SouthernBiotech 
Goat-anti-mIgG2a-HRP SouthernBiotech 
Goat-anti-mIgG2b-HRP SouthernBiotech 
Goat-anti-mIgM-HRP SouthernBiotech 
Goat-anti-rat-HRP SouthernBiotech 
Rabbit-anti-goat-IgG-HRP Santa Cruz 
Goat-anti-rabbit-IgG-HRP SouthernBiotech 
 
4.1.5  Commercial detection and isolation systems (kits) 
Table 4.4: Commercial detection and isolation systems 
Kit Source 
BCA Protein Assay Pierce 
ECL Western Blotting Detection GE Healthcare 
ECL Western Blotting Detection Plus GE Healthcare 
Chemoluminescent Substrate 
SuperSignal West Dura Pierce 
Chemoluminescent Substrate 
SuperSignal West FEMTO Pierce 
Coomassie Protein Assay Pierce 
Materials and Methods  44  
IL-8 ELISA (CytoSet) BioSource 
Non radioactive JNK-Actvity Assay Cell Signalling 
QIAprep Spin Mini Kit Qiagen 
QIAprep Maxi Kit Qiagen 
QIAquick Gel Extraction kit Qiagen 
RevertAidTM H Minus first strand 
cDNA synthesis kit Fermentas 
TNT Quick coupled 
Transcription/Translation System Promega 
pcDNA3.1V5/His TOPO Directional 
Expression kit Invitrogen 
SuperScript III Reverse Transcriptase  Invitrogen 
 
4.1.6  Instruments 
Table 4.5: Instruments 
Instrument Source 
Biofuge Stratos Heraeus 
Blotting equipment X cell IITM Novex 
Electrophoresis chamber Biorad 
Flow Cytometer FACSCalibur Becton Dickinson 
GelSystem Flexi 4040 Biostep 
Hyper Processor X-Ray film Developer Amersham Bioscience 
Incubator Stericult 200 Forma Scientific 
Microscope Axiovant 25 Zeiss 
Mithras Luminometer LB 940 Berthold Technologies 
Multifuge 3S-R Heraeus 
Multiskan Ascent Thermo Labsystems 
Multitron Incubator Shaker Appropriate Technical Resources 
NanoDrop Spectrophotometer ND-1000 NanoDrop Technologies 
Photometer Ultrospec 3100 pro Amersham Bioscience 
Sonifier Branson Ultrasonics Corporation 
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4.1.7  Bacteria strains 
Table 4.6: Bacteria strains 
Strain Genotype Application 
Top10F’ 
F'[lacIq Tn10(tetR)] mcrA ∆(mrr-hsdRMS-
mcrBC) φ80lacZ∆M15 ∆lacX74 deoR nupG 
recA1 araD139 ∆(araleu) 7697 galU galK 
rpsL(StrR) endA1 λ- 
plasmid amplification 
BL21(DE3) F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) expression of GST fusion proteins 
 
4.1.8  Additional materials 
Table 4.7: Additional materials 
Material Source 
Dialysis Membrane 
12,000-14,000 MWCO KMF 
GSTrap FF Amersham Pharmacia 
HisTrap FF Amersham Pharmacia 
Hybond ECL Nitrocellulose Membrane Amersham Bioscience 
NuPAGE SDS-Gels Invitrogen 
SDS-Sample buffer Invitrogen 
SeeBlueTM Plus2 Pre-Stained Standards Novex 
SmartLadder DNA Standards Eurogentec 
Sterile filter (0.22 µm and 0,45 µm pore 
size) Millipore 
Tissue culture equipment TPP 
X-Ray film HyperfilmTM ECL Amersham Bioscience 
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4.2  Cell biological methods 
4.2.1  Cell lines 
4.2.1.1  HEK293T 
HEK293T cells were generated by transformation of human embryonic kidney (HEK) cell 
cultures with sheared adenovirus 5 DNA (Graham et al., 1977). HEK293T cells are highly 
transfectable due to expression of the SV40 large T-antigen and support the 
extrachromosomal replication of plasmids, which bear the SV40 origin of replication. 
 
4.2.1.2  HEK293-NFκB 
HEK293-NFκB cells were purchased from Panomics (Fremont, USA). The 293-NFκB cell 
line is designed for monitoring the activity of NF-κB transcription factor in cell-based 
assays. The cell line was obtained by cotransfection of a luciferase reporter construct and a 
hygromycin selection marker into HEK293 cells, followed by hygromycin selection. TNF-
induced luciferase activity was used to select clones from the hygromycin-resistant cells. 
These cells maintain a chromosomal integration of a luciferase reporter construct regulated 
by multiple copies of the NF-κB response element. 
 
4.2.1.3  HeLa 
The HeLa cell line was isolated from an adenocarcinoma of the cervix in 1952 and was the 
first human epithelial cancer cell line established in long-term cell culture (Scherer et al., 
1953). The cells have a hypertriploid chromosome number (3n+), specific numerical 
deviations, 20 clonally abnormal chromosomes and contain multiple copies of the HPV type 
18 (HPV18), integrated at specific sites (Chen, 1988; Popescu et al., 1987). 
 
4.2.1.4  MCF-7 
The human breast carcinoma cell line MCF-7 was first described in 1973 by Brooks and 
colleagues (Brooks et al., 1973). 
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4.2.1.5  U937 
The human hematopoietic cell line U937 was derived from a patient with generalised 
histiocytic lymphoma and first described in 1976 by Sundstrom and Nilsson (Sundstrom and 
Nilsson, 1976). 
 
4.2.1.6  THP-1 
The human cell line THP-1 is a leukaemia cell line with distinct monocytic markers and was 
established by Tsuchiya and colleagues in 1980 (Tsuchiya et al., 1980).  
 
4.2.1.7  Mouse Embryonic Fibroblasts (MEFs) 
Wt and knockout MEFs were generated from E15 embryos in accordance with standard 
procedures and were infected with SV40 large T antigen-expressing lentivirus. TRADD- 
and NEMO-deficient MEF cells were described previously (Ermolaeva et al., 2008; 
Schmidt-Supprian et al., 2000). 
 
4.2.2  Cell culturing conditions 
All adherent cell lines were cultured in a 10 % CO2 humidified atmosphere at 37 °C. MEFs, 
HeLa and HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % fetal bovine serum. MCF-7 cells were cultured in 
DMEM containing 10 % fetal bovine serum, 1 % pyruvate and 0.1 % human insulin. These 
adherent growing cells were split using a 1 x Trypsin/EDTA solution.  
U937 and THP-1 cells were maintained in RPMI supplemented with 10 % FBS at 5 % CO2 
(37 °C). Cell density was determined with a Neubauer chamber slide. Cells were centrifuged 
with a refrigerated centrifuge (Heraeus Multifuge 3 S-R) for 4 min at 300 x g and 4 °C. 
 
4.2.3  Freezing and thawing of eukaryotic cells 
For freezing, cells were harvested and resuspended in freezing medium. The cell density 
was adjusted to 1-1.5 x 106 cells/mL. Cells were kept for long-term storage in liquid 
nitrogen at -196 ºC. 
Cells were thawed rapidly to 37 °C and immediately transferred into prewarmed cell culture 
medium. After cell attachment, the medium was replaced by prewarmed fresh medium. 
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4.2.4  Transfection of adherent cells 
MCF-7 and HeLa cells were transfected with FuGene 6 (Roche Applied Science) according 
to the manufacturer’s protocol. 
HEK293T cells were transfected by the calcium phosphate method. For this purpose, 
450 µL H2O were added to a solution of plasmid DNA and 50 µL CaCl2 (2 M). While 
gently mixing, 500 µL HBS (2x) were added slowly to the DNA/ CaCl2 solution. After 
30 min incubation at room temperature, the tranfection mixture was added dropwise to the 
cell medium. 14-16 hs later, the cells were scraped off the cell culture dish and lysed in 
1 mL IP-lysis buffer.  
For transient knock down experiments siRNA smartpools targeting HOIL-1 and HOIP 
were purchased from Dharmacon (Thermo Fisher) and transfected using Dharmafect I 
(Thermo Fisher) according to the manufacturer’s protocol. 
 
4.2.5  Lentiviral infection of eukaryotic cells 
4.2.5.1  Production of recombinant viruses 
HEK293T cells were used as packaging cell line for the production of recombinant, 
lentiviral particles. These viruses were then used for the stable transduction of HeLa, THP-1 
or MCF-7 cells. HEK293T cells were split to about 50-60 % confluency prior to calcium 
phosphate transfection. The transfection mixture containing 28 µg pCMV-dR8.91 
(HIV_Gag, HIV_Rev, packaging vector), 12 µg pMD2G (VSVG, envelope vector) and 
40 µg pLKO.1 (shRNA-constructs) or pCIGW (expression constructs) were added dropwise 
to the cells. After 48 hs incubation at 37 °C, the retrovirus containing cell supernatant was 
used for transduction. 
 
4.2.5.2  Generation of stable HOIL-1/HOIP knockdown cells 
To generate THP-1, HeLa and MCF-7 cells in which the HOIL-1 expression level was 
stably reduced, pLKO.1 vectors encoding different HOIL-1-specific sh-RNAs were 
obtained from the RNAi consortium (TRC). In this study, the vectors TRCN0000007599 
(HOIL-1 shRNA, 5'-CCACAACACTCATCTGTCAAA-3´) and RHS4080 (ctr shRNA) 
were used. For the generation of stable HeLa HOIP knockdown cells, the U1 promotor and 
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the shRNA coding sequence (5'-AGACAAGGTTGAAGATGATAT-3´) from the 
pGeneClip vector (SABiosciences) was cloned into pTWEEN-GFP (Ricci-Vitiani et al., 
2004). Lentiviral particles were produced as described before (Section 4.2.6.1). Cells were 
spin-infected in the presence of 5 µg/mL polybrene (2000 x g for 4 hs at RT) and selected 
with puromycin (2.5 µg/mL) for 5 days. Knockdown efficiency was controlled by qPCR and 
western blotting. 
 
4.2.5.3  Generation of stable HOIL-1/HOIP-overexpressing cells 
For stable overexpression of HOIP, HOIL-1 and different mutants of both proteins, the 
respective cDNAs were cloned into the lentiviral pLV vector or pCIGW vector (Wenger et 
al., 2006), respectively. The cells were infected in the presence of 5 µg/mL polybrene by 
spin-infection (2000 x g for 4 hs at RT) and selected by puromycin treatment (2.5 µg/mL) 
for 5 days (Zufferey et al., 1998; Zufferey et al., 1997). For subcloning of the heterogenous 
cell populations the cell density was adjusted to 2.5 cells/mL and the cell suspension was 
spread on 96-well plates in aliquots of 0.2 mL. Single clones became visible after 5-10 days 
and were transferred to a 24-well plate. The expression efficiency was controlled by western 
blot analysis. For the coexpression of HOIP and HOIL-1, MCF-7 HOIL-1 or HeLa HOIL-1 
cells were used as parental cell line, respectively. 
 
4.2.6  Inducible Protein Expression 
cIAP1/2-deficient MEFs were infected using an inducible lentiviral system as described 
before to generate stable cell lines expressing wt mouse cIAP1 and F610A mouse cIAP1 
mutant under the control of 4-hydroxy-tamoxifen (4-HT). These cells were kindly provided 
by John Silke (Mace et al., 2008). Expression of wt and F610A mouse cIAP1 was induced 
by the addition of 4-HT (20 nM) for 20 hs. Induction of wt mouse TRAF2 or mouse TRAF2 
mutants in TRAF2/5-deficient MEFs was performed as described for cIAP1. 
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4.2.7  Treatment with Smac mimetics  
SM-164 (Smac059) was synthesised and kindly provided by Pierfausto Seneci and 
Leonardo Manzoni (Cossu et al., 2009). Before TNF stimulation, cells were pretreated with 
SM-164 (100 nM in cell culture medium) for 2 hs at 37 °C. 
 
4.3  Methods in Molecular Biology 
4.3.1  DNA digestion and restriction analysis 
For the sequence-specific cleavage of DNA molecules the samples were incubated with 
restriction endonucleases (Fermentas FastDigest®) for 1-2 hs at 37 °C.  
 
4.3.2  Agarose gel electrophoresis of nucleic acids 
For the analysis of Plasmid DNA or DNA fragments, DNA molecules were resolved by 
agarose gel electrophoresis. Gels were prepared by dissolving 0.8-2 % agarose (w/v) in TAE 
buffer. The electrophoresis was performed in a gel chamber filled with TAE buffer at 
10 Volts per cm of electrodal distance. After electrophoretic separation the gel was 
incubated for 30 min in TAE buffer + ethidium bromide (0.5 µg/mL) and DNA fragments 
were visualised by UV light (λ = 254 nm). 
 
4.3.3  Gel extraction of DNA fragments 
Isolation of DNA fragments from agarose gels was achieved with the QIAquick Gel 
Extraction kit (Qiagen) according to manufacturer’s instructions. DNA was eluted with an 
appropriate volume of ddH2O or 10 mM Tris/HCl, pH 8.0. 
 
4.3.4  Ligation of DNA fragments 
T4 DNA ligase (NEB) was used for ligation of linearised vectors and DNA fragments 
encoding proteins (inserts). For ligations of cohesive ends a molar ratio of 1:3 
(vector : insert DNA) and for ligations of blunt ends a molar ratio of 1:5 was chosen. The 
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ligation reaction was carried out in 10 µL total volume containing 1 µL T4 DNA ligase and 
1 µL 10x Ligase buffer (NEB). The reaction volume was brought up to 10 µL with ddH2O. 
Ligation reactions were incubated at room temperature for 2 hs and used directly for the 
transformation of competent bacteria. 
 
4.3.5  Generation of transformation competent E. coli bacteria 
To generate E. coli that are chemically competent for transformation of ligation reactions or 
plasmids, E. coli Top10F´ bacteria (Invitrogen) were grown in 5 mL Lysogeny Broth (LB) 
medium overnight at 37 ºC and then used to inoculate 250 mL of LB medium. This culture 
was grown until an OD600 value of 0.5 was reached. The bacteria suspension was incubated 
on ice for 10 min and then harvested at 3000 rpm at 4 °C for 10 min. The supernatant was 
removed and the bacteria were resuspended with in 80 mL ice-cold TB buffer. After 10 min 
incubation on ice, the bacteria were centrifuged and resuspended in 10 mL ice-cold 
TB buffer. DMSO was added to a final concentration of 7 %. The competent bacteria were 
flash frozen in liquid nitrogen and stored at -80 °C. 
 
4.3.6  Transformation of competent E. coli bacteria 
Competent bacteria were thawed on ice and an appropriate amount of plasmid DNA or 5 µL 
of a ligation reaction were added to the bacteria followed by incubation on ice for 30 min. 
Afterwards, a heat-shock step was performed at 42 ºC for 42 sec and the bacteria were 
subsequently cooled on ice for 3 min. 200 µL SOC medium were added and the bacteria 
suspension was incubated at 37 ºC for 60 min. Afterwards, bacteria were spread onto LB 
plates containing the respective antibiotic and selected overnight at 37 ºC.  
 
4.3.7  Isolation of Plasmid-DNA 
For the analytical plasmid isolation 5 mL LB medium (+ antibiotic) were inoculated with a 
single bacterial colony and incubated at 37 °C overnight. Next, the plasmid DNA was 
isolated using the QIAprep Spin Mini Kit (Qiagen) as per manufacturer’s instructions. For 
the production of larger amounts of plasmid DNA, 400-500 mL LB medium, supplemented 
with an appropriate antibiotic, were inoculated and the culture was grown at 37 °C in a 
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shaker (200 rpm) overnight. The preparation of plasmid DNA was carried out with the 
QIAprep Spin Maxi Kit (Qiagen) as per manufacturer’s protocol. 
 
4.3.8  Polymerase Chain Reaction (PCR) 
All PCRs were set up in a volume of 50 µL, containing 1-50 ng plasmid-DNA as template. 
The synthetic oligonucleotides were designed with 40-60 % GC content, no internal 
structure or complementarity at the 3’-ends. The final primer concentration was 0.4 µM. 
Annealing temperatures were chosen ~5-10 °C lower than the melting temperature Tm. The 
final concentration of each dNTP was 200 µM. All DNA polymerases were used with 
supplied buffers. The PCR reactions were prepared on ice and immediately put into the 
95 °C heating block (pseudo hot start). 
 
4.3.9  Site-directed Mutagenesis 
For plasmid amplification by PCR, adequate primers containing the point mutation were 
designed. These oligonucleotides contained the desired mutation (substitution, deletion or 
insertion) with ~10-15 bases of correct sequence on both sides. Following PCR, the PCR 
product was treated with Dpn I endonuclease for 1 hr at room temperature. The linearised, 
mutated plasmid was then transformed into competent bacteria (Section 4.3.6).  
 
4.3.10  Quantitative PCR 
4.3.10.1  RNA purification 
Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s 
instructions. Trizol was removed by addition of 0.2 mL chloroform followed by isopropanol 
precipitation. The concentration and purity of RNA was determined with a ND-1000 
Spectrophotometer (NanoDrop). 
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4.3.10.2  cDNA preparation 
A reverse transcription was performed on 5 µg total RNA for 1 h at 42 °C using the 
RevertAidTM H Minus first strand cDNA synthesis kit (Fermentas) according to the 
manufacturer’s instructions. 
 
4.4.10.3  Quantitative Real-time PCR 
Quantitative Real-time PCR was performed with the ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems) using the ABsoluteTM QPCR ROX Mix (ABgene). 
The ProbeFinder software (Roche) was used to design the optimal assay, comprising the 
respective labelled probe of the Universal ProbeLibrary (Roche) and gene-specific primers. 
For the RT-PCR reaction, cDNA (Section 4.3.10.2) was diluted 1:10. Amplification was 
carried out in stages of incubation at 95 °C for 15 min following 40 cycles of 95 °C for 15 s 
and 60 °C for 60 s. The mRNA levels were measured as double determinations and 
normalised with reference to the amount of housekeeping gene transcripts (GAPDH or 
HPRT1). The following gene-specific primers were used: cagcctcttctccttcctgat and 
gccagagggctgattagaga (TNF), ctggacaaacctcagcccta and tgatggcttccagcaactc (MnSOD), 
ccttcctcaccgtgtactgg and agcgtagggtaaggttcttgc (ICAM-1), gtcaaggagctgcaggagat and 
gatggccaagtgcaggaa (IκBα), agtctctgccgcccttct and gtgactggggcattgattg (MCP-1), 
gctgctttgatgtcagtgct and tcaaagttgcttgctgcttc (MIP3α). 
 
4.4  Biochemical methods 
4.4.1  Determination of protein content 
To determine the protein concentration of cell lysates, the bicinchoninic acid (BCA)-
containing protein assay was applied (Pierce). Therefore, 5 µL of the lysate was incubated in 
1 mL BCA solution at 60 ºC for 20 min, followed by measuring light absorption at 540 nm. 
 
4.4.2  SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed based on the method of Laemmli (Laemmli, 1970) 
using 4 - 12 % Bis-Tris-NuPAGE gels from Invitrogen. Samples were mixed with SDS-
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Sample buffer and heated for 10 min at 75 °C. The SeeBlueTM Plus2 Pre-Stained marker 
(Novex) was used as a molecular weight standard. The electrophoretic separation was 
carried out at a constant voltage of 125 V for 10 min and subsequently 185 V for 55 min. 
For separation of proteins with a molecular weight above or below 40 kDa, MOPS buffer or 
MES buffer was used for the SDS-PAGE, respectively.  
 
4.4.3  Western blotting 
Western blotting was performed using the NOVEX gel-system based on the method of 
Towbin (Towbin et al., 1979). Proteins from SDS-PAGE gels were transferred onto 
nitrocellulose membranes (Amersham Pharmacia) by application a current of maximum 
160 mA (30 V) per gel for 2 hs. Afterwards, membranes were incubated for 2 hs with 
Blocking buffer at room temperature to occupy non-specific protein binding sites. 
Subsequently, membranes were subjected to immunoprobing with primary and secondary 
horseradish-peroxidase (HRP)-conjugated antibodies. Proteins were visualised using the 
ECL® detection system (Amersham Biosciences). 
 
4.4.4  Stripping of immunoblot membranes 
If nitrocellulose membranes had to be incubated with alternative antibodies, bound 
immunoglobulins were removed by incubating the nitrocellulose membranes with Stripping 
buffer at RT for 15 min. Then the membranes were washed 4-6 times with PBST, followed 
by incubation in blocking solution and probing as described in 3.4.3. 
 
4.4.5  FACS analysis of surface protein expression 
For the analysis of surface protein expression, 2-5 x 105 cells were resuspended in 50 µL 
primary antibody solution (end concentration: 10 µg/mL in FACS buffer) and incubated for 
20 min on ice. After adding 100 µL ice cold FACS buffer, cells were centrifuged and 
washed three times with 200 µL FACS buffer. Next, cells were incubated in 50 µL in 
secondary antibody solution (biotinylated, 5 µg/mL in FACS buffer) at 4 °C for 20 min. The 
cells were washed three times in FACS buffer and after addition of Streptavidin-PE (1:200), 
the cell suspension was incubated on ice for 20 min in the dark. Then the cells were washed 
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twice with 200 µL FACS buffer, resuspended in 100 µL FACS buffer and subjected to 
FACS analysis. 2 x 104 cells of each sample were monitored. 
 
4.4.6  TNF-RSC precipitation 
For analytical RSC analysis, 4.5 x 107 MCF-7 or HeLa cells per time point were either 
treated with 200 ng FLAG-tagged TNF per mL stimulation medium or left untreated. Cells 
were then lysed in IP-lysis buffer for 30 min at 4 °C on a head-to-head shaker. Afterwards, 
the lysates were centrifuged at 15.000 x g for 30 min. 1 µg FLAG-TNF was added to the 
non-stimulated control. FLAG-TNF was precipitated using M2 beads (Sigma) for 16 hs. 
The beads were washed 5 times with 1 mL IP-lysis buffer and eluted with SDS-Sample 
buffer. The TNF-RSC were analysed by immunoblotting using the indicated antibodies. 
 
4.4.7  TNT in vitro translation 
For in vitro binding assays, HOIL-1, HOIP and different deletion mutants were generated in 
vitro using the TNT Quick Coupled Transcription/Translation System (Promega). 
Therefore, 1.2 µg of each expression vector was added to an aliquot of the TNT Quick 
MasterMix and incubated in a reaction volume of 50 µL at 30 °C for 80 min. Equal protein 
production was controlled by western blotting (input: 1 µL of reaction mix). 
 
4.4.8  Protein interaction studies 
For in vivo interaction studies, 7.5 x 106 HEK293T cells were transfected with 5 µg of the 
respective DNAs by standard calcium phosphate transfection. Cells were harvested 24 hs 
post transfection and lysed in 1 mL IP-lysis buffer for 30 min at 4 °C. Subsequently, lysates 
were centrifuged at 15,000 x g for 30 min. Immunoprecipitations were performed at 4 °C for 
16 hs. Anti-V5-agarose resin (Sigma) and anti-NEMO agarose resin (Santa Cruz) were used 
for precipitations of V5-tagged proteins or NEMO, respectively. The beads were washed 
5 times with IP-lysis buffer and the proteins were eluted in 30 µL LDS sample buffer. 
Precipitated proteins were analysed by immunoblotting.  
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4.4.9  Ubiquitin pull-down assay 
10 µg of purified GST, GST-HOIL-1 or GST-HOIP N-term were incubated with 
glutathione-sepharose resin in 600 µL Pull-down buffer (PDB) at 4 °C for 6 hs. Beads were 
washed three times with PDB, split into three aliquots and incubated at 4 °C overnight with 
2 µg recombinant K48-, K63- or linear-linked ubiquitin chains in 450 µL PDB. The beads 
were washed five times with PDB. The bound proteins were eluted using 2x LDS sample 
buffer and subsequently subjected to SDS-PAGE and immunoblotting using ubiquitin 
specific antibodies. 
 
4.4.10  Enzyme-Linked Immuno Sorbent Assay (ELISA) 
The IL-8 ELISA was performed using the Human IL-8 CytoSetTM kit from Biosource. For 
coating 96-well plates, the coating antibody (anti-human IL-8; 1 mg/mL) was diluted 1:1000 
in PBS. 100 µL of this coating solution were added to each well and incubated for 12 hs at 
4 °C. The plate was washed once with Washing buffer and blocked with 300 µL Assay 
buffer per well for 1 h at room temperature. After washing twice, 100 µL of samples and 
standards (recombinant human IL-8) were transferred into the designated wells in 
duplicates. Following this step, 50 µL of PBS, containing the detection antibody 
(biotinylated anti-human IL-8; 0.05 mg/mL) were added into each well and incubated for 
2 hs at room temperature with continual shaking. Subsequently the plate was washed five 
times and 100 µL of the streptavidin-HRP solution (1.7 µL of streptavidin-HRP in 10 mL of 
Assay buffer) were transferred into each well. After incubation for 45 min at room 
temperature with continual shaking, the plate was washed 7 times and 100 µL of the 
substrate solution (10 mg o-Phenylene-diaminedihydrochloride (OPD) + 12 µL H2O2 (30 %) 
in 10 mL Citrate buffer) was added to each well. To stop the enzymatic reaction, 50 µL of 
stop solution (3 N H2SO4) was added and the absorbance was measured at a wavelength of 
450 nm. 
 
4.4.11  JNK Kinase-Assay 
5 x 106 cells (MCF-7 or HeLa cells) were starved for 4 hs prior to TNF stimulation 
(100 ng/mL or 5 ng/mL, respectively). To perform a non-radioactive JNK assay (Cell 
Signaling), cells were lysed in 1 mL IP-lysis buffer and a cJun fusion protein linked to 
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agarose beads was used to pull down JNK from cell lysates. Upon addition of ATP, the 
phosphorylation of cJun by active JNK was carried out at 30 °C for 30 min. Phosphorylated 
cJun was then visualised by western blotting. 
 
4.4.12  NF-κB Luciferase assay 
MCF-7 or HEK293-NFκB cells (20,000 cells/well) were seeded into 96-well plates and 
cultured for 10 to 12 hs in DMEM + 10% FCS before transfection. MCF-7 cells were 
cotransfected with 45 ng of NF- B-luciferase reporter plasmid DNA (Stratagene) and with 
5 ng/well of the pCMV-RLuc plasmid (Stratagene) using FuGENE 6 (Roche). 16 to 24 hs 
after transfection, cells were stimulated with TNF (0.1 to 100 ng/mL) for 4 hs. After TNF 
stimulation, cells were lysed with 1 x Passive lysis buffer (Promega) and the luminescence 
was measured. Firefly luciferase data were either normalised to total cell number 
(HEK293-NFkB cells) or to Renilla luciferase activity (MCF-7 cells). 
 
4.4.13  In vitro ubiquitination assay 
For in vitro ubiquitination assays, 0.8 µg recombinant HOIP and HOIL-1 were incubated 
with 5 µg ubiquitin, 0.2 µg E1 (UBE1), 0.3 µg E2 (UbcH5c) and 1 x Energy Regeneration 
Solution (Boston Biochem) in Ubiquitination buffer. After 2 hs incubation at 37 °C the 
reaction was stopped by adding SDS-Sample buffer. The samples were analysed by western 
blotting. 
 
4.4.14  Expression and Purification of recombinant proteins 
4.4.14.1  Expression and Purification of GST fusion proteins 
Recombinant GST-tagged HOIL-1 and HOIP N-term (residues 1-485) were expressed from 
a pET41a vector (Novagen; Merck). The DNA constructs were transformed into E. coli 
BL21(DE3) pLysS (Invitrogen) and 500 mL LB/Amp medium were inoculated with 10 mL 
overnight culture of a single BL21 colony and grown until an OD600 of approximately 0.6. 
GST fusion protein expression was induced with 1 mM IPTG (Isopropyl-β-D-thio-
galactoside). The bacteria suspension was shaken at 18 °C for 16 hs, centrifuged at 
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4600 rpm and 4 °C for 15 min, and the supernatant was discarded. The bacterial pellet was 
resuspended in 10 mL Bacteria lysis buffer and the lysate was incubated on ice for 15 min 
after addition of lysozyme (50 µg/mL). The bacteria were sonicated six times for 20 s, 
incubated on ice for 10 min and centrifuged at 6000 rpm and 4 °C for 15 min. The 
supernatant was then filtered using 0.45 µm syringe filters and applied to a 1 mL GSTrap 
column (GE Healthcare). The column was washed with 10 mL PBS (+ 1 mM DTT). Elution 
of the GST fusion proteins was carried out at 4 °C using 10 mL GST-elution buffer and the 
eluate was collected in 1 mL fractions. Protein elution was determined by Coomassie 
staining. GST fusion protein containing fractions were dialysed in 2.5 L of Maintenance 
buffer. 
For in vitro ubiquitination assays (Section 4.4.13), recombinant HOIL-1 and HOIP 
were expressed from a pGEX-6P2-vector (GE Healthcare) in E. coli BL21(DE3) pLysS 
after addition of 1 µM IPTG and 200 µM ZnSO4 at 18 °C overnight. The GST-tag was 
removed by incubation with PreScission protease (GE Healthcare) for 4 hs at 4 °C and 
quality was controlled by SDS-PAGE and Coomassie staining. 
 
4.4.14.2  Expression and Purification of human HF-TNF 
The cDNA encoding human full-length TNF was a gift from Martin R. Sprick. The 
extracellular portion of TNF was cloned into a pQE32 expression vector (Qiagen), in which 
the 3 x FLAG epitope was integrated by oligonucleotide cloning. Protein expression and 
bacteria lysis were performed as described above (Section 4.4.14.1) and His/FLAG-TNF 
(HF-TNF) was purified using a HisTrap FF Agarose column (Amersham Pharmacia) 
according to manufacturer's instructions. The expression and purification of HF-TNF was 
controlled by SDS-PAGE and Coomassie staining. Dialysed fractions, containing HF-TNF 
in Maintenance buffer, were stored at -80 °C. 
 
4.5  Cell death and viability assays 
4.5.1  Clonogenicity assay 
For long-term survival assays, MCF-7 cells were treated with 50 ng/mL TNF for 24 hs. 
Afterwards, cells were washed twice with PBS and the stimulation medium was replaced by 
MCF-7 growth medium. After the respective time interval, the adherent cells were washed 
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twice with PBS, fixed with 10 % formaldehyde in PBS for 30 min at room temperature and 
stained with a crystal violet solution. 
 
4.5.2  Cell viability assays  
Cell viability was quantified by the measurement of ATP levels (CellTiter-Glo® Assay) or 
the quantification of mitochondrial activity (MTT assay).  
 
4.5.2.1  MTT assay 
The MTT [3-(4,5-Dimethylthiazol-2-yl) 2,5-diphenyl-tetrazoliumbromide] method is based 
on the reduction of the yellow soluble tetrazolium salt by mitochondrial dehydrogenases of 
the respiratory chain leading to the formation of blue formazan crystals (Gerlier and 
Thomasset, 1986). 25,000 cells per well were seeded on a 96-well plate and stimulated with 
TNF or TRAIL respectively for 24 hs. After the addition of 25 µL MTT solution, the cells 
were incubated at 37 °C for 2 hs. Afterwards, the medium was discarded and the MTT 
reaction was stopped by adding 100 µL of an acetic acid solution (5 % acetic acid in 
isopropanol). The luminescence was measured at a wavelength of 570 nm. 
 
4.5.2.2  CellTiter-Glo® Assay 
To quantify cell viability, a CellTiter-Glo® Luminescent Cell Viability Assay (Promega) 
was performed. 24 hs after TNF or TRAIL treatment CellTiter-Glo® reagent was added to 
the medium and, following a shaking step for 2 min, the luminescent signal was measured. 
 
4.5.3  Quantification of apoptosis (Nicoletti staining) 
A specific propidium staining of genomic DNA, established by Nicoletti and colleagues 
(Nicoletti et al., 1991), was used to discriminate between apoptotic and living cells. 2 x 105 
cells were lysed in the dark in 100 µL Nicoletti buffer at 4 °C for 12 hs. The portion of cells 
showing a subdiploid DNA-fraction (< 2n) was detected by flow cytometry. This subdiploid 
DNA peak is a characteristic feature for the nuclei of cells undergoing apoptosis, due to 
DNA-fragmentation after caspase-activation, whereas living cells show a diploid (2n) or a 
tetraploid (4n) DNA content. 
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5.  Results 
5.1  Biochemical identification of two RING domain proteins as constituents of the 
native TNF-RSC 
To be able to comprehend the complex network of signalling pathways induced by TNF, the 
TNF-RSC and its molecular composition need to be understood. Therefore a novel modified 
tandem affinity purification (moTAP) procedure was developed, which allowed the physical 
determination of the molecular TNF-RSC composition in an unbiased manner (Haas, 2008). 
moTAP is based on a modified TAP-tag directly attached to the extracellular portion of 
TNF (aa 78-233) and facilitates the purification of native TNF-RSCs without the need to tag 
or overexpress any of its intracellular constituents (Figure 5.1.1). This moTAP-tagged 
ligand is fully biologically active as stimulation with moTAP-TNF leads to the 
phosphorylation and degradation of IκBα in HT1080 and U937 cells and induces cell death 
in TNF-sensitive U937 cells (Haas, 2008). 
 
PreSci AviTag TNF [aa 78-233]
Bio
3xFLAGNH2-
60 aa 156 aa
 
Figure 5.1.1: Schematic representation of moTAP-tagged TNF (PreSci: PreScission cleavage site). 
 
The moTAP technique combines a first high-affinity purification via the FLAG-tag with 
mild elution using a site-specific protease (PreScissionTM, GE Healthcare) and a second 
precipitation step via a biotinylated Avi-tag to obtain protein complexes with high 
efficiency and specificity. Furthermore, the low temperature optimum of the PreScission 
protease enables protein complex purification at 4 °C. These parameters are highly 
discriminating against unspecific binding of proteins throughout the biochemical 
purification procedure yet retain all essential components of the complex. 
Following complex purification using the moTAP technique, many of the known 
components of the TNF-RSC, including TNF-R1, TRADD, TRAF2, RIP1, ubiquitin, 
cIAP2, ABIN1 (A20 binding inhibitor of NF-κB) and the IKK and TAK/TAB complexes 
were identified by nanoscale liquid-chromatography tandem mass spectrometry (MS) (Haas, 
2008). In addition, this analysis also revealed the presence of two novel proteins, heme-
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oxidized IRP2 ubiquitin ligase 1 (HOIL-1) and HOIL-1-interacting protein (HOIP), which 
had not been reported to be associated with TNF-R1 signalling at that time. Instead, HOIL-1 
was described to be a RING finger ubiquitin ligase for heme-oxidized IRP2 (Yamanaka et 
al., 2003). Both HOIL-1 and HOIP belong to the RING-In Between RING (IBR)-RING 
(RBR) family, a subgroup of the RING finger protein family (Marin et al., 2004). RBR 
family members are characterized by three groups of specifically clustered cysteine and 
histidine residues and IBR domains often facilitate a close arrangement of the adjacent 
RING1 and RING2 domains to allow protein interactions and subsequent ubiquitination 
(Eisenhaber et al., 2007). However, the exact molecular function of the IBR domain remains 
to be resolved. Besides the RBR domains, HOIP contains a UBA domain and three Ran-
BP2-type zinc finger (ZF) domains. HOIL-1 in turn carries a Ubiquitin-like (UBL) domain 
and a Ran-BP2 ZF (Hicke et al., 2005) in addition to its RBR domains (Figure 5.1.2). 
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Fig 5.1.2: Domain structure of HOIL-1 and HOIP (ZF: Zinc finger; NZF: Npl4-type zinc finger; UBA: 
Ubiquitin-Associated; RING: Really Interesting New Gene; IBR: In Between RING; UBL: Ubiquitin-Like). 
 
Due to the identification of HOIL-1 and HOIP as constituents of the native TNF-RSC, both 
their functional relevance for TNF-R1-mediated signal transduction as well as the 
mechanism of recruitment to the TNF-RSC were analysed in this thesis. 
 
5.2  Stimulation-dependent recruitment of HOIL-1 and HOIP to the TNF-RSC 
Upon TNF stimulation, HOIL-1 and HOIP were recruited to the native TNF-RSC, which 
was precipitated from cell lysates using FLAG-tagged TNF. This recruitment process could 
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be demonstrated in different cell lines like U937 cells, HeLa cells as well as mouse 
embryonic fibroblasts (MEFs) (Fig. 4.2.1) confirming the data obtained by MS. To rule out 
any unspecific binding or a constitutive association of HOIL-1 and HOIP with TNF-R1, the 
ligand was added to the unstimulated lysate prior to immunoprecipitation (Section 4.4.6). 
Although this procedure resulted in a prominent co-precipitation of TNF-R1 in unstimulated 
cells, no interaction of HOIL-1 and HOIP or other TNF-RSC signalling proteins like RIP1 
and TRAF2 with TNF-R1 was detected if the ligand was added after cell lysis (Fig. 4.2.1). 
Thus, HOIL-1 and HOIP are recruited to the TNF-RSC in a stimulation-dependent manner. 
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Figure 5.2.1: HOIL-1 and HOIP are recruited to the TNF-RSC in a stimulation-dependent manner in 
different cell lines. (A) U937 cells (1 x 108), (B) HeLa cells (2 x 107) or (C) MEFs (2 x 107) were left 
untreated or treated with FLAG-tagged TNF (1 µg/mL) for the indicated times. After cell lysis, 1 µg FLAG-
TNF was added to the non-stimulated control (unst.) and FLAG-TNF was precipitated using M2 beads 
(Sigma) for 16 hs. The isolated proteins were analysed by immunoblotting with the indicated antibodies. 
 
To determine, which of the two TNF-binding receptors, TNF-R1 or TNF-R2, was 
responsible and essential for HOIL-1/HOIP recruitment, the surface expression of these two 
receptors was investigated in cells used for TNF-RSC analysis. In contrast to U937 cells, 
which express TNF-R1 as well as TNF-R2 on their plasma membrane, only TNF-R1 is 
present on the surface of HeLa cells as measured by flow cytometry (Figure 5.2.2). Given 
the TNF-R2-independent co-precipitation of HOIL-1 and HOIP with TNF-R1 in HeLa cells 
(Figure 5.2.1), these results therefore suggest that HOIL-1 and HOIP are recruited to 
TNF-R1 and that this recruitment does not require simultaneous stimulation of TNF-R2. 
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This is strengthened by the observation that under physiological conditions, human TNF, 
which was used for the stimulation, does not bind and activate mouse TNF-R2 (Ameloot et 
al., 2001; Ranges et al., 1989). Thus, in MEFs, stimulation using human HF-TNF only 
triggers signalling events mediated by TNF-R1, but not TNF-R2. However, a potential 
recruitment of HOIL-1 and HOIP also to TNF-R2 cannot be completely excluded. 
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Fig 5.2.2: FACS analysis of the TNF-R1/2 surface expression. HeLa and U937 cells were stained with 
TNF-R1/2-specific or isotype control antibodies (Section 4.4.5) and the receptor levels on the surface of 
2 x 104 cells were analysed by FACS (black line: TNF-R1/2; grey area: isotype-matched control mIgG1 mAb). 
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5.3  HOIL-1 and HOIP form a linear ubiquitin chain assembly complex (LUBAC) 
HOIL-1 and HOIP have been found in the cytosol of HeLa and SH-SY5Y cells to form a 
600 kDa protein complex, independently of a stimulus like TNF (Kirisako et al., 2006). 
Since the molecular masses of HOIL-1 and HOIP are 58 and 123 kDa, respectively, it is 
likely that the endogenous 600 kDa complex is composed of several HOIL-1 and HOIP 
molecules. However, the accurate stoichiometry has not been resolved yet. 
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Figure 5.3.1: Schematic representation of the HOIL-1 mutants generated. Asterisks in the RING domains 
indicate specific cysteine to serine point-mutations in HOIL-1 mutR1 (C699,702S) and HOIL-1 mutR2 
(C871,C874S). 
 
Consistent with these findings, it is demonstrated in this thesis by performing HOIL-1 
pulldown experiments using different HOIL-1 mutants (Figure 5.3.1), that HOIP binds 
directly to HOIL-1. Furthermore, the N-terminus of HOIL-1 containing the UBL domain 
was shown to be required for this interaction, because a UBL-lacking mutant (∆N term) did 
not interact with HOIP while HOIL-1 N-term alone did (Figure 5.3.2).  
In addition, it has been shown by the group of K. Iwai that HOIP, in which the UBA 
domain was deleted, failed to co-precipitate with HOIL-1 (Kirisako et al., 2006). Therefore, 
the interaction between these two domains seems to be crucial for formation of the 
stimulation-independent HOIL-1/HOIP complex. So far, protein-protein interactions 
involving UBL and UBA domains are best characterised for proteins like Rad23, Dsk2 and 
Ddi1, which have been implicated in the transfer of ubiquitinated proteins to the 
proteasome. These proteins can function as adaptors between ubiquitinated substrates and 
the proteasomal machinery due to a direct interaction of their UBL domain with the 26S 
proteasome (Welchman et al., 2005). Notably, the binding of UBL-UBA proteins to 
ubiquitinated proteins or the proteasome was shown to be only transient and loose (Elsasser 
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and Finley, 2005). However, Upadhya and Hegde reported that the UBL domain of HOIL-1 
is structurally distinct from UBLs harbouring the proteasome interacting motif (Upadhya 
and Hegde, 2003). This unique feature of the HOIL-1 UBL domain may hence enable the 
stable interaction between HOIL-1 and HOIP. 
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Figure 5.3.2: HOIL-1 interacts with HOIP via its N-terminal part containing the UBL domain. 
HEK293T cells were transfected with HOIP wt and different V5-tagged HOIL-1 variants (Figure 5.3.1). HOIP 
was immunoprecipitated and the blot was probed with a anit-V5 antibody.  
 
 
As the recruitment of HOIL-1 and HOIP increases the number of RING-containing proteins 
directly associated with the TNF-RSC, it seems likely that HOIL-1/HOIP are involved in 
TNF signal transduction by mediating ubiquitination-dependent signalling events. Hence, it 
was next analysed whether the complex composed of HOIL-1 and HOIP is indeed able to 
assemble polyubiquitin chains. Therefore, in vitro ubiquitination assays using mono-
ubiquitin as a model substrate were performed. As detected by ubiquitin chains of different 
lengths, mono-ubiquitin was ubiquitinated in the presence of E1, the E2 UbcH5c, HOIL-1 
and HOIP, but not in control samples, in which HOIL-1 or HOIP were tested individually 
(Figure 5.3.3). Furthermore, the ubiquitination assay revealed that E1 and E2 alone were not 
sufficient to generate polyubiquitin conjugates (Figure 5.3.3), indicating that the 
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HOIL-1/HOIP complex acts as a RING E3 which is necessary for the enzymatic ubiquitin 
conjugation activity of UbcH5c.  
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Figure 5.3.3: HOIL-1 and HOIP assemble polyubiquitin chains in vitro. Purified, recombinant HOIL-1 and 
HOIP proteins were incubated with monoubiquitin (Boston Biochem), E1 and E2 (UbcH5) ligases and ATP at 
37 °C for 2 hs. Polyubiquitin laddering was analysed by western blotting using ubiquitin antibodies. 
 
 
In addition, HOIL-1 and HOIP together were shown to possess a peculiar E3 activity, 
demonstrated by the fact that they could only generate ubiquitin chain ladders with wild-
type (wt) but not with His-tagged ubiquitin (Figure 5.3.4). As N-terminal tagged versions of 
ubiquitin are able to contribute to all ubiquitin chain linkages other than linear, this result 
demonstrates that HOIL-1 and HOIP are involved in the formation of linear head-to-tail 
ubiquitin chains. Due to these characteristics, the protein complex formed by HOIL-1 and 
HOIP was named ‘linear ubiquitin chain assembly complex’ (LUBAC) (Kirisako et al., 
2006).  
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Figure 5.3.4: HOIL-1/HOIP-induced generation of polyubiquitin chains is inhibited by N-terminal 
tagged versions of ubiquitin. An in vitro ubiquitination assay was performed as in Figure 5.3.3 using either 
wt or N-terminal His-tagged ubiquitin. As a control, purified TRAF6 was introduced as an E3 ligase, which is 
capable of assembling polyubiquitin conjugates using His-tagged ubiquitin monomers. 
 
 
Due to the capacity of LUBAC to act as an E3 ubiquitin ligase, it was next analysed which 
E2 ubiquitin transferring enzyme was required for LUBAC-mediated assembly of 
polyubiquitin chains. Therefore, wt ubiquitin was incubated with the indicated E2s in the 
presence of E1, recombinant LUBAC and ATP, followed by immunoblotting using specific 
anti-ubiquitin antibodies. It could be shown that LUBAC was able to generate polyubiquitin 
chains in conjunction with a broad spectrum of E2s, including UbcH2, UbcH3, UbcH5a-c or 
UbcH7 (Figures 5.3.5 and 5.3.6).  
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Figure 5.3.5: LUBAC assembles polyubiquitin chains with a broad spectrum of E2s. UbcH2, UbcH3 
UbcH5a, UbcH5b, UbcH7 and UbcH8 were used as E2s for LUBAC to generate polyubiquitin chains. HOIL-1 
and HOIP were affinity purified from E. coli and incubated together with wt ubiquitin and the indicated E2s in 
the presence of E1 and ATP at 37 °C for 2 hs. Polyubiquitin chain formation was analysed by western blotting 
using a ubiquitin-specific antibody.  
 
 
Using UbcH13 in complex with Uev1a, the human homolog of the yeast Mms2 protein, it 
was found that pure UbcH13/Uev1a assembles free ubiquitin chains without LUBAC 
(Figure 5.3.6). The type of ubiquitin chain generated by UbcH13/Uev1a could be 
determined as K63-linked due to an antibody specific for K63-linked ubiquitin chains 
(Wang et al., 2008a). Therefore, in contrast to the other E2s tested (Figures 5.3.5 and 5.3.6), 
the chain linkage specificity of UbcH13/Uev1a seems to be an intrinsic property of this E2. 
However, it can not be excluded that also the formation of linear ubiquitin chains is 
catalysed by the combination of UbcH13/Uev1a and LUBAC in these in vitro assays, but 
certainly to a lower degree than in conjugation with other E2s (Figure 5.3.6). 
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Figure 5.3.6: Pure UbcH13/Uev1a complexes assemble free K63-linked chains in the absence of an E3. 
Ubiquitin (wt) was incubated either with UbcH5c, UbcH6, UbcH10 or UbcH13/Uev1a in the presence of E1, 
ATP with or without purified HOIL-1 and HOIP at 37 °C for 2 hs, followed by immunoblotting with anti-
ubiquitin or an antibody specific for K63-linked ubiquitin chains.  
 
 
In summary, this demonstrates, that LUBAC’s E3 ligase activity is not dependent on a 
specific E2 ligase and suggests, in line with data from Kirisako and colleagues (Kirisako et 
al., 2006), that LUBAC but not the E2s determines the type of linkage in the polyubiquitin 
chain. 
Next, it was investigated whether LUBAC, due to its presence in the TNF-RSC, does have a 
physiological target protein, which is also part of the TNF-RSC. Therefore, nine known 
components of the TNF-RSC (i.e. TNF-R1, RIP1, TRADD, TRAF2, cIAP2, TAK1, ABIN1, 
IKKβ and NEMO) were tested in parallel as potential substrates by performing in vitro 
ubiquitination assays (B. Gerlach, manuscript submitted). Tagged versions of these proteins 
were overexpressed in HEK293T cells, immunoprecipitated and subsequently incubated 
together with LUBAC, E1 and UbcH5c. Interestingly, only NEMO, but none of the other 
proteins analysed, was specifically polyubiquitinated by LUBAC (Figure 5.3.7 B). In line 
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with the function of an E3 ligase as an adaptor for the specific interaction between substrate 
and E2, it was found that LUBAC strongly binds to NEMO in vivo (Figure 5.3.7 A). These 
findings are in line with a recent report showing that LUBAC can bind to NEMO and 
attaches linear ubiquitin chains to this signalling protein (Tokunaga et al., 2009). 
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Figure 5.3.7: LUBAC attaches linear ubiquitin chains to NEMO. (A) LUBAC binds to NEMO. Lysates 
from HEK293T cells expressing V5-HOIP, V5-HOIL-1 and FLAG-NEMO were incubated with M2 beads 
(Sigma). NEMO-bound HOIP and HOIL-1 were detected by immunoblotting with the indicated antibodies. 
Protein expression was controlled by western blotting. (B) LUBAC-induced in vitro ubiquitination of NEMO. 
FLAG-tagged NEMO was expressed in 293T cells, immunoprecipitated using anti-NEMO coupled beads and 
employed as a target in an in vitro ubiquitination assay (Section 4.2.13). (C) The in vitro ubiquitination assay 
was performed as shown in Figure 5.3.4 using either wt ubiquitin (wt Ub) or His-tagged ubiquitin (His Ub). 
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In addition, the result showing that coexpression of HOIP enhanced the association of 
HOIL-1 with NEMO (Figure 5.3.7 A), indicates that HOIP is the main component of 
LUBAC for binding to NEMO. Together with the finding that the ubiquitin chains 
conjugated to NEMO were linear because they could be generated with wild-type ubiquitin 
but not with His-tagged ubiquitin in which the N-terminus is blocked (Figure 5.3.7 C), this 
identifies NEMO as a target for LUBAC-mediated linear ubiquitination within the TNF-R1 
signal transduction pathway. 
 
5.4  LUBAC recruitment to the TNF-RSC is dependent on cIAP1/2 
To understand the mechanism of how HOIL-1 and HOIP are recruited to the TNF-RSC and 
to identify potential interaction partners, the TNF-RSC was immunoprecipitated from 
several MEF cell lines, which were deficient for one of the main components of the RSC. 
The analysis of the TNF-RSC isolated from cells lacking the main adaptor protein TRADD 
revealed that RIP1 was still recruited to the complex, probably due to a direct DD-DD 
interaction with TNF-R1 (Figure 5.4.1). However, consistent with previous observations 
(Ermolaeva et al., 2008; Pobezinskaya et al., 2008), ubiquitination of RIP1 was completely 
abrogated. In addition, neither TRAF2 nor HOIL-1 could be detected in the TNF-RSC of 
TRADD-deficient MEFs (Figure 5.4.1), underlining the pivotal role of the adaptor protein 
TRADD in the formation of a functional TNF-RSC.  
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Figure 5.4.1: HOIL-1 is recruited to the TNF-RSC in a TRADD-dependent manner. Wild-type and 
TRADD-deficient MEFs were stimulated with 1 µg/mL HF-TNF for the designated times. Cells were lysed 
and the endogenous TNF-RSC was precipitated from cell lysates. Samples were analysed by western blotting 
using the indicated antibodies. 
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Next the TNF-RSC isolated from MEFs lacking RIP1 was analysed for the presence of 
TRAF2, TRADD and HOIL-1. In the absence of RIP1, TRADD and TRAF2 as well as 
HOIL-1 were still present in the TNF-RSC, indicating that their recruitment is independent 
of RIP1 (Figure 5.4.2). Interestingly, the TNF-induced recruitment of TRADD and TRAF2 
was stronger in RIP1-deficient cells than in wild-type MEFs. Together with results shown in 
Figure 5.4.1, this suggests a model in which TRADD and TRAF2 can compete with RIP1 
for the binding to TNF-R1 or TRADD respectively and in which TRADD but not RIP1 is 
required for the recruitment of HOIL-1 to the TNF-RSC. 
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Figure 5.4.2: RIP1 is not required for the recruitment of HOIL-1 to the TNF-RSC. The native TNF-RSC 
was isolated from wild-type and RIP1-deficient MEFs upon TNF stimulation (1 µg/mL). The complex was 
then analysed by western blotting using antibodies against TNF-R1, RIP1, HOIL-1, TRAF2 and TRADD. 
 
 
As LUBAC can bind to NEMO (Figure 5.3.7 A), it therefore seemed possible that this 
interaction was responsible for the recruitment of HOIL-1 to the TNF-RSC. However, 
HOIL-1 was still recruited to the TNF-RSC in NEMO-deficient MEFs (Haas et al., 2009), 
indicating that, although LUBAC can bind to NEMO, NEMO is not required for HOIL-1 
recruitment to the TNF-RSC. 
 
To investigate the role of TRAF2 and cIAP1/2 for HOIL-1 recruitment, TRAF2-deficient 
MEFs were treated with the IAP inhibitor SM-164, which leads to degradation of cIAP1 and 
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cIAP2 (Lu et al., 2008; Sun et al., 2007; Vince et al., 2007). Treatment of TRAF2-/- cells 
with this inhibitor resulted in complete abrogation of HOIL-1’s association with the 
TNF-RSC (Figure 5.4.3), suggesting that TRAF2 and cIAP1/2 function together at the 
TNF-RSC to promote recruitment of LUBAC. 
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Figure 5.4.3: HOIL-1 is recruited to the TNF-RSC in a TRAF2-, and cIAP1/2-dependent manner. (A) wt 
MEFs and TRAF2-deficient MEFs were treated with DMSO or 100 ng/mL of the IAP inhibitor SM-164 and 
incubated at 37 °C for 2 hs. Cells were stimulated with 1 µg/mL TNF for the indicated times and endogenous 
TNF-RSC was precipitated from cell lysates. (B) Expression of cIAP1/2 in untreated and SM-164-treated cells 
was controlled by western blotting. 
 
 
Furthermore, the absence of TRAF2 and cIAP1/2 resulted in increased levels of unmodified 
RIP1 bound to the TNF-RSC and, consistently, ubiquitination of RIP1 was non-detectable 
(Figure 5.4.3). Thus, these results confirm that TRAF2 and cIAP1/2 play important roles in 
RIP1 ubiquitination (Bertrand et al., 2008; Park et al., 2004; Varfolomeev et al., 2008; 
Wertz et al., 2004). 
Given the fact that TRAF2 and cIAP1/2 belong to the RING family of ubiquitin 
ligases and given their importance for the interaction of HOIL-1 with the TNF-RSC, it 
seems likely that ubiquitination events mediated by these E3 ligases are involved in the 
recruitment process of LUBAC. To analyse in more detail which of these proteins, TRAF2 
or cIAP1/2, is in fact essential for HOIL-1 binding to the TNF-RSC and to test whether the 
ubiquitin-ligase activities of these proteins are required for LUBAC recruitment, 
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catalytically inactive mutants of cIAP1 (F610A) or TRAF2 (∆RING) were stably re-
expressed in MEFs deficient for cIAP1/2 or TRAF2/5, respectively (Figures 5.4.4 and 
5.4.5). Mutation of the cIAP1 C-terminal phenylalanine (F) residue 610 to alanine (A) was 
shown to disrupt the E3 ubiquitination activity of cIAP1 (Mace et al., 2008). 
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Figure 5.4.4: The catalytic activity of TRAF2/5 is not required for HOIL-1 recruitment to the TNF-
RSC. (A) TRAF2/5-deficient MEFs were reconstituted with TRAF2 wt (T2 wt), RING-deficient TRAF2 
(T2 ∆RING) or a TRAF2 mutant, which lacks the cIAP1/2 interacting motif (T2 ∆CIM). Cells were stimulated 
with 1 µg/mL TNF, and the isolated receptor complexes were analysed for HOIL-1 recruitment. (B) TRAF2 
protein expression was induced for 20 hs with 4-HT and lysates were controlled for protein expression levels 
by western blotting. 
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Reconstitution with both, wt or the ∆RING mutant of TRAF2, was sufficient for RIP1 
ubiquitination and HOIL-1 recruitment to occur (Figure 5.4.4). In addition, TRAF2/5-
deficient cells reconstituted with a TRAF2 ∆CIM mutant recruited neither cIAP1/2 (Vince 
et al., 2009) nor HOIL-1 and did not restore RIP1 ubiquitination in response to TNF 
(Figure 5.4.4). Therefore, these data also imply that the reduction in HOIL-1 recruitment 
and RIP1 ubiquitination observed in TRAF2-deficient cells is due to the role of TRAF2 as a 
recruitment platform for cIAPs via its cIAP interaction motif (CIM) and that the E3 activity 
of TRAF2 is not required for this process (Vince et al., 2009). 
 
This hypothesis was confirmed, as reconstitution of cIAP1/2-deficient MEFs with wt cIAP1 
was sufficient to restore both ubiquitination of RIP1 and the stimulation-dependent 
recruitment of HOIL-1 to the TNF-RSC whereas re-expression of catalytically inactive 
cIAP1 (F610A) failed to rescue either of these two events (Figure 5.4.5).  
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Figure 5.4.5: The catalytic activity of cIAP1/2 is essential for HOIL-1 recruitment to the TNF-RSC. (A) 
MEFs deficient for cIAP1/2 expression were reconstituted with inducible cIAP1 wt and catalytically inactive 
F610A mutant. Upon TNF stimulation, the endogenous TNF-RSC was isolated and analysed by western 
blotting (*, nonspecific band). (B) Protein expression was induced as described in the Materials and Methods 
section (Section 4.2.7). 
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Taken together, these results demonstrate that the E3 ligase function of cIAPs is required for 
recruitment of HOIL-1 to the TNF-RSC whereas the catalytic activity of TRAF2 is not 
essential.  
 
Since murine HOIP could not be detected with the HOIP antibody raised against human 
HOIP, the expression of cIAP1/2 was downregulated in human HeLa cells by using 
SM-164. This allows addressing the question whether in fact recruitment of both LUBAC 
components was impaired in the absence of cIAP1/2. In SM-164-treated cells, the 
association of HOIL-1 and HOIP with the TNF-RSC was severely reduced, whereas the 
levels of TRADD and TRAF2 in the TNF-RSC remained unchanged (Figure 5.4.6).  
By using different experimental settings and species, these data confirm that cIAP1 
and cIAP2 play an important role in recruiting LUBAC to the TNF-RSC. 
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Figure 5.4.6: cIAP1/2 expression is essential for LUBAC recruitment in human cells. (A) HeLa cells were 
pretreated with SM-164 (100 nM) or DMSO for 2 hs at 37 °C and were stimulated for the indicated times with 
TNF (200 ng/mL). The composition of the TNF-RSC and recruitment of HOIL-1 and HOIP were analysed 
using the indicated antibodies. (B) Degradation of cIAP1/2 by SM-164 was controlled by western blotting. 
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5.5  HOIL-1 and HOIP directly interact with specific polyubiquitin chains 
The finding that the absence of the E3 activity of cIAP1 and cIAP2 reduces the amount of 
HOIL-1 recruited to the TNF-RSC led to the hypothesis that the interaction between 
LUBAC and TNF-R1 may be mediated by cIAP1/2-generated ubiquitin chains. Consistent 
with this assumption, HOIL-1 and HOIP were precipitated in a ubiquitin-pulldown assay, 
demonstrating the capacity of both proteins to bind to ubiquitin (Figure 5.5.1). However, as 
shown in Figure 5.5.1, coexpression of HOIP strongly increased the binding of HOIL-1 to 
ubiquitin-coupled beads, suggesting that HOIP is the major contributor to the ubiquitin 
binding of LUBAC. 
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Figure 5.5.1: HOIL-1 and HOIP bind to immobilised ubiquitin. Lysates of HEK293T cells transfected 
with the indicated cDNAs were incubated with empty (control) or ubiquitin-coupled agarose beads. Ubiquitin-
bound proteins were examined by immunoblotting with anti-V5 antibody. HOIL-1 and HOIP expression levels 
were determined by western blotting.  
 
 
In order to characterise the ubiquitin-binding properties of HOIP in more detail and to map 
the ubiquitin-binding domain, several in vitro translated point mutants and truncated 
versions of HOIP were generated (Figure 5.5.2).   
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Figure 5.5.2: Schematic representation of the HOIP mutants generated. Asterisks in the RING domains 
indicate specific cysteine to serine point-mutations in HOIP mutR (C699,702S and C871,874S). 
 
 
As shown in Figure 5.5.3, the N-terminal part of HOIP, which contains the ZF domains, was 
essential for binding to ubiquitin-conjugated beads (Figure 5.5.3), whereas the UBA domain 
of HOIP was not required for the ubiquitin interaction, indicating a separate function for this 
domain. This is consistent with the data obtained by Kirisako et al., showing that the UBA 
of HOIP is essential for binding to HOIL-1 and therefore, LUBAC formation (Kirisako et 
al., 2006). 
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Figure 5.5.3: HOIP binds to ubiquitin via its N-terminal part containing the ZF domains. The indicated 
V5-tagged mutants of HOIP (Figure 5.5.2) were generated by in vitro transcription/translation and incubated 
with ubiquitin-coupled agarose beads. Ubiquitin-bound proteins were examined by western blotting with 
anti-V5 antibody. 
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To further investigate whether LUBAC preferentially binds to a certain type of ubiquitin 
chain, GST-tagged HOIL-1 and the N-terminus (including the ZF domains) of HOIP were 
recombinantly expressed in E. coli and the direct interaction with K48-, K63- and linearly 
linked polyubiquitin chains was analysed. Both, HOIL-1 and HOIP, were able to bind to 
ubiquitin chains of different linkage types including K63-, K48-linked and linear ubiquitin 
chains (Figure 5.5.4). Notably, both proteins preferentially bound longer polyubiquitin 
chains over ubiquitin chains consisting of only two or three ubiquitin subunits. 
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Figure 5.5.4: HOIL-1 and HOIP bind to ubiquitin chains of different linkage types. Purified recombinant 
GST-only, GST-tagged HOIL-1, and HOIP N-term (10 µg each) were immobilised on glutathione-sepharose 
resin. Two micrograms of the indicated K48-linked, K63-linked, or linear ubiquitin chains were added, and a 
GST pull-down assay was performed. The input control represents 10 % (0.2 mg) of the amount of ubiquitin 
used for the pull-down assay (*, GST-containing HOIP fragment). 
 
 
Furthermore, it could be demonstrated in a co-immunoprecipitation experiment that 
LUBAC can not only bind to cIAP1 but has a strong preference for the ubiquitinated form 
of cIAP1 (Figure 5.5.5). As cIAP1 can be modified with K63-linked ubiquitin chains in an 
auto-ubiquitination reaction in vitro (Blankenship et al., 2009), these data indicate that 
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LUBAC is recruited via a cIAP1/2-generated ubiquitin chain platform to the TNF-RSC and 
that cIAP1/2 can also act as acceptors for these ubiquitin chains. 
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Figure 5.5.5: LUBAC interacts with ubiquitinated cIAP1. HEK293T cells were transfected with V5-tagged 
HOIP/HOIL-1 and/or FLAG-tagged cIAP1. HOIP and HOIL-1 were immunoprecipitated with anti-V5-
agarose resin and the co-precipitation of cIAP1 was analysed by western blotting. 
 
5.6  HOIL-1 and HOIP mediate TNF-induced signalling events and gene induction 
 
Next, the functional role of LUBAC within TNF-induced signal transduction processes was 
examined. As HOIL-1 has been shown to enhance transcriptional activation in mammalian 
cells (Gustafsson et al., 2010; Tatematsu et al., 1998; Tokunaga et al., 1998), the effect of 
LUBAC on transcription was examined first. To this end, MCF-7 wt cells were transiently 
transfected with HOIL-1, HOIP or both proteins together and an NF-κB-responsive 
luciferase reporter assay was performed. Overexpression of HOIL-1 and HOIP together 
resulted in strong activation of NF-κB compared to GFP control transfected cells 
(Figure 5.6.1). In contrast, expression of either HOIL-1 or HOIP alone was not sufficient to 
activate NF-κB (Figure 5.6.1).  
Importantly, the respective abilities to activate NF-κB are in accordance with the 
finding that LUBAC, but not HOIL-1 or HOIP alone, assembles linear polyubiquitin chains 
in vitro (Figure 5.3.3). This could be explained by the finding that HOIL-1 and HOIP attach 
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linear ubiquitin chains to NEMO, thereby influencing the activation of NF-κB (Figure 5.3.7) 
and (Tokunaga et al., 2009). 
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Figure 5.6.1: LUBAC overexpression activates NF-κB. (A) MCF-7 cells were cotransfected with a NF-κB 
luciferase reporter plasmid and GFP, wt HOIP and/or wt HOIL-1 as indicated. Luminescence was determined 
16 hs after transfection and normalised to the activity of a cotransfected renilla luciferase. Average and s.d. of 
one representative out of four independent experiments are shown. (B) The expression of HOIP and HOIL-1 
was controlled by western blotting. 
 
 
Notably, specific point mutations in both RING domains of HOIL-1 did not influence the 
capacity of LUBAC to induce NF-κB activation (Figure 5.6.2). These cysteine-to-alanine 
substitutions in the RING domains, which alter structural-crucial zinc coordinating cysteine 
residues, have been used in functional studies to inactivate RING E3 ubiquitin ligase 
activity (Deshaies and Joazeiro, 2009; Itahana et al., 2007). As shown in Figure 5.6.2, 
HOIL-1 mutR1, mutR2 and mutR2 were still able to activate the NF-κB pathway when 
expressed together with HOIP. However, luciferase activity was almost completely 
abrogated in cells expressing the non-interacting HOIL-1 ∆N-term mutant (Figure 5.6.2), 
consistent with the demonstrated relevance of the UBL domain for the interaction between 
HOIP and HOIL-1 (Figure 5.3.2). 
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Figure 5.6.2: The UBL domain of HOIL-1 is required for LUBAC-mediated NF-κB activation. MCF-7 
cells were cotransfected with HOIP and HOIL-1 or the indicated HOIL-1 mutants. LUBAC-stimulated NF-κB 
activation was determined by NF-κB reporter assays. Average and s.d. of one representative out of three 
independent experiments are shown. Equal expression levels of HOIP and different HOIL-1 mutants used for 
the NF-κB luciferase assays was confirmed by western blot analysis. 
 
 
Regarding the function of HOIP within the LUBAC complex, it was found that a mutant 
LUBAC complex composed of HOIL-1 wt and HOIP mutR, which contains two point 
mutations in the HOIP RING-finger domains, was not able to activate the NF-κB signalling 
pathway (Figure 5.6.3). This suggests that HOIP must interact with HOIL-1 to form a 
functional LUBAC, but that LUBAC’s ubiquitination activity resides in HOIP. 
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Figure 5.6.3: Coexpression of wild-type HOIL-1 and HOIP mutR did not induce activation of NF-κB. 
(A) HEK293-NFκB cells were cotransfected with the indicated proteins and luciferase reporter assays were 
performed. Average and s.d. of one representative out of three independent experiments are shown. (B) Protein 
expression was controlled by western blotting. 
 
Using protein kinase C (PKC) β as bait in a yeast-two-hybrid screen, HOIL-1 was found to 
interact with PKCβ and PKCζ (Tokunaga et al., 1998). Therefore, HOIL-1 was also termed 
RBCK1 (RBCC protein interacting with PKC 1).  
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Figure 5.6.4: Inhibition of PKC activity did not reduce NF-κB activation upon LUBAC overexpression. 
(A) LUBAC-induced NF-κB activation was determined by NF-κB luciferase reporter assay in presence the 
PKC inhibitor Gö6983 (300 and 1000 nM). (B) The efficiency of Gö6983-mediated PKC inhibition was 
controlled in PMA-stimulated cells. 
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To further investigate whether PKCs are involved in LUBAC-induced NF-κB activation 
cascades, cells were treated with the PKC inhibitor Gö6983 and luciferase reporter assays 
were performed (Figure 5.6.4). Gö6983 has been shown to inhibit PKCα, PKCβ, PKCγ, 
PKCδ and PKCζ at a low nanomolar range (Young et al., 2005). Interestingly, inhibition of 
PKC activity did not lead to a reduced NF-κB activity upon LUBAC overexpression, 
indicating that PKCs do not play a role in LUBAC-mediated activation of NF-κB. Inhibition 
of PMA-induced NF-κB activation served as a control for Gö6983-mediated PKC inhibition 
(Figure 5.6.4). However, it can not be excluded that PKCs are involved in other signalling 
events, which are potentially influenced by the E3 ligase activity of LUBAC. 
 
Consistent with the data obtained in the overexpression system, knockdown of HOIL-1 
and/or HOIP resulted in reduced TNF-induced NF-κB activity in HEK293 cells 
(Figure 5.6.5) as measured by a luciferase-based NF-κB reporter assay. 
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Figure 5.6.5: LUBAC mediates TNF-induced NF-κB activity. (A) Luciferase assays were performed in 
HEK293-NFκB cells, transiently transfected with siRNA specific for HOIL-1 and HOIP. Average and s.d. of 
one representative out of three independent experiments are shown. (B) HOIL-1 and HOIP knockdown was 
controlled on protein level by western blotting. 
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Using a different experimental setting, the essential role of LUBAC for full TNF-mediated 
NF-κB activation was also confirmed by analysing IκBα phosphorylation upon TNF 
stimulation in control or LUBAC knockdown cells, respectively. As shown in Figure 5.6.6, 
phosphorylation of IκBα was significantly inhibited in cells, in which LUBAC expression 
was downregulated (Figure 5.6.6).  
 
siRNA:
0
0.3
0.6
0.9
1.2
m
RN
A
[fo
ld
in
du
c
tio
n
]
ctr HOIPctr HOIL-1
38
38M
W
 
[kD
a
]
ctr siRNA
0 5 15 30 60 12
0
H+H siRNA
0 5 15 30 60 12
0TNF [min]:
pIκBα
β-actin
A B
 
Figure 5.6.6: LUBAC mediates TNF-induced phosphorylation of IκBα. (A) MCF-7 cells were transiently 
transfected with siRNA specific for HOIL-1 and HOIP and treated with 50 ng/mL TNF for the indicated times. 
Cell lysates were analysed by western blotting. (B) HOIL-1 and HOIP knockdown was controlled on mRNA 
level by quantitative qPCR. The housekeeping gene transcripts GAPDH and HPRT1 were used for 
normalisation. 
 
 
It could also be demonstrated in this thesis that stable knockdown of HOIL-1 resulted in a 
severe reduction in TNF-induced JNK activity and cJun phosphorylation, demonstrated by 
direct measurement of JNK activity in an in vitro kinase assay upon TNF stimulation 
(Figure 5.6.7). In this assay, JNK was isolated from cell lysates via immobilised cJun after 
TNF stimulation and the JNK activity status was then determined in an ATP-dependent 
phosphorylation reaction using cJun as a substrate. In both cell lines tested, the initial 
phosphorylation of cJun was lower and vanished more rapidly in HOIL-1/HOIP knockdown 
cells as compared to wild-type cells (Figure 5.6.7 A+C). This indicates that LUBAC is not 
exclusively involved in regulation of TNF-induced NF-κB activity, but rather has a more 
general role in TNF signalling. 
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Figure 5.6.7: HOIL-1 is required for full TNF-induced JNK activation. 5 x 106 HEK293 (A and B) or 
THP-1 cells (C) were stimulated with 50 ng/mL TNF for the indicated times. After cell lysis, a nonradioactive 
JNK assay was performed. As a loading control, the total JNK and cJun levels are shown (A and C). HOIL-1 
expression was stably downregulated by shRNA (B and C). 
 
 
The physiological role of LUBAC in regulating TNF-mediated gene expression was 
analysed by ELISA in the presence or absence of LUBAC. In line with the function of 
LUBAC in TNF-induced signalling (Figures 5.6.1 - 5.6.7), siRNA-mediated inhibition of 
HOIL-1 and/or HOIP expression led to significantly reduced production of TNF target 
proteins like IL-8 after TNF stimulation in HeLa cells (Figure 5.6.8).  
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Figure 5.6.8: Suppression of HOIL-1 and HOIP expression attenuates TNF-induced IL-8 production. 
(A) HeLa cells, transfected with HOIL-1 and HOIP siRNA, were stimulated with TNF for 12 hs and the 
supernatants analysed by an IL-8-specific ELISA. Average + s.d. of a representative experiment (n = 4) done 
in triplicate are shown. (B) HOIL-1 and HOIP knockdown efficiency was analysed by quantitative qPCR. 
 
Consistently, LUBAC overexpression in MCF-7 cells resulted in a substantially increased 
secretion of IL-8 upon exposure to TNF as compared to control cells (Figure 5.6.9). 
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Figure 5.6.9: LUBAC overexpression enhances TNF-induced secretion of IL-8. (A) 3.5 x 104 MCF-7 cells 
stably expressing LUBAC were stimulated with TNF for 16 hs or left untreated. Supernatants were analysed 
by IL-8-specific ELISA. Average and SEM of three independent experiments done in triplicate are shown. (B) 
LUBAC expression was controlled by western blotting using a anti-V5 antibody. 
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To analyse whether altered gene expression occurred already on the transcriptional level, the 
mRNA induction of several TNF target genes was controlled in a short term kinetic by 
quantitative PCR (qPCR). In fact, LUBAC downregulation significantly inhibited the 
mRNA induction rates of various TNF-responsive genes (Figure 5.6.10). TNF-stimulated 
transcription of MnSOD (Manganese Superoxide dismutase), MCP-1 (Monocyte 
chemotactic protein-1), ICAM-1 (Intercellular adhesion molecule-1) and TNF itself was 
almost completely abrogated by HOIL-1/HOIP double knockdown, and IκBα and MIP3α 
(Macrophage Inflammatory Protein-3α) transcription was substantially decreased (Figure 
5.6.10). Taken together, these results indicate an important role for LUBAC in TNF-
mediated gene induction. 
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Figure 5.6.10: LUBAC is required for TNF-induced gene expression. HeLa cells, transfected with HOIL-1 
and HOIP siRNA (Figure 5.6.8 B), were treated with 10 ng/mL TNF for the indicated time periods and the 
mRNA levels of various TNF responsive genes (ICAM-1, A20, MnSOD, MCP-1 and MIP3α) were 
determined by quantitative PCR. GAPDH and HPRT1 were used as internal standards. (filled rhombs: control 
siRNA; open rhombs: HOIL-1/HOIP siRNA). 
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5.7  LUBAC protects cells from TNF-induced cell death 
In addition to the activation of transcription factors like NF-κB or AP-1, TNF is also able to 
induce cell death in a variety of cell lines. To test whether the presence or absence of 
HOIL-1 and HOIP has functional consequences for TNF signalling in terms of TNF-
mediated cytotoxicity, the expression of HOIP and HOIL-1 was individually inhibited by 
siRNA in TNF-sensitive MCF-7 cells. Knockdown of each of the two proteins led to 
markedly increased sensitivity of these cells to TNF-induced cell death (Figure 5.7.1).  
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Figure 5.7.1: Transient inhibition of HOIL-1 and HOIP expression sensitises for TNF-induced cell 
death. (A) MCF-7 cells were transfected for 96 hs with the indicated siRNAs. Subsequently, cells were treated 
with TNF for 24 hs and cell viability was measured by CellTiter-Glo® assays (Promega). Average values of 
three independent experiments (± SEM) are shown. (B) The substantial suppression of HOIL-1 and HOIP 
expression was confirmed by quantitative PCR on mRNA level.  
 
 
Notably, the HOIL-1-dependent TNF sensitisation was completely blocked in the presence 
of the caspase inhibitor zVAD-fmk (Figure 5.7.2), indicating that the increased cell death in 
HOIL-1 downregulated cells is due to caspase-mediated apoptosis. 
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Figure 5.7.2: HOIL-1-dependent sensitisation to TNF-induced cell death is blockable by zVAD-fmk 
treatment. (A) Stable HOIL-1 knockdown MCF-7 cells were treated with increasing concentrations of TNF 
for 24 hs and a CellTiter-Glo® viability assay was performed. Cell death was completely blocked in the 
presence of 20 µM zVAD-fmk which was added 10 min before TNF stimulation. Average values are of three 
independent experiments (± SEM). (B) Substantial downregulation of HOIL-1 was confirmed by western blot 
analysis on protein level after short term (passage 1) or long term (passage 15) cell culturing. 
 
 
To further confirm the correlation between TNF-sensitivity and HOIL-1 expression levels 
and to rule out any potential siRNA off-target effects, HOIL-1 and different HOIL-1 
mutants were transiently re-expressed in MCF-7 cells, in which HOIL-1 expression was 
stably repressed. Subsequently, clonogenicity assays were performed for 5 to 6 days upon 
TNF treatment. As shown in Figure 5.7.3, reconstitution with HOIL-1 wt and HOIL-1 
mutR1 but not with HOIL-1 ∆N-term rescued the knockdown phenotype, resulting in a de-
sensitisation of these cells for TNF-mediated cell death (Figure 5.7.3). 
In line with data showing that the two RING domains of HOIL-1 are dispensable for 
the NF-κB-activating function of LUBAC (Figure 5.6.2), HOIL-1 mutR1 was able to restore 
the proliferative capacity of HOIL-1 knockdown cells following TNF treatment 
(Figure 5.7.3). 
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Figure 5.7.3: HOIL-1 expression is required for clonogenic survival. MCF-7 cells, in which HOIL-1 
expression levels were stably reduced by shRNA were transfected with the expression vectors indicated 
(Figure 5.7.4 B). Cells were treated with 50 ng/mL TNF for 24 hs. Afterwards, cells were washed twice with 
PBS and the stimulation medium was replaced by MCF-7 growth medium. After the time periods indicated, a 
clonogenicity assay was performed.  
 
 
Furthermore, the requirement of a functional LUBAC for its prosurvival function was 
confirmed in a MTT assay by treating retransfected cells with TNF for 24 hs. Again, stable 
MCF-7 HOIL-1 knockdown cells were sensitised to TNF-induced cell death (Figure 5.7.4), 
an effect that could be reverted by re-expression of wt HOIL-1, but not HOIL-1 ∆N-term. 
Hence, besides its relevant role for LUBAC-mediated NF-κB activation, the UBL domain 
also seems to be essential for the anti-apoptotic function of HOIL-1 
(Figures 5.7.3 and 5.7.4). 
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Figure 5.7.4: The N-terminal part of HOIL-1 is required for its prosurvival function. (A) Stable HOIL-1 
knockdown MCF-7 cells were retransfected with GFP, HOIL-1 wt or a HOIL-1 mutant lacking the N-terminus 
(and therefore the UBL domain). Cells were treated with TNF for 24 hs, and cell viability was measured. 
Average values of three independent experiments (± SEM) are shown. (B) Stable reconstitution of MCF-7 
HOIL-1 knockdown cells (Figure 5.7.2) with HOIL-1 wt and different HOIL-1 mutants by lentiviral gene 
transduction. The expression levels were analysed by western blotting. 
 
 
In summary, it could be shown that the observed increase in TNF sensitivity is due to the 
inhibition of HOIL-1 expression and that it is not caused by any unspecific siRNA off-target 
effects. Furthermore, these results strongly indicate that HOIL-1 needs to interact with 
HOIP and that formation of LUBAC is necessary to protect cells from TNF-induced cell 
death. 
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5.8  HOIL-1 and HOIP are required for stable TNF-RSC formation  
Upon TNF stimulation, LUBAC influences pro-survival as well as pro-apoptotic signalling 
pathways. Together with its recruitment to the membrane proximal TNF-RSC, this suggests 
that LUBAC executes its function at the apex of TNF-induced signal transduction cascades. 
To analyse whether the absence or presence of LUBAC has an effect on the formation and 
overall integrity of the TNF-RSC, HOIP and HOIL were either overexpressed or 
downregulated prior to TNF stimulation and the composition of the TNF-RSC was analysed 
(Figures 5.8.1-5.8.3). 
Whereas TRADD recruitment remained almost unchanged, the levels of RIP1, TAK1 
and TRAF2 in the precipitated receptor complexes were significantly altered in LUBAC-
overexpressing cells (Figure 5.8.1). 
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Figure 5.8.1: The overexpression of LUBAC stabilises the TNF-RSC. (A) 2 x 107 HeLa cells stably 
expressing either GFP or the LUBAC were treated with 1 µg TNF/mL for the indicated times and the 
TNF-RSC was analysed using antibodies directed against TNF-R1, RIP1, TAK1, TRAF2 and TRADD. As a 
control for TNF-dependent recruitment to the TNF-R1, 1 µg TNF was added to the unstimulated samples after 
cell lysis (-). Total cell lysates (lysate) are shown that correspond to 1/80th of the cell lysate that was used to 
perform the immunoprecipitation (*, nonspecific band). (B) Expression of HOIL-1 and HOIP in LUBAC-
overexpressing cells was controlled by western blotting. 
 
 
As shown in Figure 5.8.1, the RIP1 ubiquitination pattern was dramatically altered. In HeLa 
GFP control cells, RIP1 ubiquitination was already decreased after 15 min. In contrast, RIP1 
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was ubiquitinated to a markedly higher degree in HeLa cells overexpressing LUBAC with a 
maximal ubiquitin modification after 15 to 30 min. In these cells, RIP1 ubiquitination was 
still detectable even after 60 min (Figure 5.8.1). In addition, overexpression of wt LUBAC 
increased and prolonged overall ubiquitination of TNF-RSC components (Figure 5.8.2). 
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Figure 5.8.2: LUBAC overexpression increases the total ubiquitination pattern in the native TNF-RSC. 
HeLa cells, which stably express GFP (ctr) or HOIL-1/HOIP (Figure 5.8.1 B) were stimulated with 1 µg/mL 
TNF, and the isolated receptor complexes were analysed by western blotting using a ubiquitin-specific 
antibody. 
 
 
In line with these results, siRNA-mediated inhibition of LUBAC expression resulted in a 
strongly decreased RIP1 ubiquitination pattern (Figure 5.8.3). Furthermore, the absence of 
HOIL-1 and HOIP severely reduced recruitment and/or retention of TRAF2 and TAK1 in 
the TNF-RSC (Figure 5.8.3). TRADD recruitment, however, was not altered in these cells, 
suggesting that LUBAC acts downstream of TRADD to specifically stabilise the complex 
and to allow for full activation of downstream signalling pathways. 
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Figure 5.8.3: Absence of LUBAC destabilises the TNF-RSC. Following siRNA-mediated inhibition of 
HOIL-1 and HOIP expression, cells were stimulated with 1 µg/mL TNF and the TNF-RSC composition was 
analysed by western blotting (*, nonspecific signal with the TAK1 and HOIP antibodies). 
 
 
As shown in Figure 5.3.7, NEMO interacts with LUBAC and in addition, it was reported 
recently that NEMO preferentially binds to linear ubiquitin chains (Lo et al., 2009; Rahighi 
et al., 2009). Consequently, the importance of LUBAC for the recruitment of NEMO and 
the IKK complex to the TNF-RSC was analysed. In accordance with this hypothesis, much 
less IKKα was detected in the TNF-RSC of HOIL-1/HOIP double knockdown cells when 
the complex was immunoprecipitated (Figure 5.8.4).  
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Figure 5.8.4: LUBAC mediates the stimulation-dependent interaction of the IKK complex with the 
TNF-RSC. Expression of HOIL-1 and HOIP in HeLa cells was downregulated by lentiviral shRNA delivery. 
Seven days after transduction, the cells were stimulated with 1 µg/mL TNF for the times indicated, and the 
receptor complex was analysed. 
 
 
In addition, immunoprecipitation of NEMO revealed that in HOIL-1/HOIP double 
knockdown cells substantially less RIP1, TRAF2, TRADD and TNF-R1 were associated 
with NEMO after TNF-stimulation in comparison to control cells, suggesting that LUBAC 
is required for efficient recruitment of NEMO and the IKK complex to the TNF-RSC 
(Figure 5.8.5). 
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Figure 5.8.5: LUBAC is important for the stimulation-dependent interaction of NEMO with the 
TNF-RSC. Expression of HOIL-1 and HOIP in HeLa cells was downregulated by lentiviral shRNA delivery 
(Figure 5.8.4). Cells were then stimulated with 1 µg/mL TNF for 10 min and NEMO was immunoprecipitated. 
The stimulation-dependent co-precipitation of TNF-R1, RIP1, TRAF2, TRADD and cIAP1 was analysed by 
western blotting. 
 
 
Taken together, the TNF-RSC was found to be much more stable in the presence of LUBAC 
and was remarkably destabilised when HOIL-1 and HOIP were absent. In particular, NEMO 
recruitment to the TNF-RSC is significantly enhanced either by a direct LUBAC-NEMO 
interaction or by LUBAC-mediated assembly of linear ubiquitin chains, which then act as a 
recruitment platform for NEMO. 
 
Finally the question whether TNF-RSC stabilisation results from the mere presence of 
LUBAC in the complex or from LUBAC’s function as an E3 ligase was addressed in this 
study. To answer this, HOIL-1 wt was expressed together with HOIP wt or HOIP mutR, a 
mutant, which renders LUBAC functionally inactive (Figure 5.6.3). When compared to 
untransfected cells or cells overexpressing wt LUBAC, expression of HOIL-1/HOIP mutR 
resulted in normal initial recruitment and modification of RIP1 but rapid loss of RIP1 from 
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the complex, demonstrating that the E3 activity of LUBAC rather than its mere presence is 
required for the observed TNF-RSC stabilisation (Figure 5.8.6). 
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Figure 5.8.6: The E3 function of HOIP is essential for LUBAC-mediated stabilisation of the TNF-RSC. 
HeLa cells or HeLa cells stably overexpressing HOIL-1 wt together with HOIP wt or catalytically inactive 
HOIP mutR were treated with 1 µg TNF/mL for the indicated times and a TNF-R immunoprecipitation was 
performed. The TNF-RSC composition and integrity was analysed by western blotting using the indicated 
antibodies. 
 
 
In summary, these experiments show that recruitment of LUBAC to the TNF-RSC via 
TRADD, TRAF2, cIAPs and cIAP-generated ubiquitin chains stabilises the complex and 
that this stabilisation process requires LUBAC’s activity as an E3 ligase. Furthermore, 
LUBAC recruitment to the TNF-RSC and its activity are important for effective TNF-
induced gene induction and protection from TNF-mediated cell death. 
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6.  Discussion 
Multi-protein complexes are important entities of biological activity inside cells that serve 
to create functional diversity by organising the large number of different proteins into 
functional units. On many occasions, when studying protein complexes rather than 
individual proteins, the biological insight gained has been fundamental, particularly in cases 
in which proteins with no previous functional annotation could be placed into a functional 
context derived from their molecular environment. Due to their position at the apex of signal 
transduction cascades, receptor signalling complexes are prominent examples of multi-
protein aggregates whose composition determine cellular fate and which are involved in the 
regulation of key biological processes. 
To understand the cellular processes initiated at these receptor complexes, it is crucial 
to characterise their composition on a molecular level. In order to study TNF-R signal 
transduction in more detail and to identify new molecules mediating this proces the moTAP 
technology was developed (Haas, 2008). This system is based on a two-step affinity 
purification procedure capable of isolating the native TNF-RSC formed upon TNF 
stimulation. Using this approach it was possible to isolate the native TNF-RSC with high 
purity and to identify, in combination with nanoLC tandem mass spectrometry, almost all 
proteins which were previously described to be part of the TNF-RSC (Micheau and 
Tschopp, 2003; Wajant et al., 2003), underlining the specificity of this technique. In 
addition, the RING domain-containing proteins HOIL-1 and HOIP were identified as two 
novel components of the TNF-RSC. Together, HOIL-1 and HOIP were shown to form a 
linear ubiquitin chain assembly complex (LUBAC) that attaches head-to-tail linked 
ubiquitin chains to target proteins (Kirisako et al., 2006).  
In this thesis, it could be demonstrated, in line with Tokunaga et al. (Tokunaga et al., 
2009), that HOIL-1/HOIP can bind to NEMO and that LUBAC specifically conjugates 
linear polyubiquitin chains to NEMO, an essential adaptor protein for TNF-induced 
signalling events. Furthermore, as shown in this study, LUBAC is recruited to the TNF-RSC 
in a TRADD-TRAF2/5-cIAP1/2-dependent manner, which provides the missing link 
between TNF binding and initiation of linear NEMO ubiquitination.  
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6.1  Functional characterisation of LUBAC as an E3 ligase 
The reported finding that LUBAC assembles head-to-tail linear polyubiquitin chains 
(Kirisako et al., 2006) could be confirmed by in vitro ubiquitination assays based on 
different versions of mono-ubiquitin. Acting as an E3 ligase, LUBAC mediated the 
polymerisation of wt ubiquitin as a model substrate, but failed to link His-ubiquitin, which 
was N-terminal blocked by the His-tag. In contrast, purified TRAF6 exhibited ubiquitin 
conjugation activity towards N-terminal tagged ubiquitin, showing that His-ubiquitin can in 
principle be used to generate polyubiquitin chains. Since the His-tag blocks only the 
α-famino group of the N-terminal M1 residue, this leaves all other lysine acceptor sites 
within the ubiquitin molecule functional. These results indicate that LUBAC indeed 
exclusively generates linearly linked ubiquitin chains. Interestingly, no ubiquitin 
conjugation activity could be detected for HOIL-1 on its own when used in an in vitro 
ubiquitination assay together with UbcH5c, E1 and ATP, even though HOIL-1 was reported 
to possess K48 ligase activity when it acts as a LUBAC-independent, complex-free E3 
ligase (Tatematsu et al., 2008; Tian et al., 2007; Tokunaga et al., 1998; Yamanaka et al., 
2003).  
Most E3 ligases exhibit specificity and preference for the chain types they conjugate. 
Whereas HECT-type E3 ligases are independent of the E2 used (Nagy and Dikic, 2010), 
RING-type E3 ligases rely mostly on the E2 enzymes to specify the type of ubiquitin chain 
generated (Nagy and Dikic, 2010). The nature of ubiquitin conjugation by E2-E3 complexes 
is critical as the outcome of ubiquitination is usually determined by the topology of the 
conjugate. Thus, it is important to understand how E2-E3 complexes build different types of 
ubiquitin chains. In contrast to e.g. UbcH5a-c or UbcH10, pure Ubc13-Mms2 assembles 
free K63-linked chains even in the absence of an E3, and thus chain linkage specificity is an 
intrinsic property of this E2 regardless of its E3 partner (Hofmann and Pickart, 1999). The 
basis for this activity was revealed by the crystal structure of the ubiquitin-Ubc13-Mms2 
complex. In the crystal, ubiquitin, which is bound to the Ubc13 subunit of one complex, 
interacts noncovalently to Mms2 in an adjacent complex, such that the ε-amino group of 
K63 is within 3 angstroms (Å) of the oxy-ester bond. Chain linkage specificity hence arises 
because the noncovalent binding site for ubiquitin on the E2 positions the K63 residue of the 
acceptor ubiquitin in a way that enables it to attack the thioester bond (Eddins et al., 2006). 
Interestingly, LUBAC can catalyse the formation of linear ubiquitin chains with a 
range of different E2s (except UbcH13/Uev1a), suggesting that conjugational specificity is 
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mediated by the E3 rather than by the E2 in this case. A few possibilities can account for 
this unusual behaviour. As shown for UbcH5a-c, this E2 subfamily synthesises 
polyubiquitin chains of different linkages depending on the E3 employed. UbcH5c produces 
a mixture of K11, K48, and K63 linkages with APC/C, Murf, Chip, and Mdm2 (Kim et al., 
2007; Kirkpatrick et al., 2006). However, when assayed in conjunction with BRCA1-
BARD1, it predominantly synthesises K6-linked chains (Nishikawa et al., 2004; Wu-Baer et 
al., 2003), and in combination with LUBAC, it generates linear ubiquitin chains. It is 
possible that multiple distinct, isoenergetic, E2-Ubiquitin noncovalent complexes exist, that 
favour different chain linkages. Alternatively, the linkages that form may reflect the 
potential of each individual lysine of ubiquitin to collide randomly with the thioester. Most 
likely, RING E3s could influence chain topology by providing noncovalent docking sites 
that orient the acceptor ubiquitin for attack. In fact, ubiquitin-binding domains are present in 
many E3s, like the UBA and ZF domains in HOIL-1 and HOIP. If the E2 used did not 
possess a high-affinity noncovalent binding site for the attacking (i.e., acceptor) ubiquitin, 
there would be a minimal energetic barrier for the E3 to overcome a particular linkage 
specificity by providing its own ubiquitin-binding domain to orient the acceptor ubiquitin. 
Therefore, one possible explanation for the observed linkage specificity of LUBAC is that 
LUBAC places the E2 in a position that leaves only the N-terminal methionine of the 
preceding ubiquitin chain sterically available for conjugation. Another possible model is 
based on the successive action of HOIL-1 and HOIP. According to that, one ligase (e.g. 
HOIL-1) would be responsible for the initial linkage of ubiquitin to the substrate via an 
isopeptide bond and subsequently, the other ligase (e.g. HOIP) would take over to arrange 
the following E2s in a sterically ideal position for a head-to-tail linkage to the first ubiquitin 
molecule (Nagy and Dikic, 2010). However, to fully understand the mechanism of how 
LUBAC can attach linear chains onto its substrates, future studies will have to focus on the 
assembly and detailed structure of the HOIL-1/HOIP complex and on the interaction 
between LUBAC and different E2s.  
 
6.2  Mechanism of LUBAC recruitment 
Using MEF cell lines deficient for main TNF-RSC components, it could be shown in this 
thesis that LUBAC recruitment is abolished in the absence of TRADD, diminished in the 
absence of TRAF2 and almost undetectable in the absence of cIAP1 and cIAP2. 
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Reconstitution experiments with knockout MEFs demonstrated that the catalytic activity of 
the cIAPs, but not of TRAF2, is essential for LUBAC recruitment to the TNF-RSC.  
Notably, the reconstitution experiments comparing wt and catalytically inactive 
mutants of cIAP1 and TRAF2 respectively demonstrated that presence of a TRAF2 variant 
lacking E3 activity is sufficient for RIP1 ubiquitination to occur, whereas this modification 
cannot be detected in absence of cIAP’s catalytic activity. In line with several publications 
(Bertrand et al., 2008; Park et al., 2004; Vince et al., 2009), this indicates that TRAF2 may 
serve as an adaptor protein recruiting cIAPs to the TNF-RSC thereby bringing them in close 
proximity to RIP1, rather than as the E3 directly ubiquitinating RIP1. This hypothesis is 
corroborated by a recent study that provided evidence, based on the crystal structure of the 
TRAF2 RING and first zinc finger domains, that TRAF2 is unable to functionally interact 
with Ubc13 and other related E2s and therefore is not able to act as an E3 ubiquitin ligase 
(Yin et al., 2009). 
The requirement of cIAPs’ E3 activity suggested that ubiquitin may be involved in 
recruiting LUBAC. Indeed, both HOIL-1 and HOIP were capable of binding to ubiquitin 
chains of different linkages, although they preferentially bound to linear and/or K63-linked 
ubiquitin chains. However, the interaction of HOIL-1 with ubiquitin was strongly increased 
in the presence of HOIP, indicating that LUBAC binds to polyubiquitin mainly via HOIP. In 
order to identify the domain mediating the HOIP-ubiquitin interaction, different HOIP 
protein variants were subjected to pull down assays using immobilised ubiquitin. It was 
found that the zinc fingers of HOIP at the N-terminus of the protein are essential for binding 
to ubiquitin. 
Together, these data indicate a chronology of recruitment events, leading to 
recruitment of LUBAC to the TNF-RSC (Figure 6.1): First, the adaptor protein TRADD 
interacts directly with TNF-R1 upon TNF stimulation and mediates the recruitment of 
TRAF2. Via the TRADD/TRAF2 axis, cIAP1 and cIAP2 are then recruited to the TNF-
RSC. Subsequently, cIAP1/2 modify several components, including RIP1, with ubiquitin 
chains, which are most likely of the K63 linkage type (Bertrand et al., 2008; Mahoney et al., 
2008; Wu et al., 2006; Xu et al., 2009a). Furthermore, cIAP1/2 can also auto-ubiquitinate 
(Blankenship et al., 2009) and these cIAP-generated polyubiquitin chains then allow the 
recruitment of LUBAC due to its ubiquitin binding ability.  
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Figure 6.1: A schematic model for recruitment of LUBAC into the TNF-RSC. Following crosslinking of 
TNF-R1 by TNF, TRADD and RIP1 are recruited to the death domain of TNF-R1. TRADD then facilitates 
recruitment of TRAF2, which in turn provides a binding and activation platform for cIAP1 and cIAP2. cIAP1/2 
ubiquitinate components of the TNF-RSC, including RIP1 and the cIAPs themselves [1]. These cIAP-generated 
polyubiquitin chains serve as recruitment platforms for LUBAC as well as the TAK/TAB and IKK complexes. 
Once recruited, LUBAC is able to linearly ubiquitinate NEMO [2] and thereby facilitate the recruitment of 
additional IKK complexes. Due to the close proximity to the IKK complex, TAK1 in turn can mediate the 
phosphorylation of IKK members and the induction of MAPK cascades [3]. Phosphorylation of IκBα by IKKβ 
[4] then leads to its polyubiquitination and degradation by the 26S proteasome [5]. Finaly, the activation of both 
NF-κB and MAPK signalling pathways results in the transcription of both pro-inflammatory and anti-apoptotic 
genes. 
Discussion  104  
 
The finding that HOIL-1 and HOIP form a stimulation-independent complex in the cytsol 
(Kirisako et al., 2006) and the enhanced ubiquitin interaction of HOIL-1 in the presence of 
HOIP indicate that both proteins are not recruited independently of each other, but rather 
suggest that HOIP is the determining factor required for LUBAC recruitment to the TNF-
RSC.  
Surprisingly, RIP1, despite being a prominent target of cIAP-mediated ubiquitin 
modifications (Bertrand et al., 2008; Mahoney et al., 2008; Varfolomeev et al., 2008; Vince 
et al., 2007; Wertz et al., 2004), was not essential for HOIL-1 recruitment to the TNF-RSC. 
However, other proteins like TRAF2 and cIAP1/2, have been described to be modified with 
polyubiquitin chains (Blankenship et al., 2009; Kovalenko et al., 2003; Trompouki et al., 
2003; Vallabhapurapu et al., 2008; Yin et al., 2009) and might therefore not only provide 
additional ubiquitin chains for recruitment of LUBAC but also provide alternatives to RIP1 
as LUBAC binding platform, especially in its absence. These findings are also in line with 
recent work by Wong and colleagues, demonstrating that RIP1 is not required for TNF-
induced activation of NF-κB in RIP1-deficient MEFs (Wong et al., 2010). 
 
6.3  Role of LUBAC for TNF-mediated signalling events 
By investigating the outcome of TNF-R1 signalling both in the presence and absence of 
LUBAC, it was shown in this thesis that LUBAC overexpression led to a marked increase in 
TNF-induced IL-8 production. Consistently, specific suppression of HOIL-1 and HOIP 
expression by RNAi resulted in reduced secretion of the chemokine IL-8 and significantly 
inhibited TNF-mediated induction of several TNF-responsive genes on mRNA level. 
Intriguingly, TNF-mediated induction of IκBα was substantially less affected by the 
absence of LUBAC than that of other target genes, which were tested by qPCR. Recently, 
an elegant explanation for such differential effects has been provided by a study employing 
single cell analysis of TNF-induced NF-κB target gene induction (Tay et al., 2010). This 
work showed that induction of some NF-κB target genes, e.g. IκBα, was relatively 
independent of signal strength and occurred even at low doses of TNF while that of others, 
e.g. MCP-1, required high doses and a strong TNF response (Tay et al., 2010). Since 
downregulation of LUBAC expression results in diminished and delayed NF-κB activation 
following TNF stimulation, but does not lead to a complete blockage of the NF-κB 
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pathway, the findings by Tay and colleagues could explain the differential effects observed 
on different TNF-induced target genes.  
To address the question of how this effect on TNF signalling is mediated, luciferase-
based NF-κB reporter assays were performed to analyse the ability of LUBAC to induce 
activation of NF-κB. In agreement with Tokunaga et al. (Tokunaga et al., 2009), 
concomitant overexpression of HOIP and HOIL-1 was sufficient to activate NF-κB, 
whereas each component itself had no effect on the level of NF-κB activation. The failure to 
activate NF-κB upon single overexpression of HOIP or HOIL-1 alone makes it unlikely that 
the observed LUBAC-mediated effect is simply due to an unspecific overexpression 
artefact. Instead, these results suggest that LUBAC is indeed an integral component of the 
NF-κB activation pathway.  
Importantly, expression of the HOIL-1 ∆N-term mutant, which lacks its UBL domain, 
did not induce activation of NF-κB when coexpressed together with HOIP. Given the 
essential and sufficient role of the UBL domain for the interaction between HOIL and 
HOIP, the activation of NF-κB hence requires an intact and functional LUBAC. 
On the other hand, mutations in the two RING finger domains of HOIL-1 (mutR2) had 
no significant effect concerning the activation of NF-κB. The three-dimensional structures 
of RING domains revealed that the conserved cysteine and histidine residues are buried 
within the domain’s core, where they help to maintain the overall structure through binding 
two zinc atoms (Barlow et al., 1994; Borden et al., 1995) yielding a rigid, globular platform 
for protein-protein interaction. As RING domains play an essential role for the catalytic 
function of E3 protein-ubiquitin ligases (Yamanaka et al., 2003), this function of HOIL-1 
seems to be dispensable for LUBAC-mediated activation of NF-κB. In contrast, it could be 
shown that a mutant LUBAC composed of wt HOIL-1 and HOIP with mutations in the 
RING domains (HOIP mutR) did not induce activation of NF-κB. These data demonstrate 
that HOIP must interact with HOIL-1 to be able to function as an E3 ligase, but that the E3 
ligase activity of LUBAC resides in HOIP.  
However, besides HOIL-1, there are other RING proteins, which lack intrinsic E3 
activity, like BARD1, Bmi1 and MdmX. In each of these cases, the RING domain interacts 
with a second RING domain protein (BRCA1, Ring1b, and Mdm2, respectively) that 
possesses E3 activity and heterodimer formation greatly stimulates E3 activity of the protein 
complex (Hashizume et al., 2001; Linares et al., 2003; Wang et al., 2004). Notably, 
activation of NF-κB by co-overexpression of HOIL-1 and HOIP correlates with their ability 
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to generate linear ubiquitin chains and to modify NEMO with linear ubiquitin chains. This is 
in line with a recent report that LUBAC activates NF-κB by ubiquitinating NEMO 
(Tokunaga et al., 2009). 
However, in contrast to Tokunaga et al. (Tokunaga et al., 2009), it was demonstrated 
in this thesis that a transient LUBAC knockdown also resulted in reduced TNF-induced 
JNK activity as measured by an in vitro JNK kinase assay. This indicates that LUBAC is 
required for effective TNF-induced activation of both transcription factors, NF-κB and 
AP-1. In particular, the TNF-stimulated generation of Tnf mRNA was almost completely 
abrogated in LUBAC knockdown cells, which is probably the result of concomitant 
inhibition of both NF-κB and AP-1 transcription factors, as TNF gene induction strongly 
depends on a functional JNK pathway (Das et al., 2009). One explanation for the differences 
between these results and the observations made by Tokunaga et al. in respect to LUBAC-
influenced JNK activity could be the different experimental setting. Tokunaga et al. 
analysed JNK activation by using either an AP-1 reporter system or by determining 
phosphorylation of JNK on western blot level upon TNF stimulation (Tokunaga et al., 
2009), whereas in this thesis, a more sensitive in vitro kinase assay was performed. In 
addition, the data presented by Tokunaga et al. are not fully conclusive since a control 
showing that the AP-1 reporter is at all functional as well as detection of phosphorylated 
JNK even in wt MEFs are missing (Tokunaga et al., 2009). Taken together, LUBAC 
recruitment to the TNF-RSC and its activity is critically important for regulating the 
strength of signal transduction and hence gene expression following TNF stimulation. 
 
Despite its evident function in the regulation of inflammatory processes, TNF is also able to 
induce apoptosis in a variety of cell lines. Thus, it was tested whether the death-inducing 
capacity of TNF was influenced by the presence or absence of LUBAC. Specific 
downregulation of HOIP and HOIL expression by siRNA led to a markedly increased 
sensitivity to TNF-induced cell death. This effect could be completely blocked by treatment 
with zVAD-fmk, indicating that the LUBAC-mediated cell death protection is due to an 
inhibition of TNF-induced apoptosis. In addition, by performing clonogenicity assays using 
HOIL-1 knockdown MCF-7 cells, it could be shown that the re-expression of HOIL-1 wt or 
HOIL-1 mutR1, which possesses a functionally defective RING domain, completely 
restored cell growth of these cells after TNF treatment. As the RING domains are essential 
for the ubiquitin-ligase activity of RING finger E3 ubiquitin ligases, it can be speculated 
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that the predicted catalytic function of HOIL-1 as an independent ubiquitin ligase (Tian et 
al., 2007) is dispensable for the observed anti-apoptotic effects. In contrast, the ∆N-term 
mutant was not able to reverse the knockdown phenotype. Given the importance of the 
HOIL-1 UBL domain for the LUBAC formation and the LUBAC-mediated NF-κB 
activation, these results suggest that the protective function of HOIL-1 with regard to TNF-
mediated cell death strongly depends on a functional LUBAC.  
Taken together, these results argue for an anti-apoptotic role of LUBAC in TNF-R1 
signalling which could be due to its ability to induce pro-survival pathways like NF-κB.  
 
6.4  LUBAC is required for stable TNF-RSC formation 
The loss of TNF-induced JNK and NF-κB signalling in the absence of LUBAC, together 
with the discovery that LUBAC forms an integral component of the TNF-RSC, suggests 
that it functions within the membrane proximal receptor complex to activate these signalling 
pathways. Analysing the TNF-RSC composition in the presence or absence of LUBAC, the 
complex was found to be much more stable upon overexpression of HOIL-1 and HOIP. 
Although recruitment of TRADD was not greatly affected, RIP1, TRAF2 and TAK1 were 
retained in Complex I substantially longer in LUBAC-overexpressing cells. 
In line with that, complex stability was much lower in cells in which expression of 
HOIL-1 and HOIP was suppressed. Consistent with its function as an E3, overexpression of 
LUBAC also increased and prolonged overall ubiquitination of TNF-RSC components. 
Considering the importance of protein ubiquitination for TNF-R1-induced signal 
transduction, these results indicate that LUBAC influences TNF signalling downstream of 
TRADD and enhances TNF-RSC stability by generating linear ubiquitin chains. By 
expressing a functionally inactive mutant of HOIP it could be shown in this thesis that the 
activity of LUBAC and not its mere presence is required for the observed TNF-RSC 
stabilisation in LUBAC-expressing cells, underlining the importance of linear ubiquitin 
chains for TNF-mediated signalling events.  
Since it is most likely that the recently discovered head-to-tail linked chains generated 
by LUBAC have a role in mediating protein-protein interactions, rather than in targeting 
proteins for proteasomal degradation as it was first suggested (Kirisako et al., 2006), it can 
be speculated that they may protect proteins from degradation by inhibiting K48-
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ubiquitination. Moreover, within the TNF-RSC linear ubiquitin chains may provide a 
platform for recruitment of ubiquitin-binding proteins possessing specificity for head-to-tail 
linked ubiquitin chains. Indeed, it was recently reported that NEMO selectively binds to 
linear ubiquitin chains via a UBAN motif (Komander et al., 2009b; Lo et al., 2009; Rahighi 
et al., 2009). Consistently, the stimulation-dependent interaction of the IKK complex with 
the TNF-RSC depends on the presence of LUBAC, as recruitment of IKKα is clearly 
reduced in absence of HOIL-1 and HOIP. The contribution of linear ubiquitin chains to 
efficient recruitment of the IKK complex can also explain the observation that the ability of 
NEMO to bind linear ubiquitin chains is important for efficient TNF-induced NF-κB 
activation (Lo et al., 2009; Rahighi et al., 2009). 
Since a role for NEMO in effective TAK1-mediated JNK activation following 
stimulation with LPS, IL-1β or anti-CD40 has been described (Matsuzawa et al., 2008; 
Yamamoto et al., 2006) the regulatory mechanisms involving ubiquitin-binding or 
ubiquitination of NEMO may not only apply for NF-κB signalling, but also to the activation 
of JNK. 
 
6.5  How LUBAC influences TNF-induced signalling events – a model 
LUBAC’s activity not only promotes retention of NEMO, but also retains cIAP1, TAK1, 
RIP1 and TRAF2 in the TNF-RSC, resulting in an overall stabilisation of the complex. 
Importantly, besides NEMO, other components of the TNF-RSC such as ABINs (Komander 
et al., 2009b; Rahighi et al., 2009) and IAPs (Gyrd-Hansen et al., 2008) also have been 
reported to bind linear ubiquitin chains.  
This suggests a model according to which the initial recruitment of ubiquitin-binding 
components, including LUBAC, depends on ubiquitin chains generated by cIAP1 and 
cIAP2. Once recruited, LUBAC attaches linear chains to NEMO and, possibly, also to other 
targets, thereby providing an optimised scaffold for the recruitment and retention of several 
other TNF-RSC constituents. Due to their ability to strongly interact with these chains, 
NEMO as well as other proteins become more firmly interlocked with the complex. 
Sustained presence of cIAPs in the complex allows the generation of additional cIAP-
generated ubiquitin chains, thereby also stabilising the presence of those ubiquitin-binding 
proteins, e.g. the TAK/TAB complex, that prefer other linkage types, including K63-linked 
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polymers, over linear ubiquitin chains (Iwai and Tokunaga, 2009; Komander et al., 2009b; 
Kulathu et al., 2009). In addition, the retention of non-ubiquitin-binding components of the 
TNF-RSC may be increased indirectly via their affinity to ubiquitin-bound interaction 
partners. Hence, cIAP-generated ubiquitin chains act upstream of LUBAC-generated 
ubiquitin chains in initial complex formation, and a combination of both linkage types leads 
to enhanced stability of the TNF-RSC. To dissect their different functions and to understand 
how these linkage types differ despite their three-dimensional structural similarity will be an 
important challenge for the future. In this regard, it is interesting to mention that most 
DUBs, except CYLD, do not cleave linear ubiquitin chains, or process them less efficiently 
than other chain types (Komander et al., 2009b). Therefore, the increased stability of the 
TNF-RSC might also be due to linear chains being more refractory to DUB-mediated 
disassembly. 
 
The recruitment of LUBAC to the TNF-RSC is an early event in TNF signalling 
transduction and, as a consequence, LUBAC functions upstream of the different signalling 
pathways emanating from TNF-R1. This hypothesis is further strengthened by the 
observation that the recruitment of LUBAC to the TNF-RSC is independent of NEMO, 
placing LUBAC and its function upstream of the IKK complex. Altogether, these results can 
explain why not only the NF-κB pathway, but also the activation of JNK, is negatively 
influenced by the absence of LUBAC. Its position at the apex of TNF-induced signalling 
cascades suggests a role for LUBAC in regulating downstream signalling pathways by a 
multi-layered mechanism:  
LUBAC may affect the activation of NF-κB by generating linear ubiquitin chains that 
lead to retention of the IKK and the TAK/TAB complex within the TNF-RSC. Prolonging 
their presence in the TNF-RSC as well as keeping them in close proximity allows for TAK1 
to phosphorylate and activate the IKK complex. In addition, ubiquitination or ubiquitin 
binding might cause clustering and oligomerisation of the IKK complex, facilitating 
transactivation of the kinase subunits. Furthermore, binding of NEMO to linear ubiquitin 
chains also induces a conformational change within NEMO (Rahighi et al., 2009) and it can 
be speculated that IKKβ becomes activated due to an overall structural change in the 
IKK complex. The identification of mutations in the NEMO UBAN motif in patients 
suffering from X-linked ectodermal dysplasia and immunodeficiency caused by impaired 
NF-κB signalling (Doffinger et al., 2001; Filipe-Santos et al., 2006) provide evidence that 
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NEMO binding to linear ubiquitin chains plays an important role in NF-κB activation. A 
further possibility of regulation is added by the fact that NEMO is a direct target of 
LUBAC. Ubiquitination of NEMO may again induce conformational changes leading to 
activation of IKK but may also serve as a binding platform for further NEMO molecules 
thereby favouring oligomerisation, trans-auto-phosphorylation and possibly TAK1-
independent activation of IKK complexes.  
In the case of JNK activation, the presence of LUBAC potentially increases signal 
intensity and duration by mediating an overall stabilisation of the TNF-RSC and thereby 
retaining proteins, which are essential for the activation of the MAPK pathway such as 
TAK1 (Wang et al., 2001) within the TNF-RSC. 
Finally, LUBAC’s role in TNF-induced gene-induction may also explain its inhibitory 
effect on TNF-induced cell death. Whether LUBAC regulates TNF-induced apoptosis solely 
by increasing the expression of pro-survival proteins or whether, for example, the stabilising 
effect of linear ubiquitin chains inhibits the dissociation of Complex I from TNF-R1 remain 
open questions to date. Apoptosis induced by TNF-R1 is thought to proceed via association 
of the adaptor protein FADD and caspase-8 with TRADD and RIP1, resulting in the 
formation of the cytoplasmic Complex II (Micheau & Tschopp, 2003). Micheau et al. 
showed that Complex II comprises increased amounts of the two anti-apoptotic proteins 
cIAP1 and cFLIP in cells resistant to TNF-induced apoptosis (Micheau & Tschopp, 2003). 
As the expression of both proteins is regulated by the transcriptional activity of NF-κB, the 
availability of cIAP1 and cFLIP at the moment Complex II is formed is dependent on a 
signal previously triggered by Complex I. Such a model would argue that, if NF-κB 
activation promotes the expression of cFLIP, the pro-apoptotic activity of caspase-8 is 
inhibited and the cell survives. In contrast, if Complex I-triggered NF-κB activation is not 
productive, the amount of cFLIP is diminished and the pro-apoptotic activity of caspase-8 
will not be controlled. Thus, TNF-R1-mediated signals include a checkpoint, resulting in 
cell death (via Complex II) in instances in which the initial signal (via Complex I, NF-κB) 
fails to be activated. According to this model, it will therefore be interesting to investigate in 
future, whether the formation, composition - especially with regard to the recruitment of 
cFLIP and cIAP1 - and stability of the death inducing Complex II as well as other key steps 
in TNF-mediated cell death are affected by presence or absence of LUBAC.  
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To gain a deeper understanding of LUBAC in the context of TNF signalling, the 
identification of potential additional targets as well as the identification and more detailed 
characterisation of proteins able to bind linear ubiquitin chains will be critical. Since the 
recruitment of LUBAC increases the combinatorial complexity of ubiquitin modification 
within the TNF-R1 complex, it is an unresolved issue of great importance to determine 
which components of the TNF-RSC are modified by which type of ubiquitin chain. In 
addition, it will be essential to investigate the functional implications of modification with 
or binding to the different types of polyubiquitin chains. This is necessary to functionally 
distinguish LUBAC-mediated signalling events from other ubiquitination processes that 
play a key role in TNF-induced IKK and MAPK activation. By carefully analysing the 
ubiquitin binding capacity of TNF-RSC components in terms of specificity for differentially 
linked ubiquitin chains, it will be possible to determine a chronological order of 
ubiquitination/recruitment processes, which ultimately lead to the formation of a proper 
TNF-RSC and subsequently, to the induction of different downstream signalling pathways. 
As it is for example not known to date, which ubiquitin chains are generated by cIAP1/2 and 
what are the differential substrates of cIAP1 and cIAP2, this analysis should concentrate not 
only on the well established K48, K63 and linear ubiquitin chains, but should also include 
the analysis of unconventional linked ubiquitin polymers. Considering the fact that the 
important adaptor role of K63-linked ubiquitin chains for TNF signalling has recently been 
challenged (Xu et al., 2009a), it will be especially interesting to determine if proteins which 
are thought to bind exclusively to chains of the K63 type, such as TAB2, can also bind to 
other atypical ubiquitin chains. 
 
As ubiquitin ligases and polyubiquitin chains required for recruitment of LUBAC are not 
only present in the TNF-RSC but also in signalling complexes induced by antigen receptors, 
other TNF-R superfamily members, IL-1 receptor (IL-1R)/TLR 4, as well as Nucleotide-
binding Oligomerization Domain (NOD) 1 and NOD2 (Bertrand et al., 2009; Chen, 2005; 
Hitotsumatsu et al., 2008), it is possible that LUBAC also plays a role in the signal 
transduction triggered by other receptor-ligand systems. Investigation of this novel ubiquitin 
ligase in the context of these systems will be a fascinating area of research and is likely to 
provide insightful information on ubiquitin-dependent mechanisms of signal transduction.  
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